<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis - Ciapponi, A - 2019 | Cochrane Library</title> <meta content="Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis - Ciapponi, A - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011260.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis - Ciapponi, A - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011260.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011260.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis" name="citation_title"/> <meta content="Agustín Ciapponi" name="citation_author"/> <meta content="Institute for Clinical Effectiveness and Health Policy (IECS‐CONICET)" name="citation_author_institution"/> <meta content="aciapponi@iecs.org.ar" name="citation_author_email"/> <meta content="Ariel Bardach" name="citation_author"/> <meta content="Institute for Clinical Effectiveness and Health Policy (IECS‐CONICET)" name="citation_author_institution"/> <meta content="Lucila Rey Ares" name="citation_author"/> <meta content="Institute for Clinical Effectiveness and Health Policy (IECS‐CONICET)" name="citation_author_institution"/> <meta content="Demián Glujovsky" name="citation_author"/> <meta content="María Luisa Cafferata" name="citation_author"/> <meta content="Institute for Clinical Effectiveness and Health Policy (IECS‐CONICET)" name="citation_author_institution"/> <meta content="Silvana Cesaroni" name="citation_author"/> <meta content="Institute for Clinical Effectiveness and Health Policy (IECS‐CONICET)" name="citation_author_institution"/> <meta content="Aikant Bhatti" name="citation_author"/> <meta content="World Health Organization" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD011260.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/12/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011260.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011260.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011260.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adverse Drug Reaction Reporting Systems; Immunity, Mucosal; Immunization Schedule; Interrupted Time Series Analysis; Poliomyelitis [*prevention &amp; control]; Poliovirus [immunology]; Poliovirus Vaccine, Inactivated [*administration &amp; dosage, *adverse effects]; Poliovirus Vaccine, Oral [*administration &amp; dosage, *adverse effects]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011260.pub2&amp;doi=10.1002/14651858.CD011260.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="qy4lqFNF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011260\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011260\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011260.pub2",title:"Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis",firstPublishedDate:"Dec 5, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011260.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011260.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011260.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011260.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011260.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011260.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011260.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011260.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011260.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011260.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4825 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011260.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-sec-0170"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-sec-0069"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-sec-0161"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/appendices#CD011260-sec-0175"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/table_n/CD011260StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/table_n/CD011260StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#CD011260-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Agustín Ciapponi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#CD011260-cr-0003">Ariel Bardach</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#CD011260-cr-0004">Lucila Rey Ares</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#CD011260-cr-0005">Demián Glujovsky</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#CD011260-cr-0006">María Luisa Cafferata</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#CD011260-cr-0007">Silvana Cesaroni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information#CD011260-cr-0008">Aikant Bhatti</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information/en#CD011260-sec-0203">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 December 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011260.pub2">https://doi.org/10.1002/14651858.CD011260.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011260-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011260-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011260-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011260-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011260-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011260-abs-0001" lang="en"> <section id="CD011260-sec-0001"> <h3 class="title" id="CD011260-sec-0001">Background</h3> <p>Poliomyelitis mainly affects unvaccinated children under five years of age, causing irreversible paralysis or even death. The oral polio vaccine (OPV) contains live attenuated virus, which can, in rare cases, cause a paralysis known as vaccine‐associated paralytic polio (VAPP), and also vaccine‐derived polioviruses (VDPVs) due to acquired neurovirulence after prolonged duration of replication. The incidence of poliomyelitis caused by wild polio virus (WPV) has declined dramatically since the introduction of OPV and later the inactivated polio vaccine (IPV), however, the cases of paralysis linked to the OPV are currently more frequent than those related to the WPV. Therefore, in 2016, the World Health Organization (WHO) recommended at least one IPV dose preceding routine immunisation with OPV to reduce VAPPs and VDPVs until polio could be eradicated. </p> </section> <section id="CD011260-sec-0002"> <h3 class="title" id="CD011260-sec-0002">Objectives</h3> <p>To assess the effectiveness, safety, and immunogenicity of sequential IPV‐OPV immunisation schemes compared to either OPV or IPV alone. </p> </section> <section id="CD011260-sec-0003"> <h3 class="title" id="CD011260-sec-0003">Search methods</h3> <p>In May 2019 we searched CENTRAL, MEDLINE, Embase, 14 other databases, three trials registers and reports of adverse effects on four web sites. We also searched the references of identified studies, relevant reviews and contacted authors to identify additional references. </p> </section> <section id="CD011260-sec-0004"> <h3 class="title" id="CD011260-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs), quasi‐RCTs, controlled before‐after studies, nationwide uncontrolled before‐after studies (UBAs), interrupted time series (ITS) and controlled ITS comparing sequential IPV‐OPV schedules (one or more IPV doses followed by one or more OPV doses) with IPV alone, OPV alone or non‐sequential IPV‐OPV combinations. </p> </section> <section id="CD011260-sec-0005"> <h3 class="title" id="CD011260-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD011260-sec-0006"> <h3 class="title" id="CD011260-sec-0006">Main results</h3> <p>We included 21 studies: 16 RCTs involving 6407 healthy infants (age range 96 to 975 days, mean 382 days), one ITS with 28,330 infants and four nationwide studies (two ITS, two UBA). Ten RCTs were conducted in high‐income countries; five in the USA, two in the UK, and one each in Chile, Israel, and Oman. The remaining six RCTs were conducted in middle‐income countries; China, Bangladesh, Guatemala, India, and Thailand. We rated all included RCTs at low or unclear risk of bias for randomisation domains, most at high or unclear risk of attrition bias, and half at high or unclear risk for conflict of interests. Almost all RCTs were at low risk for the remaining domains. ITSs and UBAs were mainly considered at low risk of bias for most domains. </p> <p><b>IPV‐OPV versus OPV</b> </p> <p>It is uncertain if an IPV followed by OPV schedule is better than OPV alone at reducing the number of WPV cases (very low‐certainty evidence); however, it may reduce VAPP cases by 54% to 100% (three nationwide studies; low‐certainty evidence). There is little or no difference in vaccination coverage between IPV‐OPV and OPV‐only schedules (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.96 to 1.06; 1 ITS study; low‐certainty evidence). Similarly, there is little or no difference between the two schedule types for the number of serious adverse events (SAEs) (RR 0.88, 95% CI 0.46 to 1.70; 4 studies, 1948 participants; low‐certainty evidence); or the number of people with protective humoral response P1 (moderate‐certainty evidence), P2 (for the most studied schedule; two IPV doses followed by OPV; low‐certainty evidence), and P3 (low‐certainty evidence). </p> <p>Two IPV doses followed by bivalent OPV (IIbO) may reduce P2 neutralising antibodies compared to trivalent OPV (moderate‐certainty evidence), but may make little or no difference to P1 or P2 neutralising antibodies following an IIO schedule or OPV alone (low‐certainty evidence). Both IIO and IIbO schedules may increase P3 neutralising antibodies compared to OPV (moderate‐certainty evidence). It may also lead to lower mucosal immunity given increased faecal excretion of P1 (low‐certainty evidence), P2 and P3 (moderate‐certainty evidence) after OPV challenge. </p> <p><b>IPV‐OPV versus IPV</b> </p> <p>It is uncertain if IPV‐OPV is more effective than IPV alone at reducing the number of WPV cases (very low‐certainty evidence). There were no data regarding VAPP cases. There is no clear evidence of a difference between IPV‐OPV and OPV schedules for the number of people with protective humoral response (low‐ and moderate‐certainty evidence). IPV‐OPV schedules may increase mean titres of P1 neutralising antibodies compared to OPV alone (low‐ and moderate‐certainty evidence), but the effect on P2 and P3 titres is not clear (very low‐ and moderate‐certainty evidence). </p> <p>IPV‐OPV probably reduces the number of people with P3 poliovirus faecal excretion after OPV challenge with IIO and IIOO sequences (moderate‐certainty evidence), and may reduce the number with P2 (low‐certainty evidence), but not with P1 (very low‐certainty evidence). There may be little or no difference between the schedules in number of SAEs (RR 0.92, 95% CI 0.60 to 1.43; 2 studies, 1063 participants, low‐certainty evidence). </p> <p>The number of persons with P2 protective humoral immunity and P2 neutralising antibodies are probably lower with most sequential schemes without P2 components (i.e. bOPV) than with trivalent OPV or IVP alone (moderate‐certainty evidence). </p> <p><b>IPV (3)‐OPV versus IPV (2)‐OPV</b> </p> <p>One study (137 participants) showed no clear evidence of a difference between three IPV doses followed by OPV and two IPV doses followed by OPV, on the number of people with P1 (RR 0.98, 95% CI 0.93 to 1.03), P2 (RR 1.00, 95% CI 0.97 to 1.03), or P3 (RR 1.01, 95% CI 0.97 to 1.05) protective humoral and intestinal immunity; all moderate‐certainty evidence. This study did not report on any other outcomes. </p> </section> <section id="CD011260-sec-0007"> <h3 class="title" id="CD011260-sec-0007">Authors' conclusions</h3> <p>IPV‐OPV compared to OPV may reduce VAPPs without affecting vaccination coverage, safety or humoral response, except P2 with sequential schemes without P2 components, but increase poliovirus faecal excretion after OPV challenge for some polio serotypes. Compared to IPV‐only schedules, IPV‐OPV may have little or no difference on SAEs, probably has little or no effect on persons with protective humoral response, may increase neutralising antibodies, and probably reduces faecal excretion after OPV challenge of certain polio serotypes. </p> <p>Using three IPV doses as part of a IPV‐OPV schedule does not appear to be better than two IPV doses for protective humoral response. </p> <p>Sequential schedules during the transition from OPV to IPV‐only immunisation schedules seems a reasonable option aligned with current WHO recommendations. Findings could help decision‐makers to optimise polio vaccination policies, reducing inequities between countries. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011260-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011260-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011260-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011260-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011260-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011260-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011260-abs-0004" lang="en"> <h3>Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis </h3> <p><b>Background to the question</b> </p> <p>Poliomyelitis (most commonly called Polio) mainly affects children under the age of five who have not been vaccinated against it. Polio causes permanent paralysis and even death. Polio can be prevented by vaccines, which provide defence against the disease (antibodies) in body fluids (also called humoral immunity) and also gut mucosal immunity. Polio‐related paralysis is caused by wild polio virus (WPV) and also in rare cases by the weakened live vaccine virus in the oral polio vaccine (OPV). The number of wild polio cases has gone down dramatically since the introduction and widespread use of the OPV and inactivated polio vaccine (IPV). However, the cases of paralysis linked to the OPV are currently more frequent than those related to the WPV. Since 2016 the World Health Organization has started to recommend that before a child is given the OPV immunisation they must have had at least one dose of the IPV mainly to limit the incidence of cases of paralysis linked to the OPV until polio is wiped out worldwide. </p> <p><b>Review question</b> </p> <p>Are polio vaccine schedules that include both IPV and OPV as effective and safe as either OPV or IPV alone? </p> <p><b>Study characteristics</b> </p> <p>We searched databases of scientific studies and found 21 studies to include in this review. Studies included 16 randomised trials with 6407 infants, one additional study followed 28330 infants over time and another four were nationwide studies. </p> <p><b>Certainty of the evidence</b> </p> <p>We assessed the included evidence for how certain we are that the effects are true and would not be altered with the addition of more evidence. In general, the certainty of the evidence was judged to be low to moderate but it was very low for some outcomes. </p> <p><b>Key results</b> </p> <p>IPV‐OPV compared to OPV may reduce the cases of paralysis linked to OPV by 54% to 100% without affecting vaccination coverage, the number of serious adverse events, and humoral immunity. However, it may worsen mucosal immunity for some types of polio. </p> <p>IPV‐OPV compared to IPV may make little or no difference on serious adverse events, probably makes little or no difference in the number of persons with protective humoral immunity, may increase neutralising antibodies and probably improves intestinal mucosal immunity of vaccinated people. </p> <p>Three doses of IPV followed by OPV appears to be no different than two IPV doses followed by OPV on the number of people with protective humoral and gut immunity. </p> <p><b>Authors' conclusions</b> </p> <p>The main potential benefit of IPV‐OPV, compared to OPV, is that may reduce cases of paralysis linked to OPV. It could be a more affordable option to IPV during the final stages of polio eradication, hence reducing inequities between countries. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011260-sec-0170" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011260-sec-0170"></div> <h3 class="title" id="CD011260-sec-0171">Implications for practice</h3> <section id="CD011260-sec-0171"> <p>Compared to OPV, sequential IPV‐OPV may reduce cases of vaccine‐associated paralytic polio (VAPP) without affecting vaccination coverage, safety, or humoral response, except P2 with sequential schemes without P2 components, but reduce mucosal immunity as revealed by increased poliovirus faecal excretion after OPV challenge for some poliovirus serotypes. </p> <p>Compared to IPV, sequential IPV‐OPV may make little or no difference to serious adverse events, probably make little or no difference to the number of people with protective humoral response, may increase neutralising antibodies and probably improve mucosal immunity for some polio serotypes, depending on the schedule used. </p> <p>Sequential schedules of two full doses of IPV, compared to three, may provide adequate protective humoral response and may not affect mucosal immunity against poliovirus. Both short‐ and long‐term antibody titres and protective response of the poliovirus serotype 2 are probably lower using the most recent bOPV schedules without this component. </p> <p>Sequential schedules during the transition from an OPV to IPV‐only immunisation schedule seem a reasonable option aligned with current World Health Organization (WHO) recommendations. Our findings could help decision‐makers to optimise polio vaccination policies, and might contribute to the expansion of IPV use in OPV‐using countries, thereby reducing inequities between countries. </p> </section> <h3 class="title" id="CD011260-sec-0172">Implications for research</h3> <section id="CD011260-sec-0172"> <p>It is mandatory to improve registers of infrequent events beyond cases of wild polio virus (WPV), to include, for example, VAPP or vaccine‐derived polioviruses, and to assess the impact of the recent implementation of the WHO's recommendation to introduce of at least one dose of IPV in routine OPV immunisation programmes worldwide. </p> <p>It is imperative to find the most cost‐effective and far‐reaching schemes in a context of scarcity of IPV in vast regions of the world. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011260-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011260-sec-0022"></div> <div class="table" id="CD011260-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IPV‐OPV compared to OPV for preventing poliomyelitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IPV‐OPV compared to OPV for preventing poliomyelitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants<br/> <b>Setting:</b> USA, UK, China, Thailand, Israel, Oman, Guatemala, Bangladesh<br/> <b>Intervention:</b> IPV‐OPV<br/> <b>Comparison:</b> OPV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with OPV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV‐OPV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paralytic wild polio cases</b> </p> <p>(Change in slope at 3 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>−0.2 (−1.3 to 0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−21%</b> </p> <p>(−137% to 95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 ITS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Re‐analysis considering the year of schedule change as transition period</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Vaccine‐associated paralytic polio (VAPP) cases</b> </p> <p>(Range of follow‐up from 2 to 15 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6.6 cases per year</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.0 cases per year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−54.3%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 USA nationwide UBA study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OPV (1990‐6):</b> 46 cases (0.34 cases per million of OPV doses) </p> <p><b>IPV‐OPV (1997‐9):</b> 13 cases, none with IPV‐OPV or all‐IPV schedules </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.64 cases per million newborns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.56 cases per million newborns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−80%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 Russian Federation nationwide UBA study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OPV</b> (1998‐2007): 1 VAPP case per 1.59 million OPV doses </p> <p>I<b>PV‐OPV</b> (2008‐14): 1 case per 4.18 million doses </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 cases</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 case</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−100%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 Hungary nationwide UBA study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OPV</b> (1959‐92): 90 cases </p> <p><b>IPV‐OPV</b> (1992‐2006): 0 cases </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Persons with protective humoral response</b> </p> <p>(Range of follow‐up from 4.4 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1: 973 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>973 per 1000</b><br/> (963 to 982) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.99 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3189</p> <p>(12 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No important differences with other vaccination schemes</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2: 989 per 1000</b> #subgroup with 2 IPV doses </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>989 per 1000</b><br/> (979 to 999) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.99 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2361<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IIbO:</b> 0 (−70 to + 70) persons </p> <p><b>IbObO vs tOPV:</b> −210 (−38 to −344) persons </p> <p><b>IbObO vs bOPV:</b> + 672 (± 428 to + 1018) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3: 962 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>953 per 1000</b><br/> (933 to 972) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/> (0.97 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3184<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> −300 (−180 to −400) persons </p> <p><b>IOO / IOOO:</b> −19 (−39 to 0) persons </p> <p><b>IIO/IIOO/IIIO:</b> −10 (−39 to 10) persons </p> <p><b>IOI:</b> −9 (−47 to + 28) persons </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Neutralising antibodies with 2 IPV doses</b> </p> <p>Geometric mean titres (GMT)</p> <p>(Range of follow‐up from 5 to 16 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1</b> (IIO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>244 lower</b><br/> (−827 to + 339)<sup>SE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>795<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> + 362 (−330 to + 1054) </p> <p><b>IOO:</b> −181 (−594 to 232) </p> <p><b>IIIOO / IIIO:</b> + 439 (−355 to + 1233) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2</b> (IIO) </p> <p><b>P2</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 higher</b> (−84 to + 619)<sup>SE</sup> </p> <p><b>218 lower</b> (−305 to −130)<sup>LE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> <p>(3 RCTs)</p> <p>125</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,c</sup> </b> </p> <p>⊕⊕⊕⊝ <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> −260 (−347 to −174) </p> <p><b>IOO:</b> + 29 (−22 to + 79) </p> <p><b>IIIOO/IIIO:</b> + 486 (−698 to + 1670) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3</b> (IIO) </p> <p><b>P3</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 higher</b> (+ 9 to + 171)<sup>SE</sup> </p> <p><b>592 higher</b> (+ 185 to + 998)<sup>SE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> <p>(3 RCTs)</p> <p>125</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> + 221 (+ 10 to + 432) </p> <p><b>IOO:</b> + 44 (−1.47 to + 90) </p> <p><b>IIIOO/IIIO:</b> + 248 (−181 to + 677) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Persons with polio faecal excretion after OPV challenge</b> </p> <p>(Range of follow‐up from 4.4 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1: 86 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>193 per 1000</b><br/> (60 to 613) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.24</b><br/> (0.70 to 7.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>916<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>c,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2: 279 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>497 per 1000</b><br/> (416 to 598) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b><br/> (1.49 to 2.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>916<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>c</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3: 74 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>173 per 1000</b><br/> (108 to 276) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.35</b><br/> (1.47 to 3.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>916<br/> (2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccination coverage</b> </p> <p>(Follow‐up 24 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91.9%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92.4%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> </p> <p>(0.96 to 1.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 ITS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> (classified by MedDRA) </p> <p>(Range of follow‐up from 5 to 16 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/> (26 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/> (0.46 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1948<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> # <b>2 IPV doses (IIO)</b> was selected as the main subgroup for this outcome since it is the most studied scheme </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>P1</b> , <b>P2</b> , <b>P3</b> : Poliovirus Serotypes 1, 2, 3 respectively; <b>SE</b> : Small effect; <b>ME</b> ; Moderate effect.<b>LE</b>: Large effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>I</b> = IPV, <b>O</b> = OPV, <b>bO</b> = bOPV (see detailed acronyms in <a href="./appendices#CD011260-sec-0176">Appendix 1</a>). </p> <p><sup>a</sup>Serious study limitations: most studies have unclear risk of bias regarding random sequence generation and allocation concealment.<br/> <sup>b</sup>These are data from quasi‐experimental studies and therefore evidence was graded as low, we have not downgraded or upgraded the evidence.<br/> <sup>c</sup>Serious imprecision: confidence interval limits include clinically important increase or reduction of the effect.<br/> <sup>d</sup>Serious inconsistency: considerable heterogeneity but in the same direction. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011260-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">IPV‐OPV compared to IPV for preventing poliomyelitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IPV‐OPV compared to IPV for preventing poliomyelitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants<br/> <b>Setting:</b> USA, UK, China, Guatemala, Chile, Bangladesh<br/> <b>Intervention:</b> IPV‐OPV<br/> <b>Comparison:</b> IPV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV‐OPV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paralytic wild polio cases at 4 years</b> (Change level from IPV‐OPV to IPV) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>−1.2 (−6.2 to 3.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−<b>100%</b> </p> <p>(−517% to 317%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 ITS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Re‐analysis considering the year of schedule change as transition period</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine‐associated paralytic polio cases</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persons with protective humoral response</b> </p> <p>(Range of follow‐up from 4.4 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1</b>: 970 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>972 per 1000<br/> (961 to 980) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.99 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2858<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IOO:</b> −0 (−20 to + 20) persons </p> <p><b>IIO(O):</b> 0 (−10 to + 10) persons </p> <p><b>IbOI:</b> + 46 (0 to + 91) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2</b>: 960 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>931 per 1000<br/> (985 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/> (0.95 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2907<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> −236 (−89 to −354) persons </p> <p><b>IOO:</b> 0 (−39 to + 39) persons </p> <p><b>IbOI:</b> −43 (−103 to + 17) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3</b>: 972 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>962 per 1000<br/> (953 to 982) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/> (0.97 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2620<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IOO:</b> −10 (−30 to + 20) persons </p> <p><b>IIO(O):</b> −10 (−40 to + 20) persons </p> <p><b>IbOI:</b> + 9 (−37 to + 47) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Comment: A nationwide ITS (Denmark) reported a median proportion of persons with protective humoral response for PV1, 2 and 3 as 82.06%, 91.94% and 76.67%, respectively, during IPV scheme; the proportions were higher during IPV‐OPV scheme: 98.44%; 97.67%; and 97.57%, respectively. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Neutralising antibodies with 2 IPV doses</b> </p> <p>Geometric mean titres</p> <p>(Follow‐up 5 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1</b> (IIO) </p> <p><b>P1</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>768 higher</b> (+ 338 to + 1198)<sup>ME</sup> </p> <p><b>867 higher</b> (+ 479 to + 1254)<sup>ME</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363</p> <p>(2 RCTs)</p> <p>127</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>b,c</sup> </b> </p> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> + 1521 (+ 1085 to + 1956) </p> <p><b>IOO:</b> + 799 (+ 531 to + 1068) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2</b> (IIO) </p> <p><b>P2</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2224 higher</b> (−1146 to + 5594)<sup>LE</sup> </p> <p><b>83 lower</b> (−133 to −34)<sup>LE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362</p> <p>(2 RCTs)</p> <p>127</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Very low<sup>a,b,e</sup> </b> </p> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> −126 (−175 to −77) </p> <p><b>IOO:</b> + 142 (+ 58 to + 227) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3</b> (IIO) </p> <p><b>P3</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 higher</b> (−212 to + 581)<sup>SE</sup> </p> <p><b>698 higher</b> (+ 301 to + 1096)<sup>SE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> <p>(2 RCTs)</p> <p>127</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Very low<sup>a,b,c</sup> </b> </p> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> + 328 (+ 135 to + 520) </p> <p><b>IOO:</b> + 110 (−78 to + 299) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Persons with faecal polio excretion after OPV challenge</b> </p> <p>(Range of follow‐up from 4.4 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1</b>: 427 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000<br/> (60 to 841) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b><br/> (0.14 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a,b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ibOI:</b> −356 (−297 to −394) persons </p> <p><b>IIO/IIOO:</b> + 7 (−72 to + 148) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2</b>: 572 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000<br/> (177 to 537) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b><br/> (0.31 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1351<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ibOI/IIbO:</b> + 7 (−72 to + 148) persons </p> <p><b>IIO/IIOO:</b> −329 (−282 to −357) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3</b>: 450 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000<br/> (144 to 212) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.39</b><br/> (0.32 to 0.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ibOI:</b> −233 (−170 to −274) persons </p> <p><b>IIO/IIOO:</b> −470 (−392 to −533) persons </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccination coverage</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>(≥ 1 symptom related to study drug or not)</p> <p>(Range of follow‐up from 5 to 7 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000<br/> (57 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/> (0.60 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1063<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p># <b>2 IPV doses (IIO)</b> was selected as the main result for this outcome since it is the most frequent scheme. </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>P1</b> , <b>P2</b> , <b>P3</b>: Poliovirus Serotypes 1, 2, 3 respectively. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>I</b> = IPV, <b>O</b> = OPV, <b>bO</b> = bOPV (see detailed acronyms in <a href="./appendices#CD011260-sec-0176">Appendix 1</a>). </p> <p><sup>a</sup>Serious imprecision: confidence interval limits include clinically important increase or reduction of the effect.<br/> <sup>b</sup>Serious study limitations: most studies have unclear risk of bias regarding random sequence generation and allocation concealment.<br/> <sup>c</sup>Considerable heterogeneity but in the same direction.<br/> <sup>d</sup>Serious imprecision: only one study with low number of participants.<br/> <sup>e</sup>Very serious imprecision: confidence interval limits include a marked effect increase or reduction. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011260-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">IPV(3)‐OPV compared to IPV(2)‐OPV for preventing poliomyelitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>3 IPV‐OPV compared to 2 IPV‐OPV for preventing poliomyelitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> preventing poliomyelitis<br/> <b>Setting:</b> India<br/> <b>Intervention:</b> 3 IPV‐OPV<br/> <b>Comparison:</b> 2 IPV‐OPV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV(2)‐OPV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV(3)‐OPV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paralytic polio</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VAPP cases</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Persons with protective humoral response</b> </p> <p>(Follow‐up 7 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1: 1000 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>980 per 1000</b><br/> (930 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/> (0.93 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2: 1000 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/> (970 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.97 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3: 989 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>998 per 1000</b><br/> (959 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b><br/> (0.97 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neutralising antibodies</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persons with faecal excretion after OPV challenge</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccination coverage</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% Cl) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious imprecision: confidence interval limits include clinically important increase or reduction of the effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011260-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011260-sec-0023"></div> <p>Please see the Glossary in <a href="./appendices#CD011260-sec-0176">Appendix 1</a> for a list of acronyms used in this review. </p> <section id="CD011260-sec-0024"> <h3 class="title" id="CD011260-sec-0024">Description of the condition</h3> <p>Poliomyelitis is a communicable disease in humans that mainly affects unimmunised children under five years of age. Wild poliovirus (WPV), which has three strains (serotype 1, 2 and 3), causes paralysis. The paralysis is also caused, albeit rarely, by the oral polio vaccine (OPV), which involves the same three serotypes. </p> <p>WPV spreads primarily by faecal‐to‐oral transmission in poor sanitary conditions. It can also spread through pharyngea‐to‐oral secretions. The virus enters the body through the oral and nasal cavities, replicates in the gastrointestinal tract, and is then shed, through faeces, into the environment. Initial symptoms of polio infection include fever, fatigue, headache, vomiting, stiffness in the neck, and pain in the limbs. One in 200 infections leads to irreversible paralysis. Five to 10 per cent of those paralysed die when their breathing muscles become immobilised (<a href="./references#CD011260-bbs2-0113" title="World Health Organization. Poliomyelitis. Key facts. www.who.int/en/news‐room/fact‐sheets/detail/poliomyelitis (accessed 17 January 2016). ">WHO 2015b</a>). In the pre‐vaccination era, most cases of paralysis were caused by serotype 1. </p> <p>Since the introduction of OPV, four of the six regions of the World Health Organization (WHO) have been certified free of WPV: the Americas in 1994; Western Pacific in 2000; Europe in 2002; and South East Asia in 2014. Approximately 80% of the world’s people now live in polio‐free areas (<a href="./references#CD011260-bbs2-0039" title="Centers for Disease Control and Prevention. Updates on CDC’s polio eradication efforts. www.cdc.gov/polio/updates/2015/2015‐1211.htm (accessed 9 December 2015). ">CDC 2015</a>). Only two countries remain polio endemic in 2019 (Afghanistan and Pakistan), compared to three countries in 2018 (Afghanistan, Pakistan and Nigeria) and 125 countries in 1988 (<a href="./references#CD011260-bbs2-0064" title="Global Polio EradicationInitiative . Global wild poliovirus 2012 ‐ 2018. polioeradication.org/wp‐content/uploads/2018/01/global‐wild‐poliovirus‐2012‐2018‐20180110.pdf (accessed 10 June 2018). ">GPEI 2018</a>). The virus continues to circulate unabated in these less‐developed countries because of poor seroconversion rates among the recipients of OPV (<a href="./references#CD011260-bbs2-0057" title="FadenH . Poliovirus vaccination: a trilogy. Journal of Infectious Diseases1993;168(1):25‐8. [DOI: 10.1093/infdis/168.1.25; PUBMED: 8515124] ">Faden 1993</a>), coupled with programmatic issues such as reaching vulnerable children in remote areas and ensuring sustainable financial and political support for the programmes. Failure to eradicate polio from these few countries could result in as many as 200,000 new cases every year, within 10 years, all over the world. Thus, as long as a single child remains infected, children in all countries are at risk of contracting polio. </p> <p>While there is no cure for polio, polio vaccines can protect a child for life (<a href="./references#CD011260-bbs2-0113" title="World Health Organization. Poliomyelitis. Key facts. www.who.int/en/news‐room/fact‐sheets/detail/poliomyelitis (accessed 17 January 2016). ">WHO 2015b</a>). However, continued use of OPV has been linked to vaccine‐associated paralytic poliomyelitis (VAPP) and vaccine‐derived polioviruses (VDPVs) (<a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a>). VAPP is defined as an event of paralysis that occurs in a vaccinee between seven and 60 days after receiving a dose of OPV, with the neurological deficit remaining 60 days after onset. It is caused by the OPV virus. Using risk estimates of VAPP from previously published studies from different countries, <a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a> calculated the risk of VAPP as 4.7 cases per million births (range = 2.4 to 9.7 cases), leading to a global annual burden estimate of 498 cases (range = 255 to 1018 cases). When the analysis was restricted to estimates from countries that currently use OPV, the VAPP risk was 3.8 cases per million births (range = 2.9 to 4.7 cases) and a burden of 399 cases (range = 306 to 490) (<a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a>). The incidence of recipient VAPP in different countries has been estimated to range from 0.33 to 19.08 cases per million births (<a href="./references#CD011260-bbs2-0092" title="MinorP . Vaccine‐derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine2009;27(20):2649‐52. [DOI: 10.1016/j.vaccine.2009.02.071; PUBMED: 19428874] ">Minor 2009</a>). </p> <p>VDPVs are Sabin viruses whose genetic sequence have mutated, diverging from the original OPV strain as a result of prolonged replication or transmission and reacquired neurovirulence. VDPV can be further subcategorised into circulating vaccine‐derived poliovirus (cVDPV), which circulates in populations that are seriously under‐vaccinated; immunodeficiency‐related vaccine‐derived poliovirus (iVDPV), which occurs in people who are unable to develop an immune response (i.e. those with rare immunodeficiency disorders); and ambiguous vaccine‐derived poliovirus (aVDPV), isolated cases of which very little is known (<a href="./references#CD011260-bbs2-0114" title="World Health Organization. Circulating vaccine‐derived poliovirus cases, 2000‐2015. https://drive.google.com/file/d/1sJqwL3jaZZcBjMWU3TXcMBBB7MKIKQ7H/view?usp=sharing (accessed 17 January 2016). ">WHO 2015c</a>). Unlike serotypes 1 and 3, serotype 2 continues to cause a number of cases of cVPDP (cVPDP‐2; 65 cases in 2013, 56 in 2014, 30 in 2015 and 5 in 2016), thus complicating the epidemiology of polio as well as vaccine selection and scheduling for supplementary immunisation activities in many countries (<a href="./references#CD011260-bbs2-0117" title="World Health Organization. Polio case count. extranet.who.int/polis/public/CaseCount.aspx (accessed 6 May 2017). ">WHO 2017</a>). Fewer than 90 cVDPV cases per year were reported to the WHO between 2000 and 2016, with the exception of the year 2009 when the number of cases peaked, mainly due to a large outbreak in Nigeria. Considering that time period, more than 94% of cVDPV cases and 66% of iVDPV cases identified since the introduction of OPV were due to serotype 2; cVDPV due to serotype 1 represented 4% but in 2015 to 2016 it went up to 66% (<a href="./references#CD011260-bbs2-0077" title="JorbaJ , DiopOM , IberJ , SutterRW , WassilakSG , BurnsCC . Update on vaccine‐derived polioviruses ‐ worldwide, January 2015 ‐ May 2016. Morbidity and Mortality Weekly Report2016;65(30):763‐9. [DOI: 10.15585/mmwr.mm6530a3; PUBMED: 27491079] ">Jorba 2016</a>). cVDPV‐2 is the most represented strain, accounting for 85.8% of all reported cases (<a href="./references#CD011260-bbs2-0086" title="LopalcoPL . Wild and vaccine‐derived poliovirus circulation, and implications for polio eradication. Epidemiology and Infection2017;145(3):413‐9. [DOI: 10.1017/S0950268816002569; PUBMED: 27866483] ">Lopalco 2017</a>). Using the WHO and United Nations databases, we conducted a proportion meta‐analysis (using the random‐effects model), to determine the global incidence of cases of cVDPV by WHO region and by polio vaccination scheme. Between 2000 and 2016, 798 cases of cVDPV were reported in 25 countries around the world. None of these cases occurred with the inactivated polio vaccine (IPV), and only two cases occurred with IPV‐OPV. The remaining cases (99.7%) occurred with OPV or OPV‐IPV, representing a combined annual incidence of 14 cVDPV/million (95% confidence interval (CI) 13 to 15), ranging annually from 3 to 26 cVDPV/million. Probably the most remarkable finding is that there is no evidence that cVDPV tends to disappear and it is virtually only associated with exclusive use of OPV (<a href="./references#CD011260-bbs2-0041" title="CiapponiA , GibbonsL . Global incidence of circulating vaccine‐derived poliovirus (cVDPV) during the period 2000‐2016: meta‐analysis [Incidencia mundial de poliovirus circulantes de origen vacunal (cVDPV) durante el período 2000‐2016: meta‐análisis]. XVI Reunión Anual de la Red Cochrane Iberoamericana: Síntesis y transferencia del conocimiento; 2017 Jun 5‐7; Medellín (CO). 2017. ">Ciapponi 2017</a>). </p> </section> <section id="CD011260-sec-0025"> <h3 class="title" id="CD011260-sec-0025">Description of the intervention</h3> <p>Immunisation against poliovirus infection represents one of the world's greatest medical achievements. The incidence of poliomyelitis has declined dramatically since the introduction and widespread use of live oral polio vaccine (OPV) and inactivated polio vaccine (IPV). It is now recommended that all children should receive four doses of vaccine before entering school. Regimens of IPV only, OPV only, sequential IPV and OPV (IPV‐OPV), the inverse (OPV‐IPV) or simultaneous IPV + OPV are acceptable. Each regimen has advantages and disadvantages. In special circumstances, one of the regimens is preferred or recommended. </p> <p><b>OPV</b> contains a live, attenuated (weakened) vaccine‐virus (Sabin vaccine‐virus). Low‐ and middle‐income countries (LMICs) rely on OPV to control WPV transmission because of its low cost, ease of administration, as well as induction of mucosal (gut) and herd (i.e. the indirect protection of unvaccinated children) immunity that limit the spread of the virus. There are four different types of OPV: trivalent OPV (tOPV); monovalent OPV serotype 1 (mOPV1); monovalent OPV serotype 3 (mOPV3); and bivalent OPV (bOPV), which contains serotypes 1 and 3. </p> <p>tOPV has a simplified immunisation schedule, and consequently, has been the vaccine of choice for routine immunisation and achieving global polio eradication. Three doses given at least two months apart are sufficient to develop an optimal immune response; antibody prevalence to all three serotypes approximates 96% after the third dose (<a href="./references#CD011260-bbs2-0089" title="McBeanAM , ThomsML , AlbrechtP , CuthieJC , BernierR . Serologic response to oral polio vaccine and enhanced‐potency inactivated polio vaccines. American Journal of Epidemiology1988;128(3):615‐28. [DOI: 10.1093/oxfordjournals.aje.a115009; PUBMED: 2843039] ">McBean 1988</a>), with 84% to 98% of those vaccinated showing detectable serum antibodies to all three serotypes five years after primary immunisation (<a href="./references#CD011260-bbs2-0080" title="KrugmanRD , HardyGEJr , SellersC , ParkmanPD , WitteJJ , MeyerBC , et al. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine. Pediatrics1977;60(1):80‐2. [PUBMED: 195265] ">Krugman 1977</a>). </p> <p>In developing countries, however, multiple doses of tOPV given at 6, 10, and 14 weeks of age, as recommended by the WHO Expanded Program for Immunization (EPI) (<a href="./references#CD011260-bbs2-0106" title="SutterRW , PrevotsDR , CochiSL . Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States. Pediatric Clinics of North America2000;47(2):287‐308. [PUBMED: 10761505] ">Sutter 2000</a>), have been shown to produce active immunity in only a small proportion of infants. Following this three‐dose regimen, low seroconversion rates have been documented in many locations, averaging 73% for serotype 1, 90% for serotype 2 and 70% for serotype 3 (<a href="./references#CD011260-bbs2-0096" title="PatriarcaPA , WrightPF , JohnTJ . Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Reviews of Infectious Diseases1991;13(5):926‐39. [PUBMED: 1660184] ">Patriarca 1991</a>). Diarrhoeal disease and co‐infection with other enteroviruses at the time of immunisation are major factors that affect immunity following immunisation. </p> <p>With the eradication of WPV serotype 2 by 1999, and continued circulation of WPV serotypes 1 and 3 in select geographic areas, bOPV was introduced in endemic areas. Like monovalent OPV (either serotype 1 or serotype 3), bOPV was developed to support global polio eradication efforts in resource‐limited settings (<a href="./references#CD011260-bbs2-0044" title="CáceresVM , SutterRW . Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clinical Infectious Diseases2001;33(4):531‐41. [DOI: 10.1086/321905; PUBMED: 11462191] ">Cáceres 2001</a>; <a href="./references#CD011260-bbs2-0066" title="GrasslyNC , FraserC , WengerJ , DeshpandeJM , SutterRW , HeymannDL , et al. New strategies for the elimination of polio from India. Science2006;314(5802):1150‐3. [DOI: 10.1126/science.1130388; PUBMED: 17110580] ">Grassly 2006</a>; <a href="./references#CD011260-bbs2-0107" title="SutterRW , JohnTJ , JainH , AgarkhedkarS , RamananPV , VermaH , et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double‐blind, controlled trial. Lancet2010;376(9753):1682‐8. [DOI: 10.1016/S0140‐6736(10)61230‐5; PUBMED: 20980048] ">Sutter 2010</a>). Schemes containing bOPV are attractive approaches because these formulations, like monovalents formulations, have superior immunogenicity to tOPV for the corresponding serotype (<a href="./references#CD011260-bbs2-0044" title="CáceresVM , SutterRW . Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clinical Infectious Diseases2001;33(4):531‐41. [DOI: 10.1086/321905; PUBMED: 11462191] ">Cáceres 2001</a>; <a href="./references#CD011260-bbs2-0066" title="GrasslyNC , FraserC , WengerJ , DeshpandeJM , SutterRW , HeymannDL , et al. New strategies for the elimination of polio from India. Science2006;314(5802):1150‐3. [DOI: 10.1126/science.1130388; PUBMED: 17110580] ">Grassly 2006</a>; <a href="./references#CD011260-bbs2-0107" title="SutterRW , JohnTJ , JainH , AgarkhedkarS , RamananPV , VermaH , et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double‐blind, controlled trial. Lancet2010;376(9753):1682‐8. [DOI: 10.1016/S0140‐6736(10)61230‐5; PUBMED: 20980048] ">Sutter 2010</a>), and without the interference from the serotype 2 component of the trivalent formulation, they may be more effective in treating outbreaks caused by a single WPV serotype (<a href="./references#CD011260-bbs2-0067" title="GrasslyNC , JafariH , BahlS , DurraniS , WengerJ , SutterRW , et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. Journal of Infectious Diseases2009;200(5):794‐801. [DOI: 10.1086/605330; PUBMED: 19624278] ">Grassly 2009</a>). </p> <p><b>IPV</b> is an inactivated (dead) form of WPV, which is produced from the three serotypes. Since 1978, a new method of production resulted in higher potency per dose and significantly greater immunogenicity than the original IPV (<a href="./references#CD011260-bbs2-0063" title="GoldR . Enhanced inactivated poliovirus vaccine. Canadian Journal of Infectious Diseases1994;5(4):152. [DOI: 10.1155/1994/153783] ">Gold 1994</a>). In this review, when we use the term IPV we are referring to enhanced potency IPV, because the original one is obsolete. Unlike OPV, IPV never causes VAPP, and hence is the vaccine of choice for routine immunisation in high‐income countries (HICs). </p> <p><b>Sequential immunisation schedules of IPV‐OPV</b> of at least three doses, starting with one or more doses of IPV and followed by one or more doses of OPV, could offer the same benefits of both vaccines and avoid the risks of VAPP and VDPV, which are associated with OPV alone. </p> <p>The World Health Organization (WHO), the United Nations Children's Fund (UNICEF), the Rotary Foundation, the US Centers for Disease Control and Prevention (CDC) and The Gates Foundation have spearheaded the campaign to end polio through the Global Polio Eradication Initiative (GPEI), which helps to co‐ordinate vaccination campaigns worldwide, as well as environmental monitoring and evaluation of the cause of incident cases of paralysis associated to the wild or vaccinal poliovirus. </p> </section> <section id="CD011260-sec-0026"> <h3 class="title" id="CD011260-sec-0026">How the intervention might work</h3> <p>The introduction of IPV has stimulated the prospects of using IPV and OPV simultaneously. The combined vaccine schedule could reduce the frequency of VAPP and provide good mucosal immunity. Several studies have suggested that two doses of IPV followed by two doses of OPV provide excellent systemic and local immunity against polioviruses serotypes 1, 2, and 3 (<a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0057" title="FadenH . Poliovirus vaccination: a trilogy. Journal of Infectious Diseases1993;168(1):25‐8. [DOI: 10.1093/infdis/168.1.25; PUBMED: 8515124] ">Faden 1993</a>; <a href="./references#CD011260-bbs2-0089" title="McBeanAM , ThomsML , AlbrechtP , CuthieJC , BernierR . Serologic response to oral polio vaccine and enhanced‐potency inactivated polio vaccines. American Journal of Epidemiology1988;128(3):615‐28. [DOI: 10.1093/oxfordjournals.aje.a115009; PUBMED: 2843039] ">McBean 1988</a>). At least two doses of IPV are necessary to induce more than 90% of protective antibodies against polioviruses before the first dose of OPV is administered. A non‐Cochrane systematic review found that IPV did not induce sufficient intestinal mucosal immunity to reduce the prevalence of faecal virus shedding after challenge with OPV, although there was some evidence that it could reduce the quantity of virus shed (<a href="./references#CD011260-bbs2-0075" title="HirdTR , GrasslyNC . Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLOS Pathogens2012;8(4):e1002599. [DOI: 10.1371/journal.ppat.1002599; PMC3330118; PUBMED: 22532797] ">Hird 2012</a>). </p> </section> <section id="CD011260-sec-0027"> <h3 class="title" id="CD011260-sec-0027">Why it is important to do this review</h3> <p>In January 1997, the Advisory Committee on Immunization Practices (ACIP) recommended the adoption of a sequential IPV‐OPV immunisation schedule for the USA (<a href="./references#CD011260-bbs2-0038" title="Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports1997;46(RR‐3):1‐25. [www.cdc.gov/mmwr/PDF/rr/rr4603.pdf; PUBMED: 9026708] ">CDC 1997</a>). The schedule of IPV at two months and four months of age, followed by OPV at 12 to 18 months and again at four to six years, was intended to minimise the risk for VAPP while maintaining population immunity to the potential introduction of WPV. This switch to a schedule containing IPV represented one of the most significant changes to US vaccine policy (<a href="./references#CD011260-bbs2-0057" title="FadenH . Poliovirus vaccination: a trilogy. Journal of Infectious Diseases1993;168(1):25‐8. [DOI: 10.1093/infdis/168.1.25; PUBMED: 8515124] ">Faden 1993</a>; <a href="./references#CD011260-bbs2-0078" title="KewOM , WrightPF , AgolVI , DelpeyrouxF , ShimizuH , NathansonN , et al. Circulating vaccine‐derived polioviruses: current state of knowledge. Bulletin of the World Health Organization2004;82(1):16‐23. [PMC2585883; PUBMED: 15106296] ">Kew 2004</a>). It resulted in considerable concern that parents might not want their children to receive numerous, simultaneous injections; that physicians might be reluctant to administer multiple injections at a single visit; and that the change to a sequential IPV‐OPV vaccination schedule would lead to reduced vaccination coverage of children. However, a study that followed children in two large, west coast, US health maintenance organisations (HMO) and evaluated a number of different measures of their immunisation coverage at one and two years of age showed that the changeover from an OPV‐only schedule to one containing IPV had little, if any, negative impact on vaccine coverage (<a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>). </p> <p>In 2012, the Strategic Advisory Group of Experts on Immunization (<a href="./references#CD011260-bbs2-0111" title="WHO . Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 ‐ conclusions and recommendations. Relevé épidémiologique hebdomadaire2013;88(1):1‐16. [www.who.int/wer/2013/wer8801.pdf; PUBMED: 23311010] ">WHO 2012</a>), the body responsible for advising the WHO on global vaccination policy, recommended the replacement of tOPV with bOPV in all countries by 2016, preceded by the introduction of at least one dose of IPV in routine immunisation programmes. This schedule was implemented in April 2016 (<a href="./references#CD011260-bbs2-0095" title="Pan American Health Organization. Switch from tOPV to bOPV. www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=11015:topv‐bopv‐supporting‐technical‐documents&amp;Itemid=1707&amp;lang=en (accessed 6 May 2017). ">PAHO 2017</a>). </p> <p>At present, 49 countries use sequential IPV‐OPV vaccination schedules (<a href="#CD011260-tbl-0004">Table 1</a>), and 17 countries have used it in the past (<a href="#CD011260-tbl-0005">Table 2</a>); 86 countries use an OPV‐IPV schedule; four countries use OPV + IPV; 51 countries use IPV exclusively; and five use OPV exclusively. Although the WHO strategy aims to stop OPV vaccination completely and replace it with IPV vaccination, this goal is not yet close, and the sequential IPV‐OPV vaccination schedule could have an important role during the transition. A systematic review of the evidence on sequential IPV‐OPV vaccination schedules could facilitate an evidence‐based, decision‐making process. </p> <div class="table" id="CD011260-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Countries currently using sequential IPV‐OPV schemes</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Year of introduction in entire country</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>IPV</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>OPV</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Doses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Schedule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Doses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Schedule</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigua and Barbuda</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months; 2, 6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Argentina</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 15‐18 months; 6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bahamas (the)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bahrain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 18 months; 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 5 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barbados</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 18 months; 4.5, 10‐11 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 4.5, 10‐11 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belize</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bolivia (Plurinational State of)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bosnia and Herzegovina</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 5‐6 months; 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months; 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 15 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chile</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4, months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 5 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dominica</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 3, 10‐12 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dominican Republic (the)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ecuador</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, &gt; 1 year</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Georgia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 3, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 7, 18 months; 4‐5, ≥ 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grenada</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guatemala</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guyana</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18, months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haiti</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5, 3.5, 9 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Honduras</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Israel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jamaica</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5, 3, 5‐6, 18 months; 4‐6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 5‐6, 18 months; 4‐6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jordan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4, 5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 9, 18 months; 6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kazakhstan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months OR 3, 18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kuwait</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 12, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lebanon</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4‐5, 10‐12, 16‐18 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexico</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 6 months; &lt; 5 Years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montenegro</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9, 17, 23 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months; 6, 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicaragua</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oman</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 weeks‐2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 6, 18 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paraguay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peru</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qatar</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4‐6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russian Federation (the)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4.5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18, 20 months; 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saint Kitts and Nevis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4.5‐5, 15 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saint Lucia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 5, 11‐12 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saint Vincent and the Grenadines</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saudi Arabia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 12, 18 months; 6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serbia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 3.5, 18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suriname</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The former Yugoslav Republic of Macedonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐3.5, 6‐18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trinidad and Tobago</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 3, 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4‐5 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tunisia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 6,12, 18 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 18 months; 6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ukraine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1959</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 18 months; 6, 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>United Arab Emirates</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 5‐6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venezuela (Bolivarian Republic of)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4‐5 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>IPV:</b> inactivated poliovirus vaccine; <b>OPV:</b> oral poliovirus vaccine. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Sources:</b> WHO vaccine‐preventable diseases: monitoring system. 2018 global summary, available at: <a href="http://apps.who.int/immunization_monitoring/globalsummary/schedules" target="_blank">apps.who.int/immunization_monitoring/globalsummary/schedules</a> (accessed 6 June 2018) and <a href="http://www.who.int/entity/immunization/monitoring_surveillance/data/year_vaccine_introduction.xls?ua=1" target="_blank">www.who.int/entity/immunization/monitoring_surveillance/data/year_vaccine_introduction.xls?ua=1</a> (accessed 6 June 2018) </p> <p>In summary, <b>86</b> countries use <b>OPV‐IPV</b> , <b>3 OPV + IPV</b> , <b>51 exclusively IPV</b> and <b>5 exclusively OPV.</b> </p> <p>The number of countries using use a single IPV dose varies according the scheme used: with IPV‐OPV scheme, 21/49 countries (43%) and with OPV‐IPV or OPV+IPV 82/89 (92%). </p> </div> </div> <div class="table" id="CD011260-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Countries that have used sequential IPV‐OPV schemes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Schemes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Belarus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 IPV, 3 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014‐2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bermuda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 1 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978‐1979</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyprus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 3 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003‐2008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Croatia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV, 6 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003‐2008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV, 3 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1968‐1997</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gaza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 OPV, 2 IPV/OPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978‐1988</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hungary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV, 5 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1992‐2006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999‐2002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latvia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV, 3 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001‐2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithuania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004‐2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 IPV, 1 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009‐2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 IPV, 1 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1958‐2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV, 5 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008‐2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syrian Arab Republic (The)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 IPV, 4 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2008‐2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 1 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997‐1999</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>West Bank</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 IPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978‐1988</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>IPV:</b> inactivated poliovirus vaccine; <b>OPV:</b> oral poliovirus vaccine. </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011260-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011260-sec-0028"></div> <p>To assess the effectiveness, safety, and immunogenicity of sequential inactivated poliovirus vaccine‐oral poliovirus vaccine (IPV‐OPV) immunisation schemes compared to either OPV or IPV alone. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011260-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011260-sec-0029"></div> <section id="CD011260-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011260-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), quasi‐RCTS, controlled before‐and‐after studies (CBAs), uncontrolled before‐and‐after studies (UBAs), interrupted time series studies (ITSs) and controlled interrupted time series studies (CITSs) that meet the inclusion criteria listed in the <a href="./references#CD011260-bbs2-0053" title="EffectivePractice , Organisation ofCare . Cochrane Effective Practice and Organisation of Care Review Group: data collection checklist. bit.ly/1zXPg9y (accessed 12 May 2014). ">EPOC 2011a</a> data collection checklist (See <a href="./appendices#CD011260-sec-0177">Appendix 2</a>). </p> <p>For vaccine‐associated paralytic polio (VAPP) only, we also accepted nationwide UBA studies evaluating the impact of changing the vaccination policy to sequential IPV‐OPV vaccination schemes (See <a href="./appendices#CD011260-sec-0177">Appendix 2</a>). </p> </section> <section id="CD011260-sec-0032"> <h4 class="title">Types of participants</h4> <p>People entitled to receive IPV‐OPV vaccination schemes.</p> </section> <section id="CD011260-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD011260-sec-0034"> <h5 class="title">Experimental intervention</h5> <p> <ul id="CD011260-list-0001"> <li> <p>Sequential IPV‐OPV schedule: one or more doses of IPV followed by one or more doses of OPV. </p> </li> </ul> </p> </section> <section id="CD011260-sec-0035"> <h5 class="title">Comparator intervention</h5> <p> <ul id="CD011260-list-0002"> <li> <p>IPV alone.</p> </li> <li> <p>OPV alone.</p> </li> <li> <p>Non‐sequential combinations of IPV‐OPV.</p> </li> </ul> </p> </section> </section> <section id="CD011260-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD011260-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011260-list-0003"> <li> <p>Paralytic polio, measured as change in level and change in slope by ITS.</p> </li> </ul> </p> </section> <section id="CD011260-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011260-list-0004"> <li> <p>Vaccine‐associated paralytic polio (VAPP), measured as number of VAPPs or VAPP per million of OPV doses. </p> </li> <li> <p>Vaccine‐derived poliovirus (VDPV) shedding in stool, measured as number of VDPVs or VDPV per million of OPV doses. </p> </li> <li> <p>Protective immune responses, measured as risk ratio (RR) of protective humoral response and mean titres of neutralising antibody by serotype (humoral). </p> </li> <li> <p>Intestinal immunity, measured as RR of polio faecal excretion after OPV challenge by serotype. </p> </li> <li> <p>Vaccination coverage in children, measured as average proportion of vaccine coverage.</p> </li> <li> <p>Safety, measured as RR of serious adverse events (SAEs), and proportion of SAEs.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011260-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011260-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We did not use any methods filters or limit the searches by date or language. We first searched the following databases in August 2014, We updated the searches in August 2015, July 2016, August 2018 and May 2019, Exact search dates for each search are reported in <a href="./appendices#CD011260-sec-0178">Appendix 3</a>. </p> <p> <ul id="CD011260-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 5) in the Cochrane Library and which includes the Cochrane Developmental, Psychosocial and Learning Problems Specialised Register (searched 14 May 2019). </p> </li> <li> <p>MEDLINE Ovid (1946 to April Week 3 2019).</p> </li> <li> <p>Embase Ovid (1980 to 2019 Week 18).</p> </li> <li> <p>Science Citation Index Web of Science (1970 to 14 May 2019).</p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science Web of Science (1990 to 23 July 2019).</p> </li> <li> <p>Scopus Elsevier (searched 23 July 2019).</p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database; <a href="http://regional.bvsalud.org/php/index.php?lang=en" target="_blank">regional.bvsalud.org/php/index.php?lang=en</a>; searched 14 May 2019). </p> </li> <li> <p><i>Cochrane Database of Systematic Reviews</i> (CDSR; 2019, Issue 7), part of the Cochrane Library (searched 31 July 2019). </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE; 2015, Issue 2, final issue of DARE), part of the Cochrane Library (searched 11 August 2015). </p> </li> <li> <p>IndMED (Indian Medical Journals; <a href="http://indmed.nic.in/" target="_blank">indmed.nic.in</a>; last searched 11 May 2018; access attempted 31 July 2019 but website could not be reached). </p> </li> <li> <p>IBECS (Spanish Bibliographical Index in Health Sciences; <a href="http://regional.bvsalud.org/php/index.php?lang=en" target="_blank">regional.bvsaud.org/php/index.php?lang=en</a>; searched 14 May 2019). </p> </li> <li> <p>PAHO HQ Library Catalog (Pan American Health Organization Headquarters Library Catelogue; <a href="http://regional.bvsalud.org/php/index.php?lang=en" target="_blank">regional.bvsalud.org/php/index.php?lang=en</a>; searched 2 June 2019). </p> </li> <li> <p>WHOLIS (World Health Organization Library Information System; <a href="http://regional.bvsalud.org/php/index.php?lang=en" target="_blank">regional.bvsalud.org/php/index.php?lang=en</a>; searched 23 July 2019). </p> </li> <li> <p>IMSEAR (Index Medicus for South‐East Asia Region; <a href="https://www.globalindexmedicus.net/" target="_blank">www.globalindexmedicus.net/</a>; searched 31 July 2019). </p> </li> <li> <p>SciELO (Scientific Electronic Library Online; <a href="http://regional.bvsalud.org/php/index.php?lang=en" target="_blank">regional.bvsalud.org/php/index.php?lang=en</a>; searched 1 June 2019). </p> </li> <li> <p>African Index Medicus (AIM; <a href="http://indexmedicus.afro.who.int/" target="_blank">indexmedicus.afro.who.int</a>; searched 31 July 2019). </p> </li> <li> <p>IMEMR (Index Medicus for the Eastern Mediterranean Region;<a href="https://www.globalindexmedicus.net/" target="_blank">www.globalindexmedicus.net/</a>; searched 31 July 2019). </p> </li> <li> <p>ICTRP (International Clinical Trials Registry Platform; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>; searched 31 July 2019). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 2 June 2019). </p> </li> <li> <p>ISRCTN registry (previously mRCT; <a href="https://www.isrctn.com/" target="_blank">www.isrctn.com/</a>; searched 2 June 2019). </p> </li> </ul> </p> <p>The search strategies for each database are reported in <a href="./appendices#CD011260-sec-0179">Appendix 4</a>. </p> </section> <section id="CD011260-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of relevant studies, and contacted authors of included studies to identify any additional published or unpublished data. In addition, we searched for reports of adverse effects on the websites of the following organisations. </p> <p> <ul id="CD011260-list-0006"> <li> <p>Current Problems in Pharmacovigilance (<a href="http://www.mhra.gov.uk" target="_blank">www.mhra.gov.uk</a>). </p> </li> <li> <p>Australian Adverse Drug Reactions Bulletin (from 1995 to 2009), which was replaced by the <a href="https://www.tga.gov.au/committee/advisory-committee-safety-medicines-acsom" target="_blank">Advisory Committee on the Safety of Medicines (ACSOM)</a> in January 2010. </p> </li> <li> <p>European Public Assessment Reports from the European Medicines Evaluation Agency (<a href="http://www.emea.eu" target="_blank">www.emea.eu</a>). </p> </li> <li> <p>Food and Drug Administration (FDA) Medwatch (<a href="http://www.fda.gov/medwatch" target="_blank">www.fda.gov/medwatch</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011260-sec-0042"> <h3 class="title" id="CD011260-sec-0042">Data collection and analysis</h3> <p>We performed the systematic review following the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011260-bbs2-0072" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We report here only the methods that we were able to use. Methods that we had planned to use (<a href="./references#CD011260-bbs2-0123" title="CiapponiA , BardachA , Rey AresL , GlujovskyD , CafferataML , RomanoM , et al. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD011260] ">Ciapponi 2014</a>), but could not be performed, are reported in <a href="#CD011260-tbl-0006">Table 3</a>. </p> <div class="table" id="CD011260-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Planned methods that could not be performed</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Section</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unused methods</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason for nonuse</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of treatment effect</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dichotomous data</b> </p> <p>We planned to use the Peto odds ratio (OR) for very infrequent outcomes. We planned to report the risk difference (RD) if the result obtained by this measure was different from the RR. </p> <p><b>Continuous</b> </p> <p>We planned to calculate the standardised mean difference (SMD) with 95% CI if the same outcomes were measured by different scales. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not necessary.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unit of analysis issues</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For studies in which clusters of individuals were randomised (cluster‐RCTs, cluster quasi‐RCTs) or allocated (cluster CBAs) to intervention groups, but where inference is intended at the level of the individual, we planned to analyse them appropriately to account for correlation of observations within clusters. Standard statistical methods assume independence of observations, and their use in these types of studies will generally result in artificially small P values and overly narrow CIs for the effect estimates (<a href="./references#CD011260-bbs2-0110" title="UkoumunneOC , GullifordMC , ChinnS , SterneJA , BurneyPG . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999; Vol. 3, issue 5:iii‐92. [PUBMED: 10982317] ">Ukoumunne 1999</a>). These studies can generally be re‐analysed by making assumptions about the intra‐cluster correlation (ICC). We planned to obtain estimates of the ICC by contacting study authors or imputing them from data presented in the study. Where this was not feasible, we planned to use external estimates from similar studies, if available (<a href="./references#CD011260-bbs2-0037" title="CampbellM , GrimshawJ , SteenN . Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). Journal of Health Services Research and Policy2000;5(1):12‐6. [DOI: 10.1177/135581960000500105; PUBMED: 10787581] ">Campbell 2000</a>). If this was not possible, we planned not to combine the findings of these studies in a meta‐analysis, but to present the results in an additional table. We also planned to combine the adjusted measures of effects of cluster‐RCTs with the results of non‐cluster trials, and to perform a <a href="#CD011260-sec-0067">Sensitivity analysis</a> on meta‐analyses, including cluster‐RCTs, in which we would compare the effect estimates with and without the inclusion of the cluster trials. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not include cluster trials.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dealing with missing data</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to impute missing dichotomous data through an intention‐to‐treat (ITT) analysis based on the available data (all participants analysed in the group to which they were allocated, whether they received the allocated intervention or not). We also planned to perform a <a href="#CD011260-sec-0067">Sensitivity analysis</a>, assigning the worst outcome to those lost to follow‐up, to assess the impact of a 'worse case' scenario. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not impute dichotomous data.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup analysis and investigation of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to conduct the following subgroup analyses.</p> <p> <ul id="CD011260-list-0007"> <li> <p>Comorbidities (for example, HIV or tuberculosis)</p> </li> <li> <p>Baseline socioeconomic status (where available)</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not have enough data to perform these subgroup analyses.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Data synthesis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where there were multiple, appropriate outcomes, we planned to selected the median effect. Where there were only two, we planned to selected the more conservative result. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This scenario did not arise.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to use the generic inverse‐variance model of analysis if we needed to combine continuous and dichotomous data or clustered and non‐clustered data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This scenario did not arise.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to estimate a regression coefficient (with its standard error) that describes the effect of the interventions. We planned to standardise the direction of effect (for example, positive or negative) so that a negative coefficient planned to describe an improvement in outcome attributable to the intervention. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We performed an ARIMA analysis.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It may not be appropriate to combine the results quantitatively when the assessed outcomes, settings, and interventions are diverse. For these results, we planned to provide a descriptive summary of the data using one of the following methods: </p> <p> <ul id="CD011260-list-0008"> <li> <p>median effect size across included studies;</p> </li> <li> <p>interquartile ranges of effect sizes across included studies; and</p> </li> <li> <p>range of effect sizes across included studies.</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In these cases, we presented the results of the subgroup analysis.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to conduct sensitivity analyses based on the following characteristics.</p> <p> <ul id="CD011260-list-0009"> <li> <p>Risk of bias in the included studies: we planned to repeat the analysis excluding trials at high risk of bias for allocation concealment in order to test the robustness of the results. </p> </li> <li> <p>Unit of analysis: we planned to compare outcomes from cluster‐randomised with outcomes from individually‐randomised trials. </p> </li> </ul> </p> <p>We also planned to conduct additional sensitivity analyses:</p> <p> <ul id="CD011260-list-0010"> <li> <p>based on specific decisions made during the review process, such as how the intra‐cluster correlation coefficients were imputed for cluster trials; </p> </li> <li> <p>if one or more studies reported outcomes using either a continuous scale or a dichotomous scale and, in either scenario, were transformed into a dichotomous or continuous variable respectively; and </p> </li> <li> <p>based on the effect of including those lost to follow‐up or not, where the available cases were used as the basis for analysis. </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not perform the first analysis because no study was at high risk of bias for allocation concealment. </p> <p>We did not include cluster trials so did not perform the third analysis. The last three scenarios did not arise. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ARIMA: autoregressive integrated moving average; CBAs: controlled before and after study; CI: confidence interval; RCT: randomised controlled trial. </p> </div> </div> <section id="CD011260-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Pairs of review authors independently considered studies for possible inclusion using EROS (Early Review Organizing Software) (<a href="./references#CD011260-bbs2-0062" title="GlujovskyD , BardachA , García MartíS , ComandeD , CiapponiA . EROS: a new software for early stage of systematic reviews. Value in Health2011;14(7):A564. [DOI: 10.1016/j.jval.2011.08.1689; PRM2] ">Glujovsky 2011</a>; <a href="./references#CD011260-bbs2-0040" title="CiapponiA , GlujovskyD , BardachA , García MartíS , ComandeD . EROS: a new software for early stage of systematic reviews. HTA for Health Systems Sustainability 8th Annual Meeting; 2011 Jun 27‐9; Rio de Janeiro (BR). 2011:66. [242; www.gapcongressos.com.br/eventos/z0082/documentos/Program_HTAi.pdf] ">Ciapponi 2011</a>; <a href="./references#CD011260-bbs2-0061" title="GlujovskyD , BardachA , García MartíS , ComandeD , CiapponiA . New software for early stage of systematic reviews. XVIII Cochrane Colloquium. The Joint Colloquium of the Cochrane and Campbell Collaborations; 2010 Oct 18‐22. 2010. ">Glujovsky 2010</a>). First, the review authors independently screened the titles and abstracts of all records identified by the searches, discarding any that were clearly irrelevant. Second, they independently examined the full texts of all potentially relevant records, or those for which more information was needed to determine eligibility, to identify those that met the inclusion criteria (<a href="#CD011260-sec-0030">Criteria for considering studies for this review</a>). Any disagreements were discussed amongst all review authors until a consensus was reached. We presented our selection process in a PRISMA diagram (<a href="./references#CD011260-bbs2-0084" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009; Vol. 6, issue 7:e1000100. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>; <a href="./references#CD011260-bbs2-0094" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLOS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097; PMC2707599 ; PUBMED: 19621072] ">Moher 2009</a>). </p> </section> <section id="CD011260-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>We used an adapted, electronic version of a data collection checklist developed by Cochrane Effective Practice and Organisation of Care (<a href="./references#CD011260-bbs2-0053" title="EffectivePractice , Organisation ofCare . Cochrane Effective Practice and Organisation of Care Review Group: data collection checklist. bit.ly/1zXPg9y (accessed 12 May 2014). ">EPOC 2011a</a>). We piloted the form prior to use. </p> <p>Pairs of review authors independently extracted descriptive, risk of bias, and numerical outcome data from each study using EROS. For descriptive data, a review author extracted the data onto a Google spreadsheet, which a second review author verified. Discrepancies were resolved by discussion with the entire team. We collected the following information from each study. </p> <section id="CD011260-sec-0045"> <h5 class="title">Study references</h5> <p> <ul id="CD011260-list-0011"> <li> <p>Name of author(s) and year of publication</p> </li> <li> <p>Start and stop dates for study</p> </li> <li> <p>Location of the study (for example, country, region or district, and city)</p> </li> </ul> </p> </section> <section id="CD011260-sec-0046"> <h5 class="title">Study characteristics</h5> <p> <ul id="CD011260-list-0012"> <li> <p>Study design (RCT, quasi‐RCT, CBA, UBA, ITS and CITS)</p> </li> </ul> </p> </section> <section id="CD011260-sec-0047"> <h5 class="title">Intervention and comparisons: description and characteristics</h5> <p> <ul id="CD011260-list-0013"> <li> <p>Number and type of vaccines</p> </li> <li> <p>OPV poliovirus types</p> </li> <li> <p>Timing (frequency of intervention, and duration of intervention)</p> </li> <li> <p>Schedule of IPV (I) or OPV (O) sequence (for example, IOO, IOOO, IIO, IIOO)</p> </li> <li> <p>Setting of the intervention (rural or urban)</p> </li> </ul> </p> </section> <section id="CD011260-sec-0048"> <h5 class="title">Participants</h5> <p> <ul id="CD011260-list-0014"> <li> <p>Age</p> </li> <li> <p>Sex</p> </li> <li> <p>Socioeconomic status</p> </li> <li> <p>Baseline health problems</p> </li> </ul> </p> <p>In addition, for quasi‐RCTs, we also recorded whether the study restricted participant selection, or demonstrated balance or matching between intervention and control groups on possible confounders (such as age, sex), or both. </p> </section> <section id="CD011260-sec-0049"> <h5 class="title">Methods</h5> <p> <ul id="CD011260-list-0015"> <li> <p>Unit of allocation</p> </li> <li> <p>Unit of analysis</p> </li> <li> <p>Criteria for assessment of risk of bias for:</p> <ul id="CD011260-list-0016"> <li> <p>RCTs and quasi‐RCTs (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias); </p> </li> <li> <p>CBA studies (baseline measurement, characteristics of studies using second site as control, blinded assessment of primary outcome(s)* (protection against detection bias), protection against contamination (studies using second site as control), reliable primary outcome measure(s), follow‐up of professionals (protection against exclusion bias), and follow‐up of participants); and </p> </li> <li> <p>Interrupted time series (ITS) studies (protection against secular changes (intervention is independent of other changes, data were analysed appropriately, reason for the number of points pre‐ and postintervention given, and shape of the intervention effect was specified), and protection against detection bias (intervention unlikely to affect data collection, blinded assessment of primary outcome(s), completeness of data set, reliable primary outcome measure(s)). </p> </li> </ul> </li> </ul> </p> </section> <section id="CD011260-sec-0050"> <h5 class="title">Outcomes</h5> <p> <ul id="CD011260-list-0017"> <li> <p>Primary outcome (paralytic polio)</p> </li> <li> <p>Secondary outcomes (VAPP, VDPV shedding in stool, protective immune responses (humoral and intestinal immunity), vaccination coverage of children, and safety) </p> </li> </ul> </p> </section> </section> <section id="CD011260-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>In EROS, pairs of review authors independently assessed the risk of bias in each included study using the ‘Risk of bias’ tool, described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011260-bbs2-0073" title="HigginsJP , AltmanDG , SterneJAC , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>) for RCTs, with additional criteria developed by EPOC for non‐clinical studies (<a href="./references#CD011260-bbs2-0056" title="Cochrane EffectivePractice , Organisation of Care(EPOC) . Suggested risk of bias criteria for EPOC reviews. epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources‐for‐authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf (accessed 7 April 2017). ">EPOC 2017</a>). </p> <p>We assessed the risk of bias as described below. All review authors discussed any disagreements until they reached a consensus. </p> <p>We present the results of our 'Risk of bias' assessment in the 'Risk of bias' tables (beneath the <a href="./references#CD011260-sec-0209" title="">Characteristics of included studies</a> tables). We generated a 'Risk of bias' summary graph using RevMan 5 (<a href="./references#CD011260-bbs2-0100" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We considered our 'Risk of bias' judgements when evaluating study limitations while preparing 'Summary of findings’ tables when assessing the overall certainty of the evidence for each outcome (<a href="./references#CD011260-bbs2-0069" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011; Vol. 64, issue 4:383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026; PUBMED: 21195583] ">Guyatt 2011</a>; <a href="./references#CD011260-bbs2-0076" title="HultcrantzM , RindD , AklEA , TreweekS , MustafaRA , IorioA , et al. The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology2017;87:4‐13. [DOI: 10.1016/j.jclinepi.2017.05.006; PMC6542664; PUBMED: 28529184] ">Hultcrantz 2017</a>). </p> <section id="CD011260-sec-0052"> <h5 class="title">RCTs</h5> <p>Using the criteria set out in <a href="./appendices#CD011260-sec-0200">Appendix 5</a>, we assessed the risk of bias in RCTs as low, high or unclear, across each of the following domains from the Cochrane ‘Risk of bias’ tool: sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessors; incomplete outcome data; selective outcome reporting; and other potential threats to validity (<a href="./references#CD011260-bbs2-0073" title="HigginsJP , AltmanDG , SterneJAC , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). Where we scored a study at unclear risk of bias, one review author attempted to obtain further information from the authors of the trial. </p> </section> <section id="CD011260-sec-0053"> <h5 class="title">CBA and UBA studies</h5> <p>For CBAs, we used the following criteria: baseline measurement; characteristics for studies using the second site as control; blinded assessment of primary outcome(s); reliable primary outcome measure(s); follow‐up of professionals (protection against exclusion bias); and follow‐up of patients. </p> <p>For UBAs, we used the same criteria, with the exception of baseline measurement and characteristics for studies using the second site as control. </p> <p>For each included study, we rated the risk of bias in each domain as low, high or unclear using the criteria set out in <a href="./appendices#CD011260-sec-0201">Appendix 6</a>, </p> </section> <section id="CD011260-sec-0054"> <h5 class="title">ITS and CITS studies</h5> <p>For ITS studies, we assessed the risk of bias associated with the following seven domains: intervention independent of other changes; shape of intervention effect pre‐specified; intervention unlikely to affect data collection; blinding of outcome assessors to intervention allocation; incomplete outcome data; selective outcome reporting; and other sources of bias (<a href="./references#CD011260-bbs2-0056" title="Cochrane EffectivePractice , Organisation of Care(EPOC) . Suggested risk of bias criteria for EPOC reviews. epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources‐for‐authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf (accessed 7 April 2017). ">EPOC 2017</a>). For each included study, we rated the risk of bias in each domain as low, high or unclear using the criteria set out in <a href="./appendices#CD011260-sec-0201">Appendix 6</a>, </p> <p>As for CBAs, for CITS studies we included three additional domains that assess design‐specific threats to validity: imbalance of outcome measures at baseline; comparability of intervention and control group characteristics at baseline; and protection against contamination (<a href="./references#CD011260-bbs2-0056" title="Cochrane EffectivePractice , Organisation of Care(EPOC) . Suggested risk of bias criteria for EPOC reviews. epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources‐for‐authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf (accessed 7 April 2017). ">EPOC 2017</a>). We rated the risk of bias in each domain as low, high or unclear using the criteria set out in <a href="./appendices#CD011260-sec-0201">Appendix 6</a>. </p> </section> </section> <section id="CD011260-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011260-sec-0056"> <h5 class="title">RCTs</h5> <section id="CD011260-sec-0057"> <h6 class="title">Dichotomous outcomes</h6> <p>We calculated the risk ratio (RR) with 95% confidence intervals (CIs).</p> </section> <section id="CD011260-sec-0058"> <h6 class="title">Continuous outcomes</h6> <p>We calculated the mean difference (MD) with 95% CI when the same outcomes were measured using similar scales (such as immune responses). </p> </section> </section> <section id="CD011260-sec-0059"> <h5 class="title">CBA and UBA studies</h5> <p>For continuous variables, we reported, if possible, the relative change, adjusted for baseline differences in the outcome measures; that is, the absolute post‐intervention difference between the intervention and control groups minus the absolute pre‐intervention difference between the intervention and control groups divided by the post‐intervention level in the control group. We re‐analysed CBA studies as ITS studies, if possible, using the methods described below. </p> </section> <section id="CD011260-sec-0060"> <h5 class="title">ITS and CITS studies</h5> <p>The most basic approach is to graph the time series, and look for trends and patterns. We present the results for outcomes as changes along two dimensions: 'change in level' and 'change in slope'. </p> <p>'Change in level' is the immediate effect of the policy. It is measured as the difference between the fitted values for the first post‐intervention data point (one month after the intervention) minus the predicted outcome one month after the intervention based on the pre‐intervention slope only. We calculated the relative change in level by dividing the change in level by the predicted outcome one month after the intervention based on the pre‐intervention slope only and then multiplying by 100%. </p> <p>'Change in slope' is the change in the trend from pre‐ to post‐intervention that reflects the long‐term effect of the intervention. Since the interpretation of change in slope can be difficult, we presented the long‐term effects in a similar way to how we calculated and presented the relative immediate effects. </p> </section> </section> <section id="CD011260-sec-0061"> <h4 class="title">Unit of analysis issues</h4> <p>We did not included cluster‐trials (see <a href="#CD011260-tbl-0006">Table 3</a> for planned methods to address this issue should they arise in future updates of this review). </p> </section> <section id="CD011260-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>If information was missing or unclear, we contacted the study investigators for additional information or clarification. To reduce the risk of overly positive answers, we used open‐ended questions (as recommended in Chapter 16 the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>; <a href="./references#CD011260-bbs2-0074" title="HigginsJP , DeeksJJ , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> <p>We imputed missing continuous data when necessary (calculating standard deviations from standard errors or using standard deviations from other studies). </p> </section> <section id="CD011260-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>Statistical heterogeneity exists if the observed intervention effects are more different from each other than one would expect due to random error (chance) alone. We obtained an initial visual overview of heterogeneity through scrutinising the forest plots and looking at the overlap between CIs around the estimate for each included study. To quantify the inconsistency across studies, and thus the impact of heterogeneity on the meta‐analysis, we used the I<sup>2</sup> statistic to detect heterogeneity (<a href="./references#CD011260-bbs2-0071" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003; Vol. 327, issue 7414:557‐60. [DOI: 10.1136/bmj.327.7414.557; PMC192859; PUBMED: 12958120] ">Higgins 2003</a>). In the latter case, we defined an I<sup>2</sup> of &gt; 50% as revealing substantial heterogeneity. We also interpreted the significance of the I<sup>2</sup> test in light of (i) the magnitude and direction of effects and (ii) the strength of evidence for heterogeneity (for example, a CI for the I<sup>2</sup>, or the P value for the Chi<sup>2</sup> test). </p> <p>We assessed observable heterogeneity among the study questions and methods, to determine whether a meta‐analysis was appropriate. We also looked at the study participants, settings, interventions, and reported outcomes. We paid particular attention to the homogeneity of the methodology (such as variances in blinding and concealment of allocation) within and across included studies. </p> <p>If we found evidence of statistical heterogeneity, we examined it in a subgroup analysis and a sensitivity analysis, as outlined in the respective sections below (<a href="#CD011260-sec-0066">Subgroup analysis and investigation of heterogeneity</a>; <a href="#CD011260-sec-0067">Sensitivity analysis</a>). </p> </section> <section id="CD011260-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>To reduce possible publication bias, we employed strategies to search for and include relevant unpublished studies. These strategies included searching the grey literature and prospective trial registration databases to overcome time‐lag bias. </p> <p>To investigate the likelihood of overt publication bias, when we found more than eight studies of different sizes we drew a funnel plot, plotting trial effects against inverse standard errors of the effects. Funnel plot asymmetry is found through 'eyeballing' the funnel plot. We recognise that the funnel plot is not the most reliable method of investigating reporting biases, since asymmetry can also result from other sources of selection bias (delayed publication, location biases, selective outcome reporting), and methodological issues leading to spuriously inflated effects in smaller studies, true heterogeneity, artefactual, and chance (<a href="./references#CD011260-bbs2-0104" title="SterneJA , EggerM , MoherD , on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> </section> <section id="CD011260-sec-0065"> <h4 class="title">Data synthesis</h4> <p>For each comparison, we reported summary statistics for each of the included studies (RCTs, quasi‐RCTs, CBAs, UBAs, and controlled or non‐controlled ITSs). We used forest plots to display the data graphically. </p> <p>For dichotomous data, we used the Mantel‐Haenszel method, and for continuous data, we used the inverse variance method. </p> <p>We pooled the results from individual studies in a meta‐analysis using the random‐effects model by DerSimonian and Laird (<a href="./references#CD011260-bbs2-0046" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986; Vol. 7, issue 3:177‐88. [PUBMED: 3802833] ">DerSimonian 1986</a>). We chose this method because we could not assume a single, underlying (fixed) treatment effect. When the impact of the intervention was assessed in individual studies on more than one outcome measure, we selected the outcome that best reflects the targeted intervention for pooling data. </p> <p>We analysed ITS and UBAs studies separately to RCTs.</p> <p>We analysed ITS data using the guidelines of the EPOC group (<a href="./references#CD011260-bbs2-0054" title="EffectivePractice , Organisation ofCare . Draft EPOC methods paper: including Interrupted Time Series (ITS) designs in a EPOC review. bit.ly/1Eq6Zbf (accessed 16 March 2012). ">EPOC 2011b</a>; <a href="./references#CD011260-bbs2-0055" title="EffectivePractice , Organisation ofCare . Presentation of data from EPOC studies (RCTs and CBAs). bit.ly/1y5dRDI (accessed 16 March 2012). ">EPOC 2011c</a>), and reported outcomes in natural units. We reported pre‐intervention and post‐intervention means or proportions for both study and control groups, and calculated the unadjusted and adjusted (for any baseline imbalance) absolute change from baseline with 95% CIS. We used either a regression analysis with time trends before and after the intervention, which adjust for autocorrelation and any periodic changes, or an autoregressive, integrated, moving average (ARIMA) model to isolate the effect of the intervention from existing time trends (<a href="./references#CD011260-bbs2-0090" title="McCainLJ , McClearyR . The statistical analysis of the simple interrupted time‐series quasi‐experiment. In: CookTD , CampbellDT editor(s). Quasi‐Experimentation: Design &amp; Analysis Issues for Field Settings. Boston (MA): Houghton Mifflin, 1979:233‐93. ">McCain 1979</a>). </p> </section> <section id="CD011260-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following subgroup analyses, where possible, to check if the intervention effect varied with different populations, interventions, or settings. </p> <p> <ul id="CD011260-list-0018"> <li> <p>Timing of the first dose (at birth or at two months).</p> </li> <li> <p>Type of dose sequence (IOO, IOOO, IIO, or IIOO).</p> </li> <li> <p>Country (according to the current <a href="https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups" target="_blank">World Bank classification</a>). </p> </li> </ul> </p> <p>When we were not able to perform a meta‐analysis, we summarised the results for these subgroups within the text of the review. </p> <p>We also used an I<sup>2</sup> of &gt; 50% to test for subgroup differences, since substantial heterogeneity would suggest differential interventions effects. </p> <p>Due to a lack of studies, we were unable to conduct other preplanned subgroup analyses (<a href="./references#CD011260-bbs2-0123" title="CiapponiA , BardachA , Rey AresL , GlujovskyD , CafferataML , RomanoM , et al. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD011260] ">Ciapponi 2014</a>), which can be found in <a href="#CD011260-tbl-0006">Table 3</a>. </p> </section> <section id="CD011260-sec-0067"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analyses based on the following characteristic.</p> <p> <ul id="CD011260-list-0019"> <li> <p>Method of meta‐analysis: we compared the results from the random‐effects and fixed‐effect models if there was unexplained heterogeneity between studies, to assess the robustness of the results. </p> </li> </ul> </p> <p>Due to a lack of studies, we were unable to conduct our other preplanned analyses (<a href="./references#CD011260-bbs2-0123" title="CiapponiA , BardachA , Rey AresL , GlujovskyD , CafferataML , RomanoM , et al. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD011260] ">Ciapponi 2014</a>), which can be found in <a href="#CD011260-tbl-0006">Table 3</a>. </p> <p>We conducted a post hoc sensitivity analysis of studies at low risk of bias for allocation concealment for persons with P1 protective humoral response. </p> <section id="CD011260-sec-0068"> <h5 class="title">Summarising and interpreting results</h5> <p>We imported data from RevMan 5 (<a href="./references#CD011260-bbs2-0100" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) to GRADE profiler (<a href="./references#CD011260-bbs2-0065" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 05 September 2015. ">GRADEpro GDT</a>), and created 'Summary of findings' tables for the following comparisons: </p> <p> <ul id="CD011260-list-0020"> <li> <p>IPV‐OPV compared to OPV alone;</p> </li> <li> <p>IPV‐OPV compared to IPV alone; and</p> </li> <li> <p>IPV(3)‐OPV compared to IPV(2)‐OPV.</p> </li> </ul> </p> <p>The critical/important outcomes reported in all thee 'Summary of findings' tables are: </p> <p> <ul id="CD011260-list-0021"> <li> <p>paralytic polio;</p> </li> <li> <p>VAPP cases;</p> </li> <li> <p>persons with protective humoral response;</p> </li> <li> <p>neutralising antibodies;</p> </li> <li> <p>persons with faecal excretion after OPV challenge;</p> </li> <li> <p>vaccination coverage; and</p> </li> <li> <p>serious adverse events.</p> </li> </ul> </p> <p>We grouped, analysed and presented the results according to serotypes P1, P2 and P3 protective humoral and intestinal response (outcomes 3, 4, and 5), because the effect is partially independent of each other, and in that sense, many policies, like the replacement of tOPV by bOPV, are serotype specific. If we were not able to pool the data in a meta‐analysis due to considerable heterogeneity, we presented the scheme of two IPV doses (IIO) as the main subgroup for this outcome, since it is the most studied scheme. </p> <p>Pairs of review authors independently graded the certainty of the evidence for each outcome using the GRADE approach (<a href="./references#CD011260-bbs2-0069" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011; Vol. 64, issue 4:383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026; PUBMED: 21195583] ">Guyatt 2011</a>; <a href="./references#CD011260-bbs2-0076" title="HultcrantzM , RindD , AklEA , TreweekS , MustafaRA , IorioA , et al. The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology2017;87:4‐13. [DOI: 10.1016/j.jclinepi.2017.05.006; PMC6542664; PUBMED: 28529184] ">Hultcrantz 2017</a>; <a href="./references#CD011260-bbs2-0102" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusion. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011b</a>, <a href="./references#CD011260-bbs2-0103" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. ">Schünemann 2013</a>); discrepancies were resolved by consensus. For assessments of the overall certainty of the evidence for outcomes that included pooled data from RCTs, we initially graded the evidence as high certainty, downgrading the rating (by one level from high to moderate certainty, by two levels to low certainty, or three levels to very low‐certainty evidence) depending on the extent of accomplishment across the following criteria: study limitations (risk of bias); indirectness of evidence; inconsistency; imprecision of effect estimates; or publication bias. For certainty ratings for outcomes that included pooled data from ITS, CITS, CBA and UBA studies, we initially graded the evidence from as low certainty, upgrading the rating to moderate or high certainty if the pooled estimates revealed a large magnitude of effect, negligible concerns about confounders, or a strong dose‐response gradient. We used these assessments, along with the evidence (or lack thereof) for absolute benefit or harm of the interventions, and the sum of available data on all critical and important outcomes from each study included for each comparison, to draw conclusions about the effectiveness of sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011260-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011260-sec-0069"></div> <section id="CD011260-sec-0070"> <h3 class="title">Description of studies</h3> <section id="CD011260-sec-0071"> <h4 class="title">Results of the search</h4> <p>We retrieved a total of 6960 records (6958 database records and 2 from other sources) and eliminated 3058 duplicates, We screened the remaining 3902 titles and abstracts, and from these, selected 205 full texts for further screening. We excluded 175 full‐text reports. The majority of these involved an ineligible intervention (n = 98) or ineligible study design (n = 44) and consequently are not described in the <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010971.pub2/full#CD010971-sec3-0020" target="_blank">Excluded studies</a> section. We do, however present the details of six full‐text reports that we excluded for less obvious reasons in the <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010971.pub2/full#CD010971-sec3-0020" target="_blank">Excluded studies</a> section. </p> <p>We included 21 studies (from 27 reports; we considered the six additional reports as secondary references of <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>) in this review. See <a href="./references#CD011260-bbs1-0001" title="">Included studies</a> section for more information. We also identified three ongoing studies (<a href="./references#CD011260-bbs2-0028" title="NCT02412514 . Intestinal and humoral immunity of sequential polio vaccination schedules. [Assessing the intestinal and humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for routine childhood immunization in Bangladesh]. clinicaltrials.gov/ct2/show/NCT02412514 (first received 1 April 2015). ">NCT02412514</a>; <a href="./references#CD011260-bbs2-0029" title="NCT03430349 . Phase 1 novel live attenuated serotype 2 oral polio vaccine study in IPV primed adults (nOPV2M4a) [A phase 1 study to evaluate the safety and immunogenicity of 2 novel live attenuated serotype 2 oral poliovirus vaccines, in healthy adults previously primed with inactivated polio vaccine (IPV)]. clinicaltrials.gov/ct2/show/NCT03430349 (first received 21 January 2018). ">NCT03430349</a>; <a href="./references#CD011260-bbs2-0030" title="NCT03614702 . Clinic trial to evaluate the safety and immunogenicity by different sequential schedules of bOPV and IPV [Safety and immunogenicity evaluation of different sequential immunization schedules of type 1 + 2 bivalent oral poliovirus vaccine (bOPV) co‐administered with inactived poliovirus vaccine (IPV) in infants aged 2 months: a randomized, double blind, single center, parallel trial]. clinicaltrials.gov/show/nct03614702 (first received 3 March 2017). ">NCT03614702</a>). </p> <p>See <a href="#CD011260-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011260-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011260-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011260-sec-0072"> <h4 class="title">Included studies</h4> <p>We included 16 RCTs (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0006" title="HalseyNA , BlatterM , BaderG , ThomsML , WillinghamFF , O'DonovanJC , et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two‐, four‐ and six‐month‐old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatric Infectious Disease Journal1997;16(7):675‐9. [DOI: 10.1097/00006454‐199707000‐00010; PUBMED: 9239772] ">Halsey 1997</a>; <a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0011" title="LinderN , HandsherR , GermanB , SirotaL , BachmanM , ZingerS , et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(1):F24‐7. [DOI: 10.1136/fn.83.1.f24; PMC1721105; PUBMED: 10873167] ">Linder 2000</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>; <a href="./references#CD011260-bbs2-0017" title="SimasathienS , MigasenaS , BeuveryC , vanSteenisG , SamakosesR , PitisuttithamP , et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases1994;26(6):731‐8. [DOI: 10.3109/00365549409008643; PUBMED: 7747098] ">Simasathien 1994</a>; <a href="./references#CD011260-bbs2-0018" title="SutterRW , SuleimanAJ , MalankarPG , MehtaFR , MedanyMA , ArifMA , et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. Journal of Infectious Diseases1997;175 Suppl 1:S235‐40. [DOI: 10.1093/infdis/175.Supplement_1.S235; PUBMED: 9203722] ">Sutter 1997</a>; <a href="./references#CD011260-bbs2-0020" title="WestDJ , RabalaisGP , WatsonB , KeyserlingHL , MatthewsH , HesleyTM . Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b‐hepatitis B vaccine with diphtheria‐tetanus‐pertussis, polio and measles‐mumps‐rubella vaccines. Biodrugs2001;15(6):413‐8. [DOI: 10.2165/00063030‐200115060‐00007; PUBMED: 11520252] ">West 2001</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>), three ITS (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>), and two UBA (<a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>). See <a href="./references#CD011260-sec-0209" title="">Characteristics of included studies</a> tables. </p> <section id="CD011260-sec-0073"> <h5 class="title">RCTs</h5> <section id="CD011260-sec-0074"> <h6 class="title">Setting</h6> <p>The majority of RCTs (10/16) were conducted in high‐income countries: five in the USA (<a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0006" title="HalseyNA , BlatterM , BaderG , ThomsML , WillinghamFF , O'DonovanJC , et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two‐, four‐ and six‐month‐old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatric Infectious Disease Journal1997;16(7):675‐9. [DOI: 10.1097/00006454‐199707000‐00010; PUBMED: 9239772] ">Halsey 1997</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0020" title="WestDJ , RabalaisGP , WatsonB , KeyserlingHL , MatthewsH , HesleyTM . Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b‐hepatitis B vaccine with diphtheria‐tetanus‐pertussis, polio and measles‐mumps‐rubella vaccines. Biodrugs2001;15(6):413‐8. [DOI: 10.2165/00063030‐200115060‐00007; PUBMED: 11520252] ">West 2001</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>); two in the UK (<a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>); and one apiece in Chile (<a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>); Israel (<a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>); and Oman (<a href="./references#CD011260-bbs2-0018" title="SutterRW , SuleimanAJ , MalankarPG , MehtaFR , MedanyMA , ArifMA , et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. Journal of Infectious Diseases1997;175 Suppl 1:S235‐40. [DOI: 10.1093/infdis/175.Supplement_1.S235; PUBMED: 9203722] ">Sutter 1997</a>). The six remaining studies were conducted in middle‐income countries: two in China (<a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>); and one apiece in Bangladesh (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>), Guatemala (<a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>), India (<a href="./references#CD011260-bbs2-0011" title="LinderN , HandsherR , GermanB , SirotaL , BachmanM , ZingerS , et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(1):F24‐7. [DOI: 10.1136/fn.83.1.f24; PMC1721105; PUBMED: 10873167] ">Linder 2000</a>), and Thailand (<a href="./references#CD011260-bbs2-0017" title="SimasathienS , MigasenaS , BeuveryC , vanSteenisG , SamakosesR , PitisuttithamP , et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases1994;26(6):731‐8. [DOI: 10.3109/00365549409008643; PUBMED: 7747098] ">Simasathien 1994</a>). </p> <p>The RCTs were published between 1990 and 2017, with only six of them published within the last 10 years (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>). There date of patient recruitments were from 1986 (<a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>) to 2015 (<a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>). </p> </section> <section id="CD011260-sec-0075"> <h6 class="title">Participants and sample sizes</h6> <p>The 16 RCTs involved 6407 healthy infants (mean age = 382 days, range = 96 to 975 days, median = 365 days). </p> </section> <section id="CD011260-sec-0076"> <h6 class="title">Comparisons</h6> <p>The RCTs compared a sequential IPV‐OPV schedule (one or more doses of IPV followed by one or more doses of OPV) with IPV alone (<a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>), OPV alone (<a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>; <a href="./references#CD011260-bbs2-0017" title="SimasathienS , MigasenaS , BeuveryC , vanSteenisG , SamakosesR , PitisuttithamP , et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases1994;26(6):731‐8. [DOI: 10.3109/00365549409008643; PUBMED: 7747098] ">Simasathien 1994</a>; <a href="./references#CD011260-bbs2-0018" title="SutterRW , SuleimanAJ , MalankarPG , MehtaFR , MedanyMA , ArifMA , et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. Journal of Infectious Diseases1997;175 Suppl 1:S235‐40. [DOI: 10.1093/infdis/175.Supplement_1.S235; PUBMED: 9203722] ">Sutter 1997</a>; <a href="./references#CD011260-bbs2-0020" title="WestDJ , RabalaisGP , WatsonB , KeyserlingHL , MatthewsH , HesleyTM . Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b‐hepatitis B vaccine with diphtheria‐tetanus‐pertussis, polio and measles‐mumps‐rubella vaccines. Biodrugs2001;15(6):413‐8. [DOI: 10.2165/00063030‐200115060‐00007; PUBMED: 11520252] ">West 2001</a>), both IPV and OPV (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>), IPV and IPV + OPV (<a href="./references#CD011260-bbs2-0006" title="HalseyNA , BlatterM , BaderG , ThomsML , WillinghamFF , O'DonovanJC , et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two‐, four‐ and six‐month‐old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatric Infectious Disease Journal1997;16(7):675‐9. [DOI: 10.1097/00006454‐199707000‐00010; PUBMED: 9239772] ">Halsey 1997</a>), or different schemes of IPV‐OPV (<a href="./references#CD011260-bbs2-0011" title="LinderN , HandsherR , GermanB , SirotaL , BachmanM , ZingerS , et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(1):F24‐7. [DOI: 10.1136/fn.83.1.f24; PMC1721105; PUBMED: 10873167] ">Linder 2000</a>). </p> </section> <section id="CD011260-sec-0077"> <h6 class="title">Outcomes</h6> <p>All RCTs assessed serological immune response for each serotype as geometric mean antibody titres and protective humoral response (≥ 1:8 dilutions) from completing the vaccination schedule to 18 months. <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a> also assessed mean antibody titres at five years. Five RCTs assessed poliovirus detection in stool or gastrointestinal mucosal immunity (<a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>), and seven reported on safety outcomes (<a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>; <a href="./references#CD011260-bbs2-0020" title="WestDJ , RabalaisGP , WatsonB , KeyserlingHL , MatthewsH , HesleyTM . Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b‐hepatitis B vaccine with diphtheria‐tetanus‐pertussis, polio and measles‐mumps‐rubella vaccines. Biodrugs2001;15(6):413‐8. [DOI: 10.2165/00063030‐200115060‐00007; PUBMED: 11520252] ">West 2001</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>). </p> </section> </section> <section id="CD011260-sec-0078"> <h5 class="title">ITS and UBA studies</h5> <p>We included two ITS studies (<a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>), two UBA studies (<a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>), and one study that used a mixed design (ITS + UBA analysis for VAPP cases) (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>). </p> <section id="CD011260-sec-0079"> <h6 class="title">Setting</h6> <p>Most (4/5) studies were conducted in high‐income countries: two in the USA (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>); one in Denmark (<a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>); and one in Hungary (<a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>). The fifth study was conducted in the Russian Federation (<a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>); a middle‐income country. </p> </section> <section id="CD011260-sec-0080"> <h6 class="title">Participants and sample sizes</h6> <p>Four studies were conducted nationwide (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). The other study, <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>, was conducted in two large, health maintenance organizations (HMO) in the USA and involved 28,330 infants aged one year old. </p> </section> <section id="CD011260-sec-0081"> <h6 class="title">Comparisons</h6> <p>All but one study compared a sequential IPV‐OPV schedule with OPV. The exception was <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>, who compared an IPV‐OPV schedule with IPV. </p> <p><a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a> used an OPV‐only schedule in quarter four of 1995 to quarter three of 1996 (at ages two, four and 12 to 18 months and at four to six years). This changed to an IPV‐OPV schedule in quarter four of 1996 to quarter four of 1997 (IPV at ages two to four months, OPV at ages 12 to 18 months and at four to six years). </p> </section> <section id="CD011260-sec-0082"> <h6 class="title">Outcomes</h6> <p>Both UBA studies (<a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>) and the mixed‐design study (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>) assessed the frequency of VAPP cases. Of the two ITS studies, one assessed the frequency of paralytic polio cases, percentage of persons with antibodies to type 1, 2 and 3 poliovirus, and acceptance rate (<a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). The other assessed immunisation status, immunisation up‐to‐date status and total number of missed‐opportunity visits (<a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>). </p> </section> </section> </section> <section id="CD011260-sec-0083"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies because they did not meet the inclusion criteria for this review (<a href="#CD011260-sec-0030">Criteria for considering studies for this review</a>); four because they used an ineligible study design (<a href="./references#CD011260-bbs2-0023" title="McColloughRH , GlezenWP , LambGA , ChinTD . Booster effect of oral poliovaccine. Trials in persons previously immunized with inactivated vaccine. American Journal of Diseases of Children1969;117(2):161‐8. [PUBMED: 4303394] ">McCollough 1969</a>; <a href="./references#CD011260-bbs2-0024" title="MoǐseievaHV , ZadorozhnaVI . Effectiveness of different strategies of vaccine prophylaxis for poliomyelitis in the Ukraine. Likars'ka sprava2002;‐(2):85‐8. [PUBMED: 12073271] ">Moǐseieva 2002</a>; <a href="./references#CD011260-bbs2-0025" title="SwartzTA , HandsherR , ManorY , StoeckelP , BarkayA , MendelsonE , et al. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis. Vaccine1998;16(20):2090‐5. [DOI: 10.1016/S0264‐410X(98)00071‐1; PUBMED: 9796069] ">Swartz 1998</a>; <a href="./references#CD011260-bbs2-0026" title="WattigneyWA , MootreyGT , BraunMM , ChenRT . Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics2001;107(5):E83. [DOI: 10.1542/peds.107.5.e83; PUBMED: 11331733] ">Wattigney 2001</a>), and two because they used an ineligible intervention (<a href="./references#CD011260-bbs2-0022" title="LiRC , LiCG , LiYP , LiuYP , ZhaoH , ChenXL , et al. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well‐tolerated in infants and toddlers in China. Vaccine2016;34(12):1436‐43. [DOI: 10.1016/j.vaccine.2016.02.010; PUBMED: 26873055] ">Li 2016b</a>; <a href="./references#CD011260-bbs2-0027" title="YeH , HuangT , YingZF , LiGL , CheYC , ZhaoZM , et al. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (I + III) in different dosage forms] [株脊髓灰质炎灭活疫苗与不同剂型Ⅰ+Ⅲ型脊髓灰质炎减毒活疫苗序贯接种的免疫原性和安全性比较]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2018;52(1):43‐9. [DOI: 10.3760/cma.j.issn.0253‐9624.2018.01.009; PUBMED: 29334707] ">Ye 2018</a>). See <a href="./references#CD011260-sec-0210" title="">Characteristics of excluded studies</a> tables. </p> <p>There are no studies awaiting classification.</p> <section id="CD011260-sec-0084"> <h5 class="title">Ongoing studies</h5> <p>We identified three ongoing studies, which we describe in full in the <a href="./references#CD011260-sec-0211" title="">Characteristics of ongoing studies</a> tables. In brief: </p> <p> <ul id="CD011260-list-0022"> <li> <p><a href="./references#CD011260-bbs2-0028" title="NCT02412514 . Intestinal and humoral immunity of sequential polio vaccination schedules. [Assessing the intestinal and humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for routine childhood immunization in Bangladesh]. clinicaltrials.gov/ct2/show/NCT02412514 (first received 1 April 2015). ">NCT02412514</a>: (I + O)OO (IPV + bOPV, bOPV and bOPV) versus IOO (IPV, bOPV and bOPV); </p> </li> <li> <p><a href="./references#CD011260-bbs2-0029" title="NCT03430349 . Phase 1 novel live attenuated serotype 2 oral polio vaccine study in IPV primed adults (nOPV2M4a) [A phase 1 study to evaluate the safety and immunogenicity of 2 novel live attenuated serotype 2 oral poliovirus vaccines, in healthy adults previously primed with inactivated polio vaccine (IPV)]. clinicaltrials.gov/ct2/show/NCT03430349 (first received 21 January 2018). ">NCT03430349</a>: IPV followed by novel OPV2 versus IPV followed by another novel OPV2; and </p> </li> <li> <p><a href="./references#CD011260-bbs2-0030" title="NCT03614702 . Clinic trial to evaluate the safety and immunogenicity by different sequential schedules of bOPV and IPV [Safety and immunogenicity evaluation of different sequential immunization schedules of type 1 + 2 bivalent oral poliovirus vaccine (bOPV) co‐administered with inactived poliovirus vaccine (IPV) in infants aged 2 months: a randomized, double blind, single center, parallel trial]. clinicaltrials.gov/show/nct03614702 (first received 3 March 2017). ">NCT03614702</a>: 12 arms of one or two doses of cIPV/sIPV + one dose of tOPV versus one or two doses of cIPV/sIPV + one dose of bOPV. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011260-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias for RCTs separately to that of the ITS and UBA studies. We provide a summary of the results of our assessment below and graphically in <a href="#CD011260-fig-0002">Figure 2</a> and <a href="#CD011260-fig-0003">Figure 3</a>. Further details can be found in the 'Risk of bias' tables (beneath the <a href="./references#CD011260-sec-0209" title="">Characteristics of included studies</a> tables). </p> <div class="figure" id="CD011260-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph by experimental / quasi‐experimental design: review authors' judgements about each risk of bias item presented as percentages across all studies" data-id="CD011260-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph by experimental / quasi‐experimental design: review authors' judgements about each risk of bias item presented as percentages across all studies </p> </div> </div> </div> <div class="figure" id="CD011260-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="A summary table of review authors' judgements for each 'Risk of bias' item for each study" data-id="CD011260-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>A summary table of review authors' judgements for each 'Risk of bias' item for each study </p> </div> </div> </div> <section id="CD011260-sec-0086"> <h4 class="title">RCTs</h4> <section id="CD011260-sec-0087"> <h5 class="title">Allocation (selection bias)</h5> <section id="CD011260-sec-0088"> <h6 class="title">Randon sequence generation</h6> <p>We rated six studies at low risk of bias (<a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0011" title="LinderN , HandsherR , GermanB , SirotaL , BachmanM , ZingerS , et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(1):F24‐7. [DOI: 10.1136/fn.83.1.f24; PMC1721105; PUBMED: 10873167] ">Linder 2000</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>). We considered the 10 remaining studies to be at unclear risk of bias because they did not provide a complete description of the random sequence generation process. </p> </section> <section id="CD011260-sec-0089"> <h6 class="title">Allocation concealment</h6> <p>We judged four studies at low risk of bias (<a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0011" title="LinderN , HandsherR , GermanB , SirotaL , BachmanM , ZingerS , et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(1):F24‐7. [DOI: 10.1136/fn.83.1.f24; PMC1721105; PUBMED: 10873167] ">Linder 2000</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0017" title="SimasathienS , MigasenaS , BeuveryC , vanSteenisG , SamakosesR , PitisuttithamP , et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases1994;26(6):731‐8. [DOI: 10.3109/00365549409008643; PUBMED: 7747098] ">Simasathien 1994</a>). We rated the 12 remaining studies at unclear risk of bias because they did not describe allocation concealment or the description was incomplete (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0006" title="HalseyNA , BlatterM , BaderG , ThomsML , WillinghamFF , O'DonovanJC , et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two‐, four‐ and six‐month‐old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatric Infectious Disease Journal1997;16(7):675‐9. [DOI: 10.1097/00006454‐199707000‐00010; PUBMED: 9239772] ">Halsey 1997</a>; <a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>; <a href="./references#CD011260-bbs2-0018" title="SutterRW , SuleimanAJ , MalankarPG , MehtaFR , MedanyMA , ArifMA , et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. Journal of Infectious Diseases1997;175 Suppl 1:S235‐40. [DOI: 10.1093/infdis/175.Supplement_1.S235; PUBMED: 9203722] ">Sutter 1997</a>; <a href="./references#CD011260-bbs2-0020" title="WestDJ , RabalaisGP , WatsonB , KeyserlingHL , MatthewsH , HesleyTM . Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b‐hepatitis B vaccine with diphtheria‐tetanus‐pertussis, polio and measles‐mumps‐rubella vaccines. Biodrugs2001;15(6):413‐8. [DOI: 10.2165/00063030‐200115060‐00007; PUBMED: 11520252] ">West 2001</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>). </p> </section> </section> <section id="CD011260-sec-0090"> <h5 class="title">Blinding (performance bias and detection bias)</h5> <section id="CD011260-sec-0091"> <h6 class="title">Blinding of participants and personnel</h6> <p>We rated all studies at low risk of performance bias since it is unlikely that the lack of blinding would have influenced the way in which the immunisation schedule was delivered. </p> </section> <section id="CD011260-sec-0092"> <h6 class="title">Blinding of outcome assessment</h6> <p>We rated all studies at low risk of detection bias. Although the outcome assessment was not blinded, it is unlikely that objective outcomes (like antibody titres) would have been influenced by the lack of blinding. </p> </section> </section> <section id="CD011260-sec-0093"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>We judged four studies at low risk of attrition bias (<a href="./references#CD011260-bbs2-0006" title="HalseyNA , BlatterM , BaderG , ThomsML , WillinghamFF , O'DonovanJC , et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two‐, four‐ and six‐month‐old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatric Infectious Disease Journal1997;16(7):675‐9. [DOI: 10.1097/00006454‐199707000‐00010; PUBMED: 9239772] ">Halsey 1997</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0011" title="LinderN , HandsherR , GermanB , SirotaL , BachmanM , ZingerS , et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(1):F24‐7. [DOI: 10.1136/fn.83.1.f24; PMC1721105; PUBMED: 10873167] ">Linder 2000</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>). We judged a further four studies at high risk of attrition bias because of attrition in the short term (from 14% to 30%) and long term (from 45% to 69%) (<a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>). We rated the eight remaining studies at unclear risk of attrition bias because the description of attrition was incomplete, although we consider it unlikely to impact considerably on the results, since most outcomes had early presentation. </p> </section> <section id="CD011260-sec-0094"> <h5 class="title">Selective reporting (reporting bias)</h5> <p>We considered all studies to be at of low risk of reporting bias.</p> <p>We assessed reporting bias through visual inspection of funnel plots when there was more than eight studies included in a meta‐analysis. We found no significant asymmetries for the number of people with protective humoral response P1, P2 and P3 for the comparison IPV‐OPV versus OPV (<a href="#CD011260-fig-0004">Figure 4</a>), or for the number of people with protective humoral response P1 for the comparison IPV‐OPV versus IPV (<a href="#CD011260-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD011260-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 IPV‐OPV vs OPV, outcome: 1.1 Persons with P1 Protective humoral response." data-id="CD011260-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 IPV‐OPV vs OPV, outcome: 1.1 Persons with P1 Protective humoral response.</p> </div> </div> </div> <div class="figure" id="CD011260-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 IPV‐OPV vs IPV, outcome: 2.1 Persons with P1 Protective humoral response." data-id="CD011260-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 IPV‐OPV vs IPV, outcome: 2.1 Persons with P1 Protective humoral response.</p> </div> </div> </div> </section> <section id="CD011260-sec-0095"> <h5 class="title">Other potential sources of bias</h5> <p>All trials seems to be free of other potential sources of bias</p> </section> <section id="CD011260-sec-0096"> <h5 class="title">Conflict of interest</h5> <p>Seven studies received no industry funding and we rated these studies at low risk of bias (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>; <a href="./references#CD011260-bbs2-0017" title="SimasathienS , MigasenaS , BeuveryC , vanSteenisG , SamakosesR , PitisuttithamP , et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases1994;26(6):731‐8. [DOI: 10.3109/00365549409008643; PUBMED: 7747098] ">Simasathien 1994</a>; <a href="./references#CD011260-bbs2-0018" title="SutterRW , SuleimanAJ , MalankarPG , MehtaFR , MedanyMA , ArifMA , et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. Journal of Infectious Diseases1997;175 Suppl 1:S235‐40. [DOI: 10.1093/infdis/175.Supplement_1.S235; PUBMED: 9203722] ">Sutter 1997</a>). We rated one study at high risk of bias because the director of the study was also the medical director of the sponsor (<a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>). We considered the eight remaining studies to be unclear risk of bias; six because they declared industry funding (<a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0006" title="HalseyNA , BlatterM , BaderG , ThomsML , WillinghamFF , O'DonovanJC , et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two‐, four‐ and six‐month‐old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatric Infectious Disease Journal1997;16(7):675‐9. [DOI: 10.1097/00006454‐199707000‐00010; PUBMED: 9239772] ">Halsey 1997</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>; <a href="./references#CD011260-bbs2-0020" title="WestDJ , RabalaisGP , WatsonB , KeyserlingHL , MatthewsH , HesleyTM . Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b‐hepatitis B vaccine with diphtheria‐tetanus‐pertussis, polio and measles‐mumps‐rubella vaccines. Biodrugs2001;15(6):413‐8. [DOI: 10.2165/00063030‐200115060‐00007; PUBMED: 11520252] ">West 2001</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>), and two because they did not describe funding (<a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>). There were no other potential sources of bias. </p> </section> </section> <section id="CD011260-sec-0097"> <h4 class="title">ITS and UBA studies</h4> <section id="CD011260-sec-0098"> <h5 class="title">Protection against secular changes</h5> <section id="CD011260-sec-0099"> <h6 class="title">Intervention is independent of other changes</h6> <p>We rated three studies at low risk of bias on this domain since the intervention appears to occur independently of other changes over time (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). </p> </section> <section id="CD011260-sec-0100"> <h6 class="title">Data were analysed appropriately</h6> <p>We considered two studies to be at unclear risk of bias on this domain because we re‐analysed the data as an ITS (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>). </p> <p>We considered one study to be at high risk of bias because the available data did not allow us to re‐analyse it (<a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). </p> </section> <section id="CD011260-sec-0101"> <h6 class="title">Reason for the number of points pre‐ and post‐intervention given</h6> <p>We rated three studies at low risk of bias on this domain because they provided many points pre‐ and post‐intervention (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). </p> </section> <section id="CD011260-sec-0102"> <h6 class="title">Shape of the intervention effect was specified</h6> <p>We rated the mixed study by <a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a> at low risk of bias. We rated two studies at unclear risk of bias because the data were not designed as an ITS (<a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>, which we re‐analysed; and <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>, which did not specify the shape). </p> </section> </section> <section id="CD011260-sec-0103"> <h5 class="title">Protection against detection bias</h5> <section id="CD011260-sec-0104"> <h6 class="title">Blinded assessment of primary outcome(s)</h6> <p>We rated three studies at low risk of bias because they used objective outcomes that are not likely to be influenced by the lack of blinding (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). </p> <p>We considered two studies to be at unclear risk of bias because although acute flaccid paralysis (AFP) and virological testing are objective outcomes, VAPP requires interpretation and the method by which cases were identified was not clearly stated (<a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>). </p> </section> <section id="CD011260-sec-0105"> <h6 class="title">Reliable primary outcome measure(s)</h6> <p>We rated all five studies at low risk of bias on this domain; three because the outcomes were obtained using an automated system (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>), and two because the surveillance systems had data quality controls (<a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>). </p> </section> <section id="CD011260-sec-0106"> <h6 class="title">Intervention unlikely to affect data collection</h6> <p>We rated two studies at low risk of bias because data collection methods were the same before and after the intervention (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>), and one study at unclear risk of bias because this information was not reported (<a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). </p> </section> <section id="CD011260-sec-0107"> <h6 class="title">Completeness of data set</h6> <p>We rated one study at low risk of bias (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>). We judged two studies to be at unclear risk of bias because they used national databases (<a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). </p> </section> </section> <section id="CD011260-sec-0108"> <h5 class="title">Protection against exclusion bias</h5> <section id="CD011260-sec-0109"> <h6 class="title">Follow‐up of professionals</h6> <p>We rated three studies at low risk of bias on this domain since national AFP surveillance implies a complete nationwide follow‐up; the follow‐up period was long enough; and no changes to protocols were reported (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>). </p> </section> <section id="CD011260-sec-0110"> <h6 class="title">Follow‐up of patients</h6> <p>We rated three studies at low risk of bias on this domain, since national AFP surveillance implies a complete nationwide follow‐up; the follow‐up period was long enough; and no changes to protocols were reported (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>). </p> </section> </section> <section id="CD011260-sec-0111"> <h5 class="title">Conflict of interest</h5> <p>No study received industry funding, therefore, we rated all five studies at low risk of bias on this domain. </p> </section> </section> </section> <section id="CD011260-sec-0112"> <h3 class="title" id="CD011260-sec-0112">Effects of interventions</h3> <p>See: <a href="./full#CD011260-tbl-0001"><b>Summary of findings for the main comparison</b> IPV‐OPV compared to OPV for preventing poliomyelitis</a>; <a href="./full#CD011260-tbl-0002"><b>Summary of findings 2</b> IPV‐OPV compared to IPV for preventing poliomyelitis</a>; <a href="./full#CD011260-tbl-0003"><b>Summary of findings 3</b> IPV(3)‐OPV compared to IPV(2)‐OPV for preventing poliomyelitis</a> </p> <p>See <a href="./appendices#CD011260-sec-0176">Appendix 1</a> Glossary to facilitate the reading of this section particularly for long‐combined schedules. In general, 'I' represents Inactivated Polio Vaccine (IPV) and 'O' represents Oral Polio Vaccine (OPV). Where O or OPV is used below we refer to trivalent OPV. Where bO or bOPV is used we refer to Bivalent OPV. P1, P2, and P3 refer respectively to Poliovirus Serotype 1, 2 and 3. </p> <section id="CD011260-sec-0113"> <h4 class="title">Comparison 1: IPV‐OPV versus OPV</h4> <p>See <a href="./full#CD011260-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>This comparison includes 12 RCTs with 4813 participants (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>; <a href="./references#CD011260-bbs2-0017" title="SimasathienS , MigasenaS , BeuveryC , vanSteenisG , SamakosesR , PitisuttithamP , et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases1994;26(6):731‐8. [DOI: 10.3109/00365549409008643; PUBMED: 7747098] ">Simasathien 1994</a>; <a href="./references#CD011260-bbs2-0018" title="SutterRW , SuleimanAJ , MalankarPG , MehtaFR , MedanyMA , ArifMA , et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. Journal of Infectious Diseases1997;175 Suppl 1:S235‐40. [DOI: 10.1093/infdis/175.Supplement_1.S235; PUBMED: 9203722] ">Sutter 1997</a>; <a href="./references#CD011260-bbs2-0020" title="WestDJ , RabalaisGP , WatsonB , KeyserlingHL , MatthewsH , HesleyTM . Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b‐hepatitis B vaccine with diphtheria‐tetanus‐pertussis, polio and measles‐mumps‐rubella vaccines. Biodrugs2001;15(6):413‐8. [DOI: 10.2165/00063030‐200115060‐00007; PUBMED: 11520252] ">West 2001</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>). </p> <p>We also included one interrupted time series (ITS) study (<a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>, n = 28,330), and three nationwide studies: two uncontrolled before‐and‐after (UBA) studies (<a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>), and one study that used a mixed design (ITS + UBA analysis for vaccine‐associated paralytic polio (VAPP) cases) (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>). </p> <section id="CD011260-sec-0114"> <h5 class="title">Paralytic polio</h5> <p>One nationwide ITS study assessed this outcome (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>). It is uncertain if IPV‐OPV compared to OPV reduces the number of cases of wild poliovirus (WPV) since this study provided very low‐certainty evidence of the effect of this outcome. </p> <p>In <a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>, the national vaccination policy in the USA changed in 1997 from a reliance on OPV to options for a sequential IPV‐OPV schedule. In 2000, an exclusive IPV schedule was adopted. We re‐analysed the data considering the year 1997 as transition period, our re‐analysis of the OPV to IPV‐OPV schedule on reported cases of paralytic poliomyelitis showed a change in level of −0.3 (95% confidence interval (CI) −2.2 to 1.5; −36.0%), a change in slope of 0.1 (95% CI −1.0 to 1.2), and an estimated effect at three years of −0.2 (95% CI −1.3 to 0.9; −21.0%; very low‐certainty evidence). </p> <p>Not considering a transition period, the ITS showed a change in level of 0.4 (95% CI −0.6 to 1.3; 59.0%), change in slope of −0.3 (95% CI −0.9 to 0.3), and an estimated effect at three years of −0.3 (95% CI −1.3 to 0.8; −32.0%). </p> </section> <section id="CD011260-sec-0115"> <h5 class="title">Vaccine‐associated paralytic polio (VAPP)</h5> <p>Three nationwide, UBA studies showed that the sequential IPV‐OPV scheme compared with the previous OPV schemes may substantially reduce cases of VAPP (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>; <a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>). Although there is no international standard, we judged the preventive effect size of the intervention as large (low certainty‐evidence). </p> <p><a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>, in the USA, analysed national acute flaccid paralysis (AFP) surveillance data conducted by the Centers for Disease Control and Prevention from 1990 to 1999. </p> <p> <ul id="CD011260-list-0023"> <li> <p><b>Before.</b> Exclusive use of OPV scheme OOOO (OPV at aged two, four, and 12 to 18 months and again at four to six years) between 1990 and 1996: 46 VAPP cases occurred, 1 VAPP case per 2.9 million doses or 0.34 VAPP cases per million of OPV doses. </p> </li> <li> <p><b>After.</b> Sequential scheme IIOO (IPV at two and four months of age followed by OP\/ at 12 to 18 months, and again at four to six years of age) between 1997 and 1999: 13 VAPP cases occurred, none of them occurred in persons who had followed the sequential IPV‐OPV or IPV‐only schedules. </p> </li> <li> <p><b>Before‐After.</b> Comparing 1990 to 1996 with 1998 to 1999, the average number of VAPP cases per year decreased from 6.6 to 3.0, which equates to a reduction of 54.3%. The average number of sporadic contact cases decreased by 68%; community‐acquired cases and immunologically abnormal cases both decreased by 100%. </p> </li> </ul> </p> <p><a href="./references#CD011260-bbs2-0007" title="IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , GmylAP , YakovenkoML , et al. Vaccine‐associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006‐2013 yy.) [Вакцинный паралитический полиомиелит в Российской Федерации в период изменений (2006‐2013 гг.)]. Voprosy Virusologii2016;61(1):9‐15. [DOI: 10.18821/0507‐4088‐2016‐61‐1‐9‐15; PUBMED: 27145594] IvanovaOE , EremeevaTP , MorozovaNS , ShakaryanAK , KorotkovaEA , KozlovskayaLI , et al. Vaccine‐associated paralytic poliomyelitis in the Russian Federation in 1998‐2014. International Journal of Infectious Diseases2018;76:64‐9. [DOI: 10.1016/j.ijid.2018.08.017; PUBMED: 30201507] ">Ivanova 2018</a>, in the Russian Federation, analysed national acute flaccid paralysis (AFP) surveillance data from 1998 to 2014. Out of the 6643 cases of AFP, 127 cases were VAPP: 82 cases were observed in OPV recipients and 45 cases in non‐vaccinated contacts. Poliovirus type 2 (23.7%) and type 3 (39.5%) were isolated most often. Half of the children had a burdened premorbid status and 67% had various immunological disorders before presenting with VAPP. </p> <p> <ul id="CD011260-list-0024"> <li> <p><b>Before.</b> Exclusive use of OPV scheme OOOO (OPV at ages six, 18, and 20 months and again at 14 years) between 1998 and 2007: 1 VAPP case per 1.59 million OPV doses, 7.64 VAPP cases per million newborns (5.64 and 1.99 VAPP cases per million newborns in OPV recipients (rVAPP) and non‐vaccinated contacts (cVAPP), respectively: rVAPP/cVAPP ratio = 2.83). The VAPP cases yielded mostly type 3 (38.5%): rVAPP isolates were type 3 (69.2%) or mixtures of types 2 and 3 (56.7%); and cVAPP cases yielded types 2 (44%) and 3 (40%). </p> </li> <li> <p><b>After.</b> Sequential scheme IIIOOOO ( IPV at ages three and 4.5 months; OPV at ages six, 18 and 20 months and again at 14 years) between 2008 and 2014: 1 case per 4.18 million doses, 1.56 cases per million newborns (0.23 and 1.33 VAPP cases per million newborns in OPV recipients and contacts, respectively: rVAPP/cVAPP ratio = 0.17). VAPP cases occurred mainly in unvaccinated children as a result of contact with an OPV recipient and also in recipients, who, for various reasons, received OPV in violation of the vaccination schedule. Individual serotypes were mostly isolated: 85% from cases of VAPP in general and 100% from cVAPP. During the same time period, no case was associated with poliovirus type 1. </p> </li> <li> <p><b>Before‐After.</b> Observed reduction of 79.58% of cases per million newborns with the sequential scheme (95.92% and 33.17% reduction in VAPP cases per million newborns in OPV recipients and contacts, respectively). </p> </li> </ul> </p> <p><a href="./references#CD011260-bbs2-0009" title="KapusinszkyB , MolnárZ , SzomorKN , BerencsiG . Molecular characterization of poliovirus isolates from children who contracted vaccine‐associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunology and Medical Microbiology2010;58(2):211‐7. [DOI: 10.1111/j.1574‐695X.2009.00621.x; PUBMED: 19863665] ">Kapusinszky 2010</a>, in Hungary, analysed national AFP surveillance data from 1992 to 2006. During that period, 90 VAPP cases were reported. </p> <p> <ul id="CD011260-list-0025"> <li> <p><b>Before.</b> Exclusive use of OPV scheme (mOPV1, mOPV2, mOPV3, separated by six weeks, at two to 38 months of age) between 1959 and 1992: 90 cases of VAPP. </p> </li> <li> <p><b>After.</b> Sequential scheme IOOOOO (IPV at two to 38 months of age, tOPV six weeks later‐OPV) between 1992 and 2006; zero cases of VAPP. </p> </li> <li> <p><b>Before‐After.</b> Observed reduction of 100% of cases. </p> </li> </ul> </p> <p>Out of the 90 VAPP cases, 52 were associated with Sabin 3‐related virus (76% of VAPP cases with virologic data). No evidence was found for prolonged monovalent OPV type 3 (mOPV3) replication in the VAPP patients or for spread of Sabin 3‐related viruses beyond close vaccinee contacts. We could not judge the clinical meaningfulness of this level of change, due to the lack of international standards. </p> </section> <section id="CD011260-sec-0116"> <h5 class="title">Protective immune responses</h5> <section id="CD011260-sec-0117"> <h6 class="title">Humoral and intestinal immunity</h6> <p>Twelve RCTs provided data on this outcome (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>; <a href="./references#CD011260-bbs2-0017" title="SimasathienS , MigasenaS , BeuveryC , vanSteenisG , SamakosesR , PitisuttithamP , et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases1994;26(6):731‐8. [DOI: 10.3109/00365549409008643; PUBMED: 7747098] ">Simasathien 1994</a>; <a href="./references#CD011260-bbs2-0020" title="WestDJ , RabalaisGP , WatsonB , KeyserlingHL , MatthewsH , HesleyTM . Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b‐hepatitis B vaccine with diphtheria‐tetanus‐pertussis, polio and measles‐mumps‐rubella vaccines. Biodrugs2001;15(6):413‐8. [DOI: 10.2165/00063030‐200115060‐00007; PUBMED: 11520252] ">West 2001</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>). </p> <p>We grouped, analysed and presented the results according to P1, P2 and P3 protective humoral and intestinal immunity. We also present the respective results from subgroup analyses by serotype. The efficacy of IPV‐OPV by serotype P1, P2 and P3 is presented in additional <a href="#CD011260-tbl-0007">Table 4</a>. </p> <div class="table" id="CD011260-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Efficacy of IPV‐OPV by serotype P1, P2 and P3</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serotype</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Favours</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b><i>IPV‐OPV vs OPV</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="15" valign=""> <p><b>P1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.1 Persons with protective humoral response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1.1 Sequential IOO/IOOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.98 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1.2 Sequential IIO/IIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1.3 Sequential IOI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.93 to 1.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.13 Mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13.1 Sequential IbObO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>362.12 (−329.70 to 1053.94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13.2 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−181.13 (−594.25 to 231.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13.3 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−244.37 (−827.31 to 338.57)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13.4 Sequential IIIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439.07 (−354.63 to 1232.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.16 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16.1 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.48 to 0.48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16.2 Sequential IOO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (−0.33 to 0.73)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16.3 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.22 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16.4 Sequential IIO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.01 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.19.1 Persons with polio faecal excretion after OPV challenge</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.86 (1.21 to 2.86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="19" valign=""> <p><b>P2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.7 Persons with protective humoral response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.97 to 1.04)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.1 Sequential IbObO (bOPV)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.78 to 0.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.2 Sequential IOO/IOOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.98 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.3 Sequential IIO/IIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.4 Sequential IbOI (vs bObObO)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.85 (4.10 to 8.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.5 Sequential IbOI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.75 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.6 Sequential IOI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.99 to 1.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.14 Mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.1 Sequential IbObO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−260.38 (−347.21 to −173.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.2 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.64 (−22.16 to 79.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.3 Sequential IIbO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−217.90 (−305.36 to −130.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.4 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267.40 (−83.95 to 618.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.5 Sequential IIIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>486.17 (−698.02 to 1670.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.17 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17.1 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (−0.26 to 0.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17.2 Sequential IOO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (−0.30 to 0.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17.3 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.38 to 0.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17.4 Sequential IIO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (−0.11 to 0.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.10.2 Persons with polio faecal excretion after OPV challenge</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 (1.49 to 2.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="17" valign=""> <p><b>P3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.11 Persons with protective humoral response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.96 to 1.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11.1 Sequential IbObO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.60 to 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11.2 Sequential IOO/IOOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 ([0.96 to 1.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11.3 Sequential IIO/IIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.96 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11.4 Sequential IOI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.95 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.15 Mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.1 Sequential IbObO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>221.03 (9.66 to 432.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.2 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.07 (−1.47 to 89.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.3 Sequential IIbO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>591.78 (185.14 to 998.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.4 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.97 (8.98 to 170.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.5 Sequential IIIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>248.39 (−180.58 to 677.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.18 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18.1 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.50 (−1.14 to 0.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18.2 Sequential IOO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.61 to 0.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18.3 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.02 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18.4 Sequential IIO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (−0.34 to 0.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.19.3 Persons with polio faecal excretion after OPV challenge</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42 (1.60 to 3.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>IPV‐OPV vs IPV</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="16" valign=""> <p><b>P1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1 Persons with P1 protective humoral response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.98 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1.2 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1.3 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (1.00 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.4 Mean titres of P1 neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1520.59 (1084.80 to 1956.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>799.47 (530.82 to 1068.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>866.53 (478.83 to 1254.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>767.90 (337.75 to 1198.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.7 Long‐term mean titres of P1 neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.20 (−0.73 to 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7.2 Sequential IOO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.30 (−0.83 to 0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (−0.04 to 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7.4 Sequential IIO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.40 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.1 Persons with faecal excretion after OPV challenge (ibOI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.19 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.2 Persons with faecal excretion after OPV challenge (IIO/IIOO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.59 to 1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="17" valign=""> <p><b>P2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.2 Persons with protective humoral response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.64 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.96 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2.3 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2.4 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.5 Mean titres of neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−125.93 (−174.77 to −77.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142.25 (57.65 to 226.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−83.45 (−133.40 to −33.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>787.97 (573.84 to 1002.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.8 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (−0.06 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8.2 Sequential IOO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.60 (−0.96 to −0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (−0.19 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8.4 Sequential IIO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.40 (−0.78 to −0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.3 Persons with faecal excretion after OPV challenge (ibOI/IIbO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.68 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.4 Persons with faecal excretion after OPV challenge (IIO/IIOO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.09 to 0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="16" valign=""> <p><b>P3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.3 Persons with protective humoral response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.98 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.97 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3.2 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.96 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3.3 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.96 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.6 Mean titres of neutralising</b> a<b>ntibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327.62 (134.82 to 520.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110.39 (−77.98 to 298.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>698.37 (301.06 to 1095.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184.52 (−211.93 to 580.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.9 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.60 (−1.22 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9.2 Sequential IOO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.30 (−0.76 to 0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (−0.04, 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9.4 Sequential IIO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.10 (−0.46 to 0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.5 Persons with faecal excretion after OPV challenge(ibOI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.26 to 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.6 Persons with faecal excretion after OPV challenge (IIO/IIOO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.32 to 0.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>IPV:</b> inactivated poliovirus vaccine; <b>MD:</b> mean difference; <b>NS:</b> non‐statistically significant; <b>OPV:</b> oral poliovirus vaccine; <b>P:</b> poliovirus; <b>RR:</b> risk ratio; <b>=:</b> non‐statistically and non‐clinically significant </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>For definition of each sequence (e.g. sequential IOO), see Glossary in <a href="./appendices#CD011260-sec-0176">Appendix 1</a>. </p> </div> </div> <section id="CD011260-sec-0118"> <p><b>P1 protective humoral immunity</b></p> <p>There is no difference between the two treatments for number of persons with P1 protective humoral immunity (risk ratio (RR) 1.00, 95% CI 0.99 to 1.01; P = 0.60; 12 studies, 3189 participants; <a href="./references#CD011260-fig-0006" title="">Analysis 1.1</a>; moderate‐certainty evidence). There is no heterogeneity (Tau = 0.00; Chi<sup>2</sup> = 7.80, df = 14 (P = 0.90); I<sup>2</sup> = 0%). </p> <p>Subgroup analyses </p> <p> <ul id="CD011260-list-0026"> <li> <p>Timing of the first dose: the test for subgroup differences indicates that there is no statistically significant subgroup effect (Test for subgroup differences: Chi<sup>2</sup> = 0.33, df = 1 (P = 0.57), I<sup>2</sup> = 0%; <a href="./references#CD011260-fig-0007" title="">Analysis 1.2</a>). First dose given at birth (RR 1.04 CI 0.91 to 1.20; 1 study, 50 participants); First dose given at two months (RR 1.00 CI 0.99 to 1.01; 12 studies, 3139 participants); there is no heterogeneity (Tau<sup>2</sup> = 0.00; Chi = 7.61, df = 10 (P = 0.67), I<sup>2</sup> = 0%). </p> </li> <li> <p>Type of dose sequence: the test for subgroup differences indicates that there is no statistically significant subgroup effect (Chi<sup>2</sup> = 0.51, df = 2 (P = 0.78), I<sup>2</sup> = 0%; <a href="./references#CD011260-fig-0008" title="">Analysis 1.3</a>). IOO/IOOO dose sequence: RR 1.00, 95% CI 0.98 to 1.01; 5 studies, 695 participants; moderate‐certainty evidence. There is no heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.69, df = 4 (P = 0.95), I<sup>2</sup> = 0%). IIO/IIOO/IIIO dose sequence: RR 1.00, 95% CI 0.99 to 1.01; 8 studies, 1772 participants; moderate‐certainty evidence. There is no heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 5.51, df = 7 (P = 0.60), I<sup>2</sup> = 0%). IOI dose sequence: RR 1.03 CI 0.93 to 1.14; 2 studies, 722 participants; moderate‐certainty evidence. Heterogeneity is moderately high (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.95; df = 1 (P = 0.16); I<sup>2</sup> = 49%). </p> </li> <li> <p>Country or location: the test for subgroup differences indicates that there is no statistically significant subgroup effect (Test for subgroup differences: Chi<sup>2</sup> = 0.41, df = 1 (P = 0.52), I<sup>2</sup> = 0%; <a href="./references#CD011260-fig-0009" title="">Analysis 1.4</a>). Low and middle‐income countries: RR 1.00, 95% CI 0.99 to 1.01; 4 studies, 1331 participants. Heterogeneity is low (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 3.13, df = 3 (P = 0.37); I<sup>2</sup> = 4%). High‐income countries: RR 1.01, 95% CI 0.99 to 1.02; 8 studies, 1858 participants. There is no heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 5.08, df = 7 (P = 0.65); I<sup>2</sup> = 0%). </p> </li> </ul> </p> </section> <section id="CD011260-sec-0119"> <p><b>P2 protective humoral immunity</b></p> <p>The test for subgroup differences indicates that there is a high probability of real differences between the different types of doses (Chi<sup>2</sup> = 99.08, df = 3 (P &lt; 0.001), I<sup>2</sup> = 97.0%; <a href="./references#CD011260-fig-0010" title="">Analysis 1.5</a>); therefore, we did not present potentially misleading overall effect. There is probably no difference between the treatments in terms of the number of persons with P2 protective humoral immunity for the IPV‐tOPV and IIbO dosing schemes. IbObO may be worse than tOPV and IbObO is probably better than bOPV. </p> <p>We present below a post hoc subgroup analysis of the bOPV component of the sequential schedule IPV‐tOPV versus IPV‐bOPV. </p> <p><b>IPV‐tOPV (none using bOPV) </b> </p> <p>There is probably no difference between the treatments in terms of the number of persons with P2 protective humoral immunity for the IPV‐tOPV and IIbO dosing schemes. </p> <p> <ul id="CD011260-list-0027"> <li> <p>IIO/IIOO/IIIO/IOO/IOOO: RR 1.00, 95% CI 0.99 to 1.01; 11 studies, 2361 participants; I<sup>2</sup> = 0%; low‐certainty evidence. </p> </li> </ul> </p> <p><b>IPV‐bOPV </b> </p> <p>There is probably no difference between the treatments in terms of the number of persons with P2 protective humoral immunity for IIbO dosing schemes, IbObO may be worse than tOPV and IbObO is probably better than bOPV. </p> <p> <ul id="CD011260-list-0028"> <li> <p>IIbO: RR 1.00, 95% CI 0.93 to 1.07; 1 study, 105 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence). </p> </li> <li> <p>IbObO vs tOPV: RR 0.78, 95% CI 0.64 to 0.96; 2 studies, 411 participants; I<sup>2</sup> = 80%; low‐certainty evidence). </p> </li> <li> <p>IbObO vs bOPV; RR 5.80, 95% CI 4.06 to 8.27; 1 study, 306 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence). </p> </li> </ul> </p> <p>Subgroup analyses </p> <p> <ul id="CD011260-list-0029"> <li> <p>Timing of the first dose: the test for subgroup differences indicates that there is no statistically significant subgroup effect (Test for subgroup differences: Chi<sup>2</sup> = 0.06, df = 1 (P = 0.80), I<sup>2</sup> = 0%; <a href="./references#CD011260-fig-0011" title="">Analysis 1.6</a>.) </p> </li> <li> <p>Type of dose sequence: the test for subgroup differences indicates that there is a statistically significant subgroup effect (Test for subgroup differences: Chi<sup>2</sup> = 134.11, df = 5 (P &lt; 0.001), I<sup>2</sup> = 96.3%; <a href="./references#CD011260-fig-0012" title="">Analysis 1.7</a>). Vaccination with OPV using the IbObO (bOPV) (RR 0.85, 95% CI 0.78 to 0.91; 1 study, 211 participants; moderate‐certainty evidence) and IbOI (RR 0.82, 95% CI 0.75 to 0.90; 1 study, 309 participants; moderate‐certainty evidence) dose sequences, or vaccination with IPV‐OPV using the IbOI (vs bObObO) dose sequence (RR 5.85, 95% CI 4.10 to 8.34; 1 study, 305 participants; moderate‐certainty evidence) may increase the number of persons with P2 protective humoral immunity. There are no differences between the two treatments with the other dose sequences. </p> </li> <li> <p>Country or location: the test for subgroup differences indicates that there is no statistically significant subgroup effect (Test for subgroup differences: Chi<sup>2</sup> = 2.05, df = 1 (P = 0.15), I<sup>2</sup> = 51.2%; <a href="./references#CD011260-fig-0013" title="">Analysis 1.8</a>). </p> </li> </ul> </p> </section> <section id="CD011260-sec-0120"> <p><b>P3 humoral immunity</b></p> <p>Vaccination with IPV‐OPV may make little or no difference to the number of people with P3 protective humoral immunity (RR 0.99, 95% CI 0.97 to 1.00; 12 studies, 3184 participants; <a href="./references#CD011260-fig-0014" title="">Analysis 1.9</a>; low‐certainty evidence). There is moderate heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 28.21, df = 16 (P = 0.03); I<sup>2</sup> = 43%). </p> <p>Subgroup analyses </p> <p> <ul id="CD011260-list-0030"> <li> <p>Timing of the first dose: the test for subgroup differences indicates that there is no statistically significant subgroup effect (Test for subgroup differences: Chi<sup>2</sup> = 1.20, df = 1 (P = 0.27), I<sup>2</sup> = 16.7%; <a href="./references#CD011260-fig-0015" title="">Analysis 1.10</a>). First dose at birth: RR 1.17 CI 0.87 to 1.57; 1 study, 50 participants. First dose at two months: RR 0.99 CI 0.97 to 1.01; 11 studies, 2963 participants; however, heterogeneity is high (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 29.12, df = 11 (P = 0.002); I<sup>2</sup> = 62%). </p> </li> <li> <p>Type of dose sequence: the test for subgroup differences indicates that there is a statistically significant subgroup effect (Test for subgroup differences: Chi<sup>2</sup> = 17.48, df = 3 (P &lt; 0.001), I<sup>2</sup> = 82.8%; <a href="./references#CD011260-fig-0016" title="">Analysis 1.11</a>). Vaccination with OPV using the IbObO dose sequence may increase the number of persons with P3 protective humoral immunity (RR 0.70, 95% CI 0.60 to 0.82; 1 study, 105 participants; moderate‐certainty evidence). There are no differences between the two treatments with the other dose sequences. </p> </li> <li> <p>Country or location: the test for subgroup differences indicates that there is no statistically significant subgroup effect (Test for subgroup differences: Chi<sup>2</sup> = 0.71, df = 1 (P = 0.40), I<sup>2</sup> = 0%; <a href="./references#CD011260-fig-0017" title="">Analysis 1.12</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011260-sec-0121"> <h6 class="title">Mean titres of neutralising antibodies</h6> <p>Six studies contributed data on this outcome (<a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0015" title="RamsayME , BeggNT , GandhiJ , BrownD . Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatric Infectious Disease Journal1994;13(12):1117‐21. [DOI: 10.1097/00006454‐199412000‐00009; PUBMED: 7892081] ">Ramsay 1994</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>; <a href="./references#CD011260-bbs2-0017" title="SimasathienS , MigasenaS , BeuveryC , vanSteenisG , SamakosesR , PitisuttithamP , et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases1994;26(6):731‐8. [DOI: 10.3109/00365549409008643; PUBMED: 7747098] ">Simasathien 1994</a>; <a href="./references#CD011260-bbs2-0018" title="SutterRW , SuleimanAJ , MalankarPG , MehtaFR , MedanyMA , ArifMA , et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. Journal of Infectious Diseases1997;175 Suppl 1:S235‐40. [DOI: 10.1093/infdis/175.Supplement_1.S235; PUBMED: 9203722] ">Sutter 1997</a>). We excluded the oldest RCT, <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>, from these analyses because it used a very different method to measure antibody titres than the more recent studies. In that study, sequential schemes showed higher neutralising antibodies titre than OPV, for all serotypes except for P3 when used only one dose of IPV: </p> <p> <ul id="CD011260-list-0031"> <li> <p>sequential IIO: P1 mean titre = 3044; P2 mean titre = 10693; and P3 mean titre = 2347;</p> </li> <li> <p>sequential IOO: P1 mean titre = 2174: P2 mean titre = 11110; and P3 mean titre = 857; and </p> </li> <li> <p>sequential OOO: P1 mean titre = 1470; P2 mean titre = 3378; and P3 mean titre = 1522.</p> </li> </ul> </p> <p>For this outcome, we only present the results of the subgroup analyses because there was considerable statistical heterogeneity, even in each subgroup (I<sup>2</sup> range from 83% to 97%). </p> <section id="CD011260-sec-0122"> <p><b>P1 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 3.61, df = 3 (P = 0.31), I<sup>2</sup> = 16.9%). None of the individual results were statistically significant and thus we are uncertain of the effects of vaccination with IPV‐OPV, compared with OPV, on mean titres of P1 neutralising antibodies (<a href="./references#CD011260-fig-0018" title="">Analysis 1.13</a>). </p> <p> <ul id="CD011260-list-0032"> <li> <p>IbObO dose sequence: MD 362.12, 95% CI −329.70 to 1053.94; 1 study, 125 participants; low‐certainty evidence. </p> </li> <li> <p>IOO dose sequence: MD −181.13, 95% CI −594.25 to 231.99; 3 studies, 606 participants; low‐certainty evidence. However, heterogeneity is high (Tau<sup>2</sup> = 105900.15, Chi<sup>2</sup> = 16.07, df = 2 (P &lt; 0.001; I<sup>2</sup> = 88%). </p> </li> <li> <p>IIO dose sequence: MD −244.37, 95% CI −827.31 to 338.57; 3 studies/substudies, 795 participants; low‐certainty evidence. However, heterogeneity is high (Tau<sup>2</sup> = 282922.07, Chi<sup>2</sup> = 17.51, df = 3 (P &lt; 0.001); I<sup>2</sup> = 83%). </p> </li> <li> <p>IIIOO/IIIO dose sequence: MD 439.07, 95% CI −354.63 to 1232.77; 2 studies, 551 participants; low‐certainty evidence. However, heterogeneity is high (Tau<sup>2</sup> = 317869.30, Chi<sup>2</sup> = 32.22, df = 1 (P &lt; 0.001); I<sup>2</sup> = 97%). </p> </li> </ul> </p> </section> <section id="CD011260-sec-0123"> <p><b>P2 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 48.27, df = 4 (P &lt; 0.001), I<sup>2</sup> = 91.7%). Vaccination with OPV using the IbObO and IIbO dose sequences may reduce mean titres of P2 neutralising antibodies compared to IPV‐OPV, whereas vaccination with IPV‐OPV using the IOO, IIO, and IIIOO/IIIO dose sequences may make little or no difference on the mean titres of P2 neutralising antibodies compared with OPV. See <a href="./references#CD011260-fig-0019" title="">Analysis 1.14</a>. </p> <p> <ul id="CD011260-list-0033"> <li> <p>IbObO dose sequence: MD −260.38, 95% CI −347.21 to −173.55; 1 study, 125 participants; moderate‐certainty evidence. </p> </li> <li> <p>IOO dose sequence: MD 28.64, 95% CI −22.16 to 79.43; 3 studies, 606 participants; low‐certainty evidence. There is no heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.20, df = 2 (P = 0.91); I<sup>2</sup>= 0%). </p> </li> <li> <p>IIbO dose sequence: MD −217.90, 95% CI −305.36 to −130.44; 1 study, 125 participants; moderate‐certainty of evidence of large effect. </p> </li> <li> <p>IIO dose sequence: MD 267.40, 95% CI −83.95 to 618.76; 3 studies, 667 participants; low‐certainty of evidence. There is considerable heterogeneity (Tau<sup>2</sup> = 57792.38; Chi<sup>2</sup> = 9.40, df = 2 (P = 0.009); I<sup>2</sup> = 79%). </p> </li> <li> <p>IIIOO/IIIO dose sequence: MD 486.17, 95% CI −698.02 to 1670.37; 2 studies, 551 participants; low‐certainty evidence. There is high heterogeneity (Tau<sup>2</sup> = 702371.09; Chi<sup>2</sup> = 25.67, df = 1 (P &lt; 0.001); I<sup>2</sup> = 96%). </p> </li> </ul> </p> </section> <section id="CD011260-sec-0124"> <p><b>P3 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 10.41, df = 4 (P = 0.03), I<sup>2</sup> = 61.6%). Vaccination with IPV‐OPV using the IbObO, IIbO, and IIO dose sequences may increase mean titres of P3 neutralising antibodies compared to OPV, whereas vaccination with IPV‐OPV using the IOO and IIIOO/IIIO dose sequences may make little or no difference on the mean titres of P3 neutralising antibodies compared with OPV. See <a href="./references#CD011260-fig-0020" title="">Analysis 1.15</a>. </p> <p> <ul id="CD011260-list-0034"> <li> <p>IbObO dose sequence: MD 221.03, 95% CI 9.66 to 432.40; 1 study, 125 participants; moderate‐certainty evidence. </p> </li> <li> <p>IOO dose sequence: MD 44.07, 95% CI −1.47 to 89.61; 3 studies, 606 participants; low‐certainty evidence. There is no heterogeneity (Tau = 0.00; Chi = 1.12, df = 2 (P = 0.57); I<sup>2</sup> = 0%). </p> </li> <li> <p>IIbO dose sequence: MD 591.78, 95% CI 185.14 to 998.42; 1 study, 125 participants; moderate‐certainty of evidence of moderate effect. </p> </li> <li> <p>IIO dose sequence: MD 89.97, 95% CI 8.98 to 170.97; 3 studies, 667 participants; moderate‐certainty of evidence of large effect. Heterogeneity is moderate (Tau<sup>2</sup> = 1653.80; Chi<sup>2</sup> = 2.91, df = 2 (P = 0.23); I<sup>2</sup> = 31%). </p> </li> <li> <p>IIIOO/IIIO dose sequence: MD 248.39, 95% CI −180.58 to 677.37; 2 studies, 551 participants; very low‐certainty evidence. Heterogeneity is high (Tau<sup>2</sup> = 91317.08; Chi<sup>2</sup> = 20.83, df = 1 (P &lt; 0.001); I<sup>2</sup> = 95%). </p> </li> </ul> </p> </section> </section> <section id="CD011260-sec-0125"> <h6 class="title">Long‐term mean titres of neutralising antibody</h6> <p>One study contributed data on this outcome (<a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>). </p> <p>We grouped, analysed and presented the results according to P1, P2 and P3 protective humoral immunity. We also presented the respective results from subgroup analyses by serotype and by scheme. </p> <section id="CD011260-sec-0126"> <p><b>P1 neutralising antibody</b></p> <p>Vaccination with IPV‐OPV may increase the long‐term mean titres of P1 neutralising antibodies, compared to OPV (MD 0.35, 95% CI 0.07 to 0.63; 1 study, 86 participants; <a href="./references#CD011260-fig-0021" title="">Analysis 1.16</a>; low‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.02; Chi<sup>2</sup> = 4.33, df = 3 (P = 0.23); I<sup>2</sup> = 31%). </p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 4.33, df = 3 (P = 0.23), I<sup>2</sup> = 30.7%). Vaccination with IPV‐OPV may increase the long‐term mean titres of P1 neutralising antibodies, compared to OPV, but only with the IIO and IIO + O dose sequences (<a href="./references#CD011260-fig-0021" title="">Analysis 1.16</a>; low‐certainty evidence). </p> <p> <ul id="CD011260-list-0035"> <li> <p>IOO dose sequence: MD 0.00, 95% CI −0.48 to 0.48; 1 study, 20 participants; low‐certainty evidence. </p> </li> <li> <p>IOO + O dose sequence: MD 0.20, 95% CI −0.33 to 0.73; 1 study, 20 participants; low‐certainty evidence. </p> </li> <li> <p>IIO dose sequence: MD 0.60, 95% CI 0.22 to 0.98; 1 study, 23 participants; low‐certainty evidence. </p> </li> <li> <p>IIO + O dose sequence: MD 0.50, 95% CI 0.01 to 0.99; 1 study, 23 participants; low‐certainty evidence. </p> </li> </ul> </p> </section> <section id="CD011260-sec-0127"> <p><b>P2 neutralising antibody</b></p> <p>Vaccination with IPV‐OPV may produce minimal or no difference on the long‐term mean titres of P2 neutralising antibodies, compared to OPV (MD 0.12, 95% CI −0.07 to 0.31; 1 study, 86 participants; <a href="./references#CD011260-fig-0022" title="">Analysis 1.17</a>; low‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.15, df = 3 (P = 0.77); I<sup>2</sup> = 0%). </p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 1.15, df = 3 (P = 0.77), I<sup>2</sup> = 0%). Vaccination with IPV‐OPV may make little or no difference on the long‐term mean titres of P2 neutralising antibodies compared with OPV (<a href="./references#CD011260-fig-0022" title="">Analysis 1.17</a>; low‐certainty evidence). </p> <p> <ul id="CD011260-list-0036"> <li> <p>IOO dose sequence: MD 0.10, 95% CI −0.26 to 0.46; 1 study, 20 participants; low‐certainty evidence. </p> </li> <li> <p>IOO + O dose sequence: MD 0.10, 95% CI −0.30 to 0.50; 1 study, 20 participants; low‐certainty of evidence. </p> </li> <li> <p>IIO dose sequence: MD 0.00, 95% CI −0.38 to 0.38; 1 study, 23 participants; low‐certainty evidence. </p> </li> <li> <p>IIO + O dose sequence: MD 0.30, 95% CI −0.11 to 0.71; 1 study, 23 participants; low‐certainty evidence. </p> </li> </ul> </p> </section> <section id="CD011260-sec-0128"> <p><b>P3 neutralising antibody</b></p> <p>Vaccination with IPV‐OPV may produce minimal or no difference on the long‐term mean titres of P3 neutralising antibodies, compared to OPV (MD 0.08, 95% CI −0.29 to 0.45; 1 study, 86 participants; <a href="./references#CD011260-fig-0023" title="">Analysis 1.18</a>; low‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.07; Chi<sup>2</sup> = 5.92, df = 3 (P = 0.12); I<sup>2</sup> = 49%). </p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 5.92, df = 3 (P = 0.12), I<sup>2</sup> = 49.3%). Vaccination with IPV‐OPV may increase the long‐term mean titres of P3 neutralising antibodies, compared to OPV, but only with the IIO dose sequence (<a href="./references#CD011260-fig-0023" title="">Analysis 1.18</a>; low‐certainty of evidence). </p> <p> <ul id="CD011260-list-0037"> <li> <p>IOO dose sequence: MD −0.50, 95% CI −1.14 to 0.14; 1 study, 20 participants; low‐certainty evidence. </p> </li> <li> <p>IOO + O dose sequence: MD 0.00, 95% CI −0.61 to 0.61; 1 study, 20 participants; low‐certainty evidence. </p> </li> <li> <p>IIO dose sequence: MD 0.40, 95% CI 0.02 to 0.78; 1 study, 23 participants; low‐certainty evidence. </p> </li> <li> <p>IIO + O dose sequence: MD 0.20, 95% CI −0.34 to 0.74; 1 study, 23 participants; low‐certainty evidence. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011260-sec-0129"> <h5 class="title">Intestinal immunity</h5> <p>Two studies with 916 participants contributed data on this outcome (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>). </p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect by serotype (Test for subgroup differences: Chi<sup>2</sup> = 1.25, df = 2 (P = 0.54), I<sup>2</sup> = 0%). IPV‐OPV probably increases P2 and P3 poliovirus faecal excretion after OPV challenge, compared to OPV. It may also increase or decrease P1 faecal excretion after OPV challenge. </p> <p> <ul id="CD011260-list-0038"> <li> <p>P1 faecal excretion after OPV challenge: RR 2.24, 95% CI 0.70 to 7.12; 2 studies, 916 participants; low‐certainty evidence. There is moderate heterogeneity (Tau<sup>2</sup> = 0.53; Chi<sup>2</sup> = 3.68, df = 1 (P = 0.06); I<sup>2</sup> = 73%. </p> </li> <li> <p>P2 faecal excretion after OPV challenge: RR 1.78, 95% CI 1.49 to 2.14; 2 studies, 916 participants; moderate‐certainty evidence. There is no heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.09, df = 1 ( P = 0.76); I<sup>2</sup> = 0). </p> </li> <li> <p>P3 faecal extraction after OPV challenge: RR 2.35, 95% CI 1.47 to 3.76; 2 studies, 916 participants; moderate‐certainty evidence. There is low heterogeneity (Tau<sup>2</sup> = 0.03; Chi<sup>2</sup> = 1.25, df = 1 (P = 0.26); I<sup>2</sup> = 20%). </p> </li> </ul> </p> <p>Thus, compared to OPV, vaccination with IPV‐OPV probably increases the number of people with polio faecal excretion after OPV challenge; <a href="./references#CD011260-fig-0024" title="">Analysis 1.19</a>; moderate‐certainty evidence). </p> </section> <section id="CD011260-sec-0130"> <h5 class="title">Vaccination coverage in children</h5> <p>One ITS study that involved 28,330 participants (Group Health Cooperative Puget Sound (GHC) = 2721 participants and Kaiser Permanente Northern California (KPNC) = 25,609 enrollees) assessed this outcome (<a href="./references#CD011260-bbs2-0004" title="DavisRL , LieuTA , MellLK , CapraAM , ZavitkovskyA , QuesenberryCPJr , et al. Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics2001;107(4):671‐6. [DOI: 10.1542/peds.107.4.671; PUBMED: 11335742] ">Davis 2001</a>). The changeover from an OPV‐only schedule to one containing IPV had little (if any) negative impact on vaccine coverage (average vaccine coverage: 91.9% with OPV and 92.4% with IPV‐OPV; low‐certainty evidence). There was no difference between the two treatments (RR 1.01, 95% CI 0.96 to 1.06; <a href="./references#CD011260-fig-0025" title="">Analysis 1.20</a>; low‐certainty evidence); the RR for KPNC was 1.04 (95% CI 1.00 to 1.08) and for GHC was 0.99 (95% CI 0.98 to 1.00). This outcome had high levels of heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 5.69, df = 1 (P = 0.02); I<sup>2</sup> = 82%). </p> <p>At GHC, children who received IPV were less likely to have a missed opportunity visit by 12 months of age (odds ratio (OR) 0.46, 95% CI 0.31 to 0.70), but this finding did not persist at 24 months of age. At Kaiser Permanente, children who received IPV were more likely to have a missed opportunity by 12 months of age (OR 2.06, 95% CI 1.84 to 2.30) and 24 months of age (OR 1.50, 95% CI 1.36 to 1.67). Use of IPV was associated with a small increase in the likelihood of being up to date in polio vaccinations at two years of age at one of the HMOs and, conversely, was associated with a small increase in the likelihood of having a missed opportunity visit in the other HMO. </p> </section> <section id="CD011260-sec-0131"> <h5 class="title">Safety</h5> <p>Four studies involving 1948 participants assessed serious adverse events (SAE) as classified by the Medical Dictionary for Regulatory Activities Terminology (<a href="https://www.meddra.org/" target="_blank">MedDRA</a>): <a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0010" title="LiRC , LiCG , WangHB , LuoHM , LiYP , WangJF , et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. Journal of the Pediatric Infectious Diseases Society2016;5(3):287‐96. [DOI: 10.1093/jpids/piv017; PUBMED: 26407255] ">Li 2016a</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; and <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>. The evidence suggests that vaccination with IPV‐OPV may make little or no difference to the number of persons with SAEs compared with OPV (RR 0.88, 95% CI 0.46 to 1.70; <a href="./references#CD011260-fig-0026" title="">Analysis 1.21</a>; low‐certainty evidence); heterogeneity was moderate (Tau<sup>2</sup> = 0.17, Chi<sup>2</sup> = 4.93, df = 3 (P = 0.18); I<sup>2</sup> = 39%). </p> </section> <section id="CD011260-sec-0132"> <h5 class="title">Sensitivity analysis</h5> <p>To test the robustness of the results, we performed a sensitivity analysis by method of meta‐analysis, comparing the effects of using a random‐effects model (default analysis) to a fixed‐effect model (analyses not shown). We found changes in statistical significance only, not in the direction of the effect. The results of the following analyses changed from non‐statistically significant to statistically significant with a random‐effects model compared to a fixed‐effect model respectively. </p> <p> <ul id="CD011260-list-0039"> <li> <p><a href="./references#CD011260-fig-0018" title="">Analysis 1.13</a>. Mean titres of P1 neutralising antibody: </p> <ul id="CD011260-list-0040"> <li> <p>Sequential IIO: MD −244.37, 95% CI −827.31 to 338.57, P = 0.41 versus MD −453.75, 95% CI −642.57 to −264.93, P &lt; 0.001; and </p> </li> <li> <p>Sequential IIIOO/IIIO: MD 439.07, 95% CI −354.63 to 1232.77, P = 0.28 versus MD 253.99, 95% CI 130.68 to 377.29, P &lt; 0.001. </p> </li> </ul> </li> <li> <p><a href="./references#CD011260-fig-0019" title="">Analysis 1.14</a>. Mean titre of P2 neutralising antibody &gt; Sequential IIO: MD 267.40, 95% CI −83.95 to 618.76, P = 0.14 versus MD 127.27, 95% CI 56.53 to 198.00, P &lt; 0.001. </p> </li> <li> <p><a href="./references#CD011260-fig-0020" title="">Analysis 1.15</a>. Mean titres of P3 neutralising antibody &gt; Sequential IIIOO/IIIO: MD 248.39, 95% CI −180.58 to 677.37, P = 0.26 versus MD 97.56, 95% CI 32.63 to 162.48, P = 0.003. </p> </li> <li> <p><a href="./references#CD011260-fig-0024" title="">Analysis 1.19</a>. Persons with polio faecal extraction after OPV challenge &gt; Persons with P1 faecal excretion: RR 2.24, 95% CI 0.70 to 7.12, P = 0.17 versus RR 1.86, 95% CI 1.21 to 2.86, P = 0.005). </p> </li> </ul> </p> <p>A post hoc sensitivity analysis including studies at low risk of bias for allocation concealment showed an identical effect: RR 1.00, 95% CI 0.99 to 1.02; 4 studies, 1303 participants; I<sup>2</sup> = 0% (analysis not shown). </p> </section> </section> <section id="CD011260-sec-0133"> <h4 class="title">Comparison 2: IPV‐OPV versus IPV</h4> <p>See <a href="./full#CD011260-tbl-0002">summary of findings Table 2</a>. </p> <p>This comparison includes 10 RCTs with 4675 participants (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0006" title="HalseyNA , BlatterM , BaderG , ThomsML , WillinghamFF , O'DonovanJC , et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two‐, four‐ and six‐month‐old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatric Infectious Disease Journal1997;16(7):675‐9. [DOI: 10.1097/00006454‐199707000‐00010; PUBMED: 9239772] ">Halsey 1997</a>; <a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>). We also included one ITS study, which included 2.7 million people (<a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>) and one study that used a mixed design (ITS + UBA analysis for VAPP cases) (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>). </p> <section id="CD011260-sec-0134"> <h5 class="title">Paralytic polio</h5> <p>Two nationwide ITS studies assessed this outcome (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>; <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>). It is uncertain if IPV‐OPV compared to IPV reduces the number of wild polio cases since both studies provided very low‐certainty evidence of the effect of this outcome. We were unable to combine the data in a meta‐analysis, since the studies reported the data in very different ways. Therefore, we provide a narrative summary of their results. </p> <p>We re‐analysed the ITS data of the change from an IPV‐OPV to IPV schedule in <a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a> and provided absolute change in level and relative change in level if it was estimable. Considering the year 1997 as transition period, we obtained a change in level or 'step' of −1.2 (95% CI −2.9 to 0.6; −100%), a change in slope trend of 0.0 (95% CI −1.2 to 1.2), and an estimated effect at three years of −1.2 (95% CI −5.0 to 2.7, % not estimable) and at four years of −1.2 (95% CI −6.2 to 3.8; −100%, representing a potential complete elimination of cases; very low‐certainty evidence). </p> <p>Not considering a transition period, the ITS data showed a change in level of −0.7 (95% CI −2.1 to 0.7; −100%), change in slope of 0.4 (95% CI −1.2 to 0.4), and estimated effect at three years of 0.1 (95% CI −2.5 to 2.7, % not estimable) and at four years of 0.5 (95% CI −2.9 to 3.8, % not estimable). </p> <p>The polio vaccination program in the <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a> study in Denmark reported 35 cases of AFP due to WPV with an IPV schedule and 1 case with a sequential IPV‐OPV schedule. </p> </section> <section id="CD011260-sec-0135"> <h5 class="title">Vaccine‐associated paralytic polio (VAPP) cases</h5> <p>No study reported on this outcome.</p> </section> <section id="CD011260-sec-0136"> <h5 class="title">Vaccine‐derived poliovirus</h5> <p>No study reported on this outcome.</p> </section> <section id="CD011260-sec-0137"> <h5 class="title">Protective immune responses</h5> <section id="CD011260-sec-0138"> <h6 class="title">Humoral and intestinal immunity</h6> <p>The nationwide ITS study in Denmark, <a href="./references#CD011260-bbs2-0019" title="VonMagnusH , PetersenI . Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases1984;6 Suppl 2:S471‐4. [DOI: 10.1093/clinids/6.Supplement_2.S471; PUBMED: 6740095] ">Von Magnus 1984</a>, assessed the use of an IPV‐only schedule before 1961 and the use of the sequential IPV‐OPV schedule during the period 1973 to 1980. The median proportion of people with protective humoral response for poliovirus serotypes 1, 2 and 3 was 82.06%, 91.94% and 76.67% with IPV, and it was higher with IPV‐OPV: 98.44%; 97.67%; and 97.57% respectively (low‐certainty evidence). </p> <p>We were able to combine data from 10 studies (4204 participants) that provided data on this outcome (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0003" title="AsturiasEJ , DuegerEL , OmerSB , MelvilleA , NatesSV , LaassriM , et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. Journal of Infectious Diseases2007;196(5):692‐8. [DOI: 10.1086/520546; PUBMED: 17674310] ">Asturias 2007</a>; <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0006" title="HalseyNA , BlatterM , BaderG , ThomsML , WillinghamFF , O'DonovanJC , et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two‐, four‐ and six‐month‐old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatric Infectious Disease Journal1997;16(7):675‐9. [DOI: 10.1097/00006454‐199707000‐00010; PUBMED: 9239772] ">Halsey 1997</a>; <a href="./references#CD011260-bbs2-0008" title="JainPK , DuttaAK , NangiaS , KhareS , SailiA . Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics1997;64(4):511‐5. [DOI: 10.1007/BF02737758; PUBMED: 10771880] ">Jain 1997</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>; <a href="./references#CD011260-bbs2-0021" title="YehSH , WardJI , PartridgeS , MarcySM , LeeH , JingJ , et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatric Infectious Disease Journal2001;20(10):973‐80. [DOI: 10.1097/00006454‐200110000‐00011; PUBMED: 11642632] ">Yeh 2001</a>. </p> <p>We grouped, analysed and presented the results according P1, P2 and P3 protective humoral and intestinal immunity. </p> <section id="CD011260-sec-0139"> <p><b>P1 protective humoral and intestinal immunity</b></p> <p>There is no difference between the two treatments for number of people with P1 protective humoral and intestinal immunity (RR 1.00, 95% CI 0.99 to 1.01; P = 0.96; 10 studies, 2858 participants; <a href="./references#CD011260-fig-0027" title="">Analysis 2.1</a>; moderate‐certainty evidence). There is no heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 13.27, df = 12 (P = 0.35); I<sup>2</sup> = 10%). </p> <p>Subgroup analyses </p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect by type of dosing sequence although there is moderate heterogeneity (Test for subgroup differences: Chi<sup>2</sup> = 4.68, df = 2 (P = 0.10), I<sup>2</sup> = 57.3%). Compared with IPV, vaccination with IPV‐OPV using the IbOI dose sequence may increase slightly the number of persons with P1 protective humoral and intestinal immunity (RR 1.05, 95% CI 1.00 to 1.10; 1 study, 519 participants; moderate‐certainty evidence. There are no differences between the two treatment with the other dose sequences: </p> <p> <ul id="CD011260-list-0041"> <li> <p>sequential IOO: RR 1.00, 95% CI 0.98 to 1.02; 4 studies, 572 participants; moderate‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 2.57, df = 3 (P = 0.46); I<sup>2</sup> = 0%; and </p> </li> <li> <p>sequential IIO(O): RR 1.00, 95% CI 0.99 to 1.01; 8 studies, 1767 participants; moderate‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.00, Chi<sup>2</sup> = 1.76, df = 7 (P = 0.97); I = 0%. </p> </li> </ul> </p> </section> <section id="CD011260-sec-0140"> <p><b>P2 protective humoral and intestinal immunity</b></p> <p>There is no difference between the two treatments for the number of people with P2 protective humoral and intestinal immunity (RR 0.97, 95% CI 0.95 to 1.00; P = 0.08; 10 studies, 2907; <a href="./references#CD011260-fig-0028" title="">Analysis 2.2</a>; low‐certainty evidence). However, heterogeneity is high (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 135.19, df = 13 (P &lt; 0.001); I<sup>2</sup> = 90%). </p> <p>Subgroup analyses </p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 10.82, df = 3 (P = 0.01), I<sup>2</sup> = 72.3%). Vaccination with OPV using the IbObO dose sequence may decrease the number of persons with P2 protective humoral and intestinal immunity (RR 0.76, 95% CI 0.64 to 0.91; 2 studies, 382 participants; low‐certainty evidence); however, there is considerable heterogeneity for this outcome (Tau<sup>2</sup> = 0.01; Chi<sup>2</sup> = 4.41, df = 1 (P = 0.04); I<sup>2</sup> = 77%). There are no differences between the two treatments for: </p> <p> <ul id="CD011260-list-0042"> <li> <p>sequential IOO: RR 1.00, 95% CI 0.96 to 1.04; 3 studies, 227 participants; moderate‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.49, df = 2 (P = 0.78); I<sup>2</sup> = 0%; </p> </li> <li> <p>sequential IIO(O): RR 1.00, 95% CI 0.99 to 1.01; 8 studies, 1779 participants; moderate‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.39, df = 7 (P = 0.99); I<sup>2</sup> = 0%); and </p> </li> <li> <p>sequential IbOI: RR 1.01, 95% CI 0.88 to 1.02; 1 study, 519 participants; moderate‐certainty evidence. </p> </li> </ul> </p> </section> <section id="CD011260-sec-0141"> <p><b>P3 protective humoral and intestinal immunity</b></p> <p>There is no difference between the two treatments for the number of people with P3 protective humoral and intestinal immunity (RR 0.99, 95% CI 0.97 to 1.01; P = 0.27; 9 studies, 2620 participants; <a href="./references#CD011260-fig-0029" title="">Analysis 2.3</a>; moderate‐certainty evidence). There is moderate heterogeneity (Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 23.72, df = 11 (P = 0.01); I<sup>2</sup> = 54%). </p> <p>Subgroup analyses </p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect by any of the three types of dose sequences (Test for subgroup differences: Chi<sup>2</sup> = 0.52, df = 2 (P = 0.77), I<sup>2</sup> = 0%): </p> <p> <ul id="CD011260-list-0043"> <li> <p>sequential IOO: RR 0.99, 95% CI 0.96 to 1.02; 4 studies, 570 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 4.47, df = 3 (P = 0.21); I<sup>2</sup> = 33%; </p> </li> <li> <p>sequential IIO(O): RR 0.99 CI 0.96 to 1.01; 7 studies, 1531 participants; I<sup>2</sup> = 72%; low‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 21.11, df = 6 (P = 0.002); I<sup>2</sup> = 72%; and </p> </li> <li> <p>sequential IbOI: RR 1.01, 95% CI 0.96 to 1.05; 1 study, 519 participants; moderate‐certainty evidence. </p> </li> </ul> </p> </section> </section> <section id="CD011260-sec-0142"> <h6 class="title">Mean titres of neutralising antibodies</h6> <p>We identified three studies for this outcome (<a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>; <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>; <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>). Only two of the studies were included in the analysis, <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a> and <a href="./references#CD011260-bbs2-0016" title="LaassriM , LottenbachK , BelsheR , RennelsM , PlotkinS , ChumakovK . Analysis of reversions in the 5′‐untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Journal of Infectious Diseases2006;193(10):1344‐9. [DOI: 10.1086/503366; PUBMED: 16619180] LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] RennelsMB , EnglundJA , BernsteinDI , LosonskyGA , AndersonEL , PichicheroME , et al. Diminution of the anti‐polyribosylribitol phosphate response to a combined diphtheria‐tetanus‐acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatric Infectious Disease Journal2000;19(5):417‐23. [DOI: 10.1097/00006454‐200005000‐00006; PUBMED: 10819337] ">Rennels 2000</a>. We excluded the oldest RCT, <a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>, from these analyses because it used a very different method to measure antibody titres than the more recent studies. In that study, sequential schemes showed higher neutralising antibodies titre for all serotypes except for P3 for OPV: </p> <p> <ul id="CD011260-list-0044"> <li> <p>sequential IIO: P1 mean titres = 3044; P2 mean titre = 10693; and P3 mean titre = 2347; </p> </li> <li> <p>sequential IOO: P1 mean titres = 2174; P2 mean titre = 11110; and P3 mean titre = 857; and </p> </li> <li> <p>sequential III: P1 mean titre = 1954; P2 mean titre = 5835; and P3 mean titre = 5187.</p> </li> </ul> </p> <section id="CD011260-sec-0143"> <p><b>P1 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 8.61, df = 3 (P = 0.03), I<sup>2</sup> = 65.2%; <a href="./references#CD011260-fig-0030" title="">Analysis 2.4</a>). Vaccination with IPV‐OPV, compared to IPV, may increase the mean titres of P1 neutralising antibodies across all dose sequences shown below. </p> <p> <ul id="CD011260-list-0045"> <li> <p>Sequential IbObO: MD 1520.59, 95% CI 1084.80 to 1956.38; 1 study, 127 participants; moderate‐certainty evidence. </p> </li> <li> <p>Sequential IOO: MD 799.47, 95% CI 530.82 to 1068.12; 1 study, 127 participants; moderate‐certainty evidence. </p> </li> <li> <p>Sequential IIbO: MD 866.53, 95% CI 478.83 to 1254.23; 1 study, 127 participants; moderate‐certainty evidence. </p> </li> <li> <p>Sequential IIO: MD 767.90, 95% CI 337.75 to 1198.06; 2 studies, 363 participants; low‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 68203.59; Chi<sup>2</sup> = 3.39, df = 1 (P = 0.07); I<sup>2</sup> = 70%). </p> </li> </ul> </p> </section> <section id="CD011260-sec-0144"> <p><b>P2 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 31.27, df = 3 (P &lt; 0.001), I<sup>2</sup> = 90.4%; <a href="./references#CD011260-fig-0031" title="">Analysis 2.5</a>). Vaccination with IPV using the IbObO and IIbO sequences may reduce mean titres of P2 neutralising antibodies compared to IPV‐OPV, whereas vaccination with IPV‐OPV using the IOO and IIO sequences may increase mean titres of P2 neutralising antibodies compared with IPV. </p> <p> <ul id="CD011260-list-0046"> <li> <p>Sequential IbObO: MD −125.93, 95% CI −174.77 to −77.09; 1 study, 127 participants; moderate‐certainty evidence. </p> </li> <li> <p>Sequential IOO: MD 142.25, 95% CI 57.65 to 226.85; 1 study, 127 participants; moderate‐certainty evidence. </p> </li> <li> <p>Sequential IIbO: MD −83.45, 95% CI −133.40 to −33.50; 1 study, 127 participants; moderate‐certainty evidence. </p> </li> <li> <p>Sequential IIO: MD 2224.48, 95% CI −1145.70 to 5594.67; 2 studies, 362 participants; very low‐certainty evidence of large effect; heterogeneity: Tau = 5829599.24; Chi<sup>2</sup> = 69.81, df = 1 (P &lt; 0.001); I<sup>2</sup> = 99%. </p> </li> </ul> </p> </section> <section id="CD011260-sec-0145"> <p><b>P3 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 7.71, df = 3 (P = 0.05), I<sup>2</sup> = 61.1%; <a href="./references#CD011260-fig-0032" title="">Analysis 2.6</a>). Compared to IPV, vaccination with IPV‐OPV using the IbObO and IIbO sequences increases mean titres of P3 neutralising antibodies, but makes little or no difference when using the IOO and IIO sequences. </p> <p> <ul id="CD011260-list-0047"> <li> <p>Sequential IbObO: MD 327.62, 95% CI 134.82 to 520.42; 1 study, 127 participants; moderate‐certainty evidence. </p> </li> <li> <p>Sequential IOO: MD 110.39, 95% CI −77.98 to 298.76; 1 study, 127 participants; low‐certainty evidence. </p> </li> <li> <p>Sequential IIbO: MD 698.37, 95% CI 301.06 to 1095.68; 1 study, 127 participants; moderate‐certainty evidence. </p> </li> <li> <p>Sequential IIO: MD 184.52, 95% CI −211.93 to 580.97; 2 studies, 360 participants; I<sup>2</sup> = 87%; very low‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 71965.06; Chi<sup>2</sup> = 7.76, df = 1 (P = 0.005); I<sup>2</sup> = 87%. </p> </li> </ul> </p> </section> </section> <section id="CD011260-sec-0146"> <h6 class="title">Long‐term mean titres of neutralising antibody</h6> <p>A single study contributed data on this outcome (<a href="./references#CD011260-bbs2-0005" title="FadenH . Results of a clinical study of polio vaccine: the Buffalo experience. Pediatric Infectious Disease Journal1991;10(12):973‐5. [PUBMED: 1766725] FadenH , DuffyL , SunM , ShuffC . Long‐term immunity to poliovirus in children immunized with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases1993;168(2):452‐4. [DOI: 10.1093/infdis/168.2.452; PUBMED: 8335983] FadenH , ModlinJF , ThomsML , McBeanAM , FerdonMB , OgraPL . Comparative evaluation of immunization with live attenuated and enhanced‐potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. Journal of Infectious Diseases1990;162(6):1291‐7. [DOI: 10.1093/infdis/162.6.1291; PUBMED: 2172403] ">Faden 1990</a>). </p> <section id="CD011260-sec-0147"> <p><b>P1 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 13.89, df = 3 (P = 0.003), I<sup>2</sup> = 78.4%; <a href="./references#CD011260-fig-0033" title="">Analysis 2.7</a>). Of the four dose sequences, only one was statistically significant, and suggests that vaccination with IPV‐OPV using a IIO + O dose sequence may increase long‐term mean titres of P1 neutralising antibody compared with IPV. </p> <p> <ul id="CD011260-list-0048"> <li> <p>Sequential IOO: MD −0.20, 95% CI −0.73 to 0.33; 1 study, 37 participants; very low‐certainty evidence. </p> </li> <li> <p>Sequential IOO + O: MD −0.30, 95% CI −0.83 to 0.23; 1 study, 37 participants; very low‐certainty evidence. </p> </li> <li> <p>Sequential IIO: MD 0.40, 95% CI −0.04 to 0.84; 1 study, 40 participants; very low‐certainty evidence. </p> </li> <li> <p>Sequential IIO + O: MD 0.90, 95% CI 0.40 to 1.40; 1 study, 40 participants; low‐certainty evidence. </p> </li> </ul> </p> </section> <section id="CD011260-sec-0148"> <p><b>P2 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 16.46, df = 3 (P &lt; 0.001), I<sup>2</sup> = 81.8%; <a href="./references#CD011260-fig-0034" title="">Analysis 2.8</a>. Of the four dose sequences, only two were statistically significant; both suggest that IPV with either a IOO + O or a IIO + O dose sequence may reduce long‐term mean titres of P2 neutralising antibody. </p> <p> <ul id="CD011260-list-0049"> <li> <p>Sequential IOO: MD 0.20, 95% CI −0.06 to 0.46; 1 study, 37 participants; very low‐certainty evidence. </p> </li> <li> <p>Sequential IOO + O: MD −0.60, 95% CI −0.96 to −0.24; 1 study, 37 participants; low‐certainty evidence. </p> </li> <li> <p>Sequential IIO: MD 0.10, 95% CI −0.19 to 0.39; 1 study, 40 participants; very low‐certainty evidence. </p> </li> <li> <p>Sequential IIO + O: MD −0.40, 95% CI −0.78 to −0.02; 1 study, 40 participants low‐certainty evidence. </p> </li> </ul> </p> </section> <section id="CD011260-sec-0149"> <p><b>P3 neutralising antibody</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 8.29, df = 3 (P = 0.04), I<sup>2</sup> = 63.8%; <a href="./references#CD011260-fig-0035" title="">Analysis 2.9</a>). None of the individual results were statistically significant and thus we are uncertain of the effects of vaccination with IPV‐OPV, compared with IPV, on long‐term mean titres of P3 neutralising antibody. </p> <p> <ul id="CD011260-list-0050"> <li> <p>Sequential IOO: MD −0.60, 95% CI −1.22 to 0.02; 1 study, 37 participants; very low‐certainty evidence. </p> </li> <li> <p>Sequential IOO + O: MD −0.30, 95% CI −0.76 to 0.16; 1 study, 37 participants; low‐certainty evidence. </p> </li> <li> <p>Sequential IIO: MD 0.30, 95% CI −0.04 to 0.64; 1 study, 40 participants; very low‐certainty evidence. </p> </li> <li> <p>Sequential IIO + O: MD −0.10, 95% CI −0.46 to 0.26; 1 study, 40 participants; very low‐certainty evidence. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011260-sec-0150"> <h5 class="title">Intestinal immunity</h5> <p>Three relevant studies with 2995 participants provided data on intestinal immunity assessed as polio faecal excretion after OPV challenge (<a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011260-bbs2-0012" title="ModlinJF , HalseyNA , ThomsML , MeschievitzCK , PatriarcaPA . Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine‐live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. Journal of Infectious Diseases1997;175 Suppl 1:S228‐34. [DOI: 10.1093/infdis/175.Supplement_1.S228; PUBMED: 9203721] ">Modlin 1997</a>; <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>). </p> <section id="CD011260-sec-0151"> <h6 class="title">People with P1 faecal excretion</h6> <p>There is no difference between the two treatments for the number of people with P1 faecal excretion after OPV challenge (RR 0.52, 95% CI 0.14 to 1.97; 2 studies, 822 participants I<sup>2</sup> = 94%; data not shown in analysis; very low‐certainty evidence). </p> </section> <section id="CD011260-sec-0152"> <h6 class="title">People with P2 faecal excretion</h6> <p>There is evidence that IPV‐OPV may reduce P2 faecal excretion after OPV challenge (RR 0.55, 95% CI 0.31 to 0.94; 3 studies, 1351 participants; I<sup>2</sup> = 94%; data not shown in analysis; low‐certainty evidence). </p> </section> <section id="CD011260-sec-0153"> <h6 class="title">People with P3 faecal excretion</h6> <p>There is evidence that IPV‐OPV probably reduces P3 poliovirus faecal excretion after OPV challenge compared to IPV (RR 0.39, 95% CI 0.32 to 0.47; 2 studies, 822 participants; I<sup>2</sup> = 0%; data not shown in analysis; moderate‐certainty evidence). </p> <section id="CD011260-sec-0154"> <p><b>Subroup analysis: type of dose sequence</b></p> <p>The test for subgroup differences indicates that there is a statistically significant subgroup effect by type of dose sequence (Test for subgroup differences: Chi<sup>2</sup> = 61.83, df = 5 (P &lt; 0.001), I<sup>2</sup> = 91.9%; <a href="./references#CD011260-fig-0036" title="">Analysis 2.10</a>). </p> <p>There is evidence that, compared to IPV, vaccination with IPV‐OPV probably reduces:</p> <p> <ul id="CD011260-list-0051"> <li> <p>P1 faecal excretion after OPV challenge with sequential ibOI (RR 0.27, 95% CI 0.19 to 0.39; 1 study, 519 participants; moderate‐certainty evidence but not with IIO/IIOO (RR 1.04, 95% CI 0.59 to 1.84; 1 study, 303 participants; low‐certainty evidence); </p> </li> <li> <p>P2 faecal excretion after OPV challenge with sequential IIO/IIOO (RR 0.16, 95% CI 0.09 to 0.28; 1 study, 303 participants; moderate‐certainty evidence but not with ibOI/IIbO (RR 0.85, 95% CI 0.68 to 1.06; 2 studies, 1048 participants; low‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.02; Chi<sup>2</sup> = 3.77, df = 1 (P = 0.05); I<sup>2</sup> = 73%); and </p> </li> <li> <p>P3 faecal excretion after OPV challenge with sequential ibOI (RR 0.37, 95% CI 0.26 to 0.54; 1 study, 519 participants; moderate‐certainty evidence of large effect) and with IIO/IIOO RR 0.40, 95% CI 0.32 to 0.50; 1 study, 303 participants; moderate‐certainty evidence. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011260-sec-0155"> <h5 class="title">Vaccine coverage in children</h5> <p>No study reported on this outcome.</p> </section> <section id="CD011260-sec-0156"> <h5 class="title">Safety</h5> <p>Two studies reported on this outcome. <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a> reported 81 serious adverse events (SAE), of which one was thought to possibly be vaccine‐related (intestinal intussusception four days after receiving the mOPV2 challenge). In <a href="./references#CD011260-bbs2-0014" title="QiuJ , YangY , HuangL , WangL , JiangZ , GongJ , et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non‐inferiority clinical trial. Human Vaccines &amp; Immunotherapeutics2017;13(6):1359‐68. [DOI: 10.1080/21645515.2017.1288769; PMC5489289 ; PUBMED: 28362135] ">Qiu 2017</a>, no vaccine‐related SAEs were reported. Infectious pneumonia was the main SAE (10 participants, 1.67%), followed by bronchitis (four participants, 0.67%) and hand‐foot‐and‐mouth disease (four participants, 0.67%). </p> <p>There was little or no difference between the schedules on number of people experiencing one or more serious adverse event (vaccine related or not) (RR 0.92, 95% CI 0.60 to 1.43; 2 studies, 1063 participants; <a href="./references#CD011260-fig-0037" title="">Analysis 2.11</a>; low‐certainty evidence; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.82, df = 1 (P = 0.37); I<sup>2</sup> = 0%). </p> </section> <section id="CD011260-sec-0157"> <h5 class="title">Sensitivity analysis</h5> <p>To test the robustness of the results, we performed a sensitivity analysis comparing using a random‐effects model (default analysis) to a fixed‐effect model (analyses not shown). We found changes in statistical significance only, not in the direction of the effect. The results of the following analyses changed from non‐statistically significant to statistically significant with a random‐effects model compared to a fixed‐effect model, respectively. </p> <p> <ul id="CD011260-list-0052"> <li> <p><a href="./references#CD011260-fig-0028" title="">Analysis 2.2</a>. Persons with P2 protective humoral response: RR 0.97, 95% CI 0.95 to 1.00, P = 0.07 versus RR 0.96, 95% CI 0.94 to 0.98, P &lt; 0.001. </p> </li> <li> <p><a href="./references#CD011260-fig-0029" title="">Analysis 2.3</a>.2. Persons with P3 protective humoral response &gt; Sequential IIO(O): RR 0.99, 95% CI 0.96 to 1.01, P = 0.39 versus RR 0.98, 95% CI 0.97 to 1.00, P = 0.03. </p> </li> <li> <p><a href="./references#CD011260-fig-0031" title="">Analysis 2.5</a>.4. Mean titres of P2 neutralising antibody &gt; Sequential IIO: MD 2224.48, 95% CI −1145.70 to 5594.67, P = 0.20 versus MD 787.97, 95% CI 573.84 to 1002.09, P &lt; 0.001. </p> </li> <li> <p><a href="./references#CD011260-fig-0036" title="">Analysis 2.10</a>.3. Persons with polio faecal extraction after OPV challenge &gt; persons with P2 faecal excretion after OPV challenge (IbOI/IIbO): RR 0.85, 95% CI 0.68 to 1.06, P = 0.15 versus RR 0.86, 95% CI 0.77 to 0.96, P = 0.007. </p> </li> </ul> </p> </section> </section> <section id="CD011260-sec-0158"> <h4 class="title">Comparison 3: IPV(3)‐OPV versus IPV(2)‐OPV</h4> <p>In this comparison, a single study with 137 participants reported on one outcome only: protective humoral response (<a href="./references#CD011260-bbs2-0011" title="LinderN , HandsherR , GermanB , SirotaL , BachmanM , ZingerS , et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(1):F24‐7. [DOI: 10.1136/fn.83.1.f24; PMC1721105; PUBMED: 10873167] ">Linder 2000</a>). </p> <section id="CD011260-sec-0159"> <h5 class="title">Protective immune responses: humoral and intestinal immunity</h5> <p>There is no difference between the two treatments for P1 (RR 0.98, 95% CI 0.93 to 1.03); P2 (RR 1.00, 95% CI 0.97 to 1.03); or P3 (RR 1.01, 95% CI 0.97 to 1.05) protective humoral and intestinal response (see <a href="./references#CD011260-fig-0038" title="">Analysis 3.1</a>; all moderate‐certainty evidence, <a href="./full#CD011260-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD011260-sec-0160"> <h6 class="title">Subgroup analyses</h6> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect by type of protective humoral response (test for subgroup differences: Chi<sup>2</sup> = 0.98, df = 2 (P = 0.61), I<sup>2</sup> = 0%). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011260-sec-0161" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011260-sec-0161"></div> <section id="CD011260-sec-0162"> <h3 class="title" id="CD011260-sec-0162">Summary of main results</h3> <p>The review includes 21 studies involving 6407 healthy infants in 16 randomised controlled trials (RCTs), 28,330 infants in one interrupted time series (ITS) and also four nationwide studies (from USA Denmark and Hungary). Below we summarise the main findings and outstanding uncertainties by comparison. </p> <section id="CD011260-sec-0163"> <h4 class="title">Comparison 1: IPV‐OPV versus OPV</h4> <p>See <a href="./full#CD011260-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>It is uncertain if IPV‐OPV compared to OPV reduces the number of wild polio cases (very low‐certainty evidence); however, it may substantially reduce cases of vaccine‐associated paralytic polio (VAPP) (low‐certainty‐evidence). </p> <p>We found no important difference between the two treatments for the number of persons with P1, P2 and P3 protective humoral response (moderate‐ and low‐certainty evidence); however; for P2; the sequential scheme IbObO may be worse than tOPV‐only scheme. </p> <p>The subgroup analysis showed variability in the results for all three poliovirus serotypes depending on the schedule used. The most recommended schedule, two doses of IPV followed by one or more doses of OPV (IIO/OO), probably makes little or no difference to the number of people with protective humoral response (moderate‐certainty evidence for P1 and low‐certainty evidence for P2 and P3). There were no differences with other schedules with only one IPV dose for P1, but the response for poliovirus serotype P2 may be lower with IbOI than tOPV only scheme (low‐certainty evidence) (subgroup differences I<sup>2</sup> = 96.3%). The response for poliovirus serotype P3 is probably lower with IbObO (moderate‐certainty evidence) (subgroup differences I<sup>2</sup> = 82.8%). </p> <p>Two doses of IPV followed by one or more doses of OPV (IIO/OO), may make little or no difference to P1 mean titres of neutralising antibodies across all types of dose sequences (low‐certainty evidence). There are differences for poliovirus serotypes P2 and P3. Specifically, for P2, the IIbO and IbObO dose sequences may reduce mean titres of neutralising antibodies (moderate‐certainty evidence), whereas the IOO, IIO and IIIOO/IIIO (all low‐certainty evidence) dose sequences may make little to no difference (subgroup differences: I<sup>2</sup> = 91.7%). Regarding P3, vaccination with IPV‐OPV using the IbObO, IIbO, and IIO dose sequences may increase mean titres of P3 neutralising antibodies compared to OPV, whereas using the IOO and IIIOO/IIIO dose sequences may make little or no difference on the mean titres of P3 neutralising antibodies compared with OPV (low‐certainty and very low‐certainty evidence respectively) (subgroup differences: I<sup>2</sup> = 61.6%). </p> <p>IPV‐OPV seems to generate less mucosal immunity, since it probably increases polio virus serotype P2 and P3 faecal excretion after OPV challenge (both moderate‐certainty evidence), and it may increase or decrease the number of persons with P1 polio faecal excretion after OPV challenge (low‐certainty evidence). </p> <p>There were no significant subgroup effects by time of first dose or country or location.</p> <p>Compared to OPV, vaccination with IPV‐OPV may make little or no difference to vaccination coverage or the incidence of serious adverse events (both low certainty‐evidence). </p> <p>Changing the model used for analysis, from a random‐effects to a fixed‐effect model, only changed the level of statistical significance for a few outcomes (mean titres of neutralising antibodies for IIO (P1 and P2) and IIIOO/IIIO (P1 and P3) dose sequences, and the number of people with P1 polio faecal excretion after OPV challenge). It did not change the direction or the interpretation of the results. </p> </section> <section id="CD011260-sec-0164"> <h4 class="title">Comparison 2: IPV‐OPV versus IPV</h4> <p>See <a href="./full#CD011260-tbl-0002">summary of findings Table 2</a>. </p> <p>It is uncertain if IPV‐OPV compared to IPV reduces the number of wild polio cases (very low‐certainty evidence). There were no data on the number of VAPP cases. </p> <p>Compared to IPV, IPV‐OPV probably makes little or no difference to the number of people with protective humoral response for poliovirus serotypes P1 and P3 (moderate‐certainty evidence) and makes little or no difference for P2 (low‐certainty evidence). The subgroup analysis showed no statistically significant subgroup effect for P1 and P3, but did for P2: the number of people with a protective humoral response is probably lower for P2 only, with an IbObO sequence. </p> <p>A subgroup analysis indicated differences in mean titres of neutralising antibodies for poliovirus serotypes 1, 2 and 3 by type of dose sequence. Vaccination with IPV‐OPV, compared to IPV, may increase the mean titres of P1 neutralising antibodies across all dose sequences (low‐ and moderate‐certainty evidence). Using the IbObO and IIbO sequences may reduce mean titres of P2 neutralising antibodies compared to IPV‐OPV, whereas using the IOO and IIO sequences may increase mean titres of P2 neutralising antibodies compared with IPV (moderate‐ and very low‐certainty evidence). The IbObO and IIbO sequences increases mean titres of P3 neutralising antibodies, but makes little or no difference when using the IOO and IIO sequences (very low, low, and moderate‐certainty evidence). </p> <p>IPV‐OPV probably reduces the number of people with P3 poliovirus faecal excretion after OPV challenge (moderate‐certainty evidence), and may reduce the number of people with P2 poliovirus faecal excretion after OPV challenge (low‐certainty evidence). However, there was no difference between the two treatments for P1 (very low‐certainty evidence). A subgroup analysis by dose sequence showed that the following sequences probably reduce the number of people with poliovirus faecal excretion after OPV challenge: ibOI for P1 and P3 (moderate‐certainty evidence); and IIO/IIOO for P2 and P3 (both moderate‐certainty evidence). There was no difference between the two treatments for the number of people with poliovirus faecal excretion after OPV challenge with the following dose sequences: IIO/IIOO for P1; and ibOI/IIbO for P2 (both low‐certainty evidence). </p> <p>IPV‐OPV compared to IPV may make little or no difference to the incidence of serious adverse events. </p> <p>Changing the model used for analysis, from a random‐effects to a fixed‐effect model, only changed the level of statistical significance for a few outcomes (number of people with P2 protective humoral response and P3 protective humoral response with the IIO(O) dose sequence, P2 mean titres of neutralising antibodies with the IIO dose sequence, and number of people with P2 polio faecal excretion after OPV challenge with the IbIO/IIbO dose sequence). It did not change the direction or the interpretation of the results. </p> </section> <section id="CD011260-sec-0165"> <h4 class="title">Comparison 3: IPV(3)‐OPV versus IPV(2)‐OPV</h4> <p>See <a href="./full#CD011260-tbl-0003">summary of findings Table 3</a>. </p> <p>The only outcome assessed by this study was protective humoral response. Three doses of IPV followed by two doses of OPV, compared to two doses of IPV followed by two doses of OPV probably makes little or no difference to the number of persons with protective humoral response (moderate‐certainty evidence). </p> </section> </section> <section id="CD011260-sec-0166"> <h3 class="title" id="CD011260-sec-0166">Overall completeness and applicability of evidence</h3> <p>The relevance of the evidence identified in this review is completely applicable to the review question regarding participants and interventions but not completely applicable to the reported outcomes. Our broad systematic review, in terms of eligible study designs, allowed us to deal, in part, with this limitation. The included RCTs provided a reasonable body of evidence about immunogenicity and short‐term safety concerns. Quasi‐experimental designs (most nationwide) two ITS studies, two uncontrolled before‐after (UBA) studies, and one study that used a mixed ITS and UBA design provided uncertain evidence about wild polio cases, but probably constitute the best available (albeit low‐certainty) evidence regarding the reduction of VAPP cases associated with IPV‐OPV compared to OPV. Based on these considerations we are confident in the external validity of our review. </p> <p>Considering the most recent Wordl Health Organization (WHO) recommendations, our findings align with current practice. In 2012, SAGE recommended the replacement of trivalent OPV (tOPV; containing serotypes 1, 2, and 3) with bivalent OPV (bOPV), containing only serotypes 1 and 3, in all countries by 2016, preceded by the introduction of at least one dose of IPV in routine immunisation programmes (<a href="./references#CD011260-bbs2-0111" title="WHO . Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 ‐ conclusions and recommendations. Relevé épidémiologique hebdomadaire2013;88(1):1‐16. [www.who.int/wer/2013/wer8801.pdf; PUBMED: 23311010] ">WHO 2012</a>). The Polio Eradication and Endgame Strategic Plan 2013 to 2018 recommended completion of IPV introduction and globally synchronised withdrawal of OPV serotype 2 in 2016 (<a href="./references#CD011260-bbs2-0112" title="World Health Organization. Global Polio Eradication Initiative. Polio eradication &amp; endgame strategic plan 2013–2018. polioeradication.org/wp‐content/uploads/2016/07/PEESP_EN_A4.pdf (accessed 17 January 2016). ">WHO 2015a</a>). These recommendations are based on the fact that wild polio virus (WPV) serotype 2 has not been detected since 1999 and serotype 3 since 2012. All cases detected from 2013 onwards are due to serotype 1 (<a href="./references#CD011260-bbs2-0115" title="World Health Organization. Global wild poliovirus 2013‐2018. polioeradication.org/wp‐content/uploads/2018/03/global‐wild‐poliovirus‐2013‐2018‐20180320.pdf (accessed 6 March 2018). ">WHO 2015d</a>, <a href="./references#CD011260-bbs2-0116" title="World Health Organization. Polio vaccines: WHO position paper ‐ March, 2016. Relevé épidémiologique hebdomadaire2016;91(12):145‐68. [www.who.int/wer/2016/wer9112.pdf?ua=1] ">WHO 2016</a>). However, approximately 400 to 500 cases per year of VAPP are caused by OPV (<a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a>), which means that the cases of paralytic poliomyelitis caused by vaccination already exceed those caused by WPV, and are becoming the main source of polio paralysis in the world. This means that polio‐free is not polio risk‐free because live‐attenuated Sabin viruses from OPV could revert to virulence causing VAPP or cVDPV (<a href="./references#CD011260-bbs2-0092" title="MinorP . Vaccine‐derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine2009;27(20):2649‐52. [DOI: 10.1016/j.vaccine.2009.02.071; PUBMED: 19428874] ">Minor 2009</a>). Serotype 2 vaccine‐related viruses continue to induce paralysis and cause 26% of cases of VAPP in vaccinees, 31% in contacts and more than 90% of all cVDPVs (<a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a>, <a href="./references#CD011260-bbs2-0118" title="World Health Organization. Global Polio Eradication Initiative. Global circulating vaccine‐derived poliovirus cases, 2000–17. polioeradication.org/polio‐today/polio‐now/this‐week/circulating‐vaccine‐derived‐poliovirus/ (accessed 6 June 2018). ">WHO 2018</a>). After SAGE's recommendation, 155 countries using OPV in their immunisation programs changed from tOPV to bOPV (<a href="./references#CD011260-bbs2-0111" title="WHO . Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 ‐ conclusions and recommendations. Relevé épidémiologique hebdomadaire2013;88(1):1‐16. [www.who.int/wer/2013/wer8801.pdf; PUBMED: 23311010] ">WHO 2012</a>). This globally synchronised switch in vaccination policy, during a two‐week period, represents an historical milestone reached in the polio eradication effort (<a href="./references#CD011260-bbs2-0059" title="GaronJ , SeibK , OrensteinWA , Ramirez GonzalezA , Chang BlancD , ZaffranM , et al. Polio endgame: the global switch from tOPV to bOPV. Expert Review of Vaccines2016;15(6):693‐708. [DOI: 10.1586/14760584.2016.1140041; PUBMED: 26751187] ">Garon 2016</a>). Even if the two most recent cases of WPV, in February 2018 in Afghanistan, were the last in the world, bOPV will not be retired until 2022 to 2023, after more than three years have passed since the last case (<a href="./references#CD011260-bbs2-0097" title="PengX , HuX , SalazarMA . On reducing the risk of vaccine‐associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine. Lancet2018;392(10147):610‐2. [DOI: 10.1016/S0140‐6736(18)30483‐5; PUBMED: 29605427] ">Peng 2018</a>). For this reason, WHO also decided that at least one IPV, containing the three serotypes of inactivated poliovirus, should be included in the immunisation programs of countries using only OPV schemes to protect against possible future outbreaks of poliovirus serotype 2. The main challenge to this plan is the availability of IPV; the insufficient production of these vaccines, which is unlikely to be remedied in the short term (<a href="./references#CD011260-bbs2-0032" title="AnandA , MolodeckyNA , PallanschMA , SutterRW . Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule. Vaccine2017;35(22):2993‐8. [DOI: 10.1016/j.vaccine.2017.03.008; PUBMED: 28434691] ">Anand 2017</a>). In an unpublished, ongoing study, Peng and colleagues observed five new cases of VAPP in 2016 after administration of the first dose of bOPV, due to a shortage of IPV (<a href="./references#CD011260-bbs2-0097" title="PengX , HuX , SalazarMA . On reducing the risk of vaccine‐associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine. Lancet2018;392(10147):610‐2. [DOI: 10.1016/S0140‐6736(18)30483‐5; PUBMED: 29605427] ">Peng 2018</a>). </p> <p>Given that bOPV will continue to be used widely for several more years, and that new cases of VAPP will inevitably occur, it is essential to discuss key issues such as sequence, timing, pre‐vaccination contraindication screening, relative risk of VAPP with different doses of OPV, and accessibility to IPV. A more rigorous screening of contraindications for bOPV is truly important, since the WHO suggests that immunocompromised patients should avoid vaccination with bivalent bOPV. The evidence suggests that, although bOPV administration is much safer after IPV administration, VAPP can still occur (<a href="./references#CD011260-bbs2-0047" title="DesaiS , DienerT , TanBK , LowryNJ , TalukdarC , ChruschW , et al. An unusual case of vaccine‐associated paralytic poliomyelitis. Canadian Journal of Infectious Diseases &amp; Medical Microbiology2014;25(4):227‐8. [DOI: 10.1155/2014/378320; PMC4173946; PUBMED: 25285130] ">Desai 2014</a>). This finding reminds us that the detection of contraindications cannot be avoided while using OPV. The WHO recommends one or two doses of IPV followed by at least two doses of bOPV in countries with high vaccination coverage (greater than 90%) and low risk of imported WPV (population movement with similar vaccination coverage). Conversely, in countries with endemic polio, lower vaccination coverage or high importation risk (polio importation history or countries bordering with areas of endemic polio or with recurrent outbreaks), the WHO recommends one or more doses of bOPV followed by IPV (<a href="./references#CD011260-bbs2-0115" title="World Health Organization. Global wild poliovirus 2013‐2018. polioeradication.org/wp‐content/uploads/2018/03/global‐wild‐poliovirus‐2013‐2018‐20180320.pdf (accessed 6 March 2018). ">WHO 2015d</a>). The reason for this difference is based on how WHO weights the relative risks of VAPP versus WPV in these two classifications of countries. There is a long‐standing perception that the relative risk of VAPP with the first dose of OPV is lower in low‐income countries than in high‐income countries. This is clearly reflected in a response from <a href="./references#CD011260-bbs2-0121" title="ZhangQ , LeppoldC , ShaoY , MuraY , TanimotoT . New poliovirus vaccine schedules. Lancet2016;388(10059):2477‐8. [DOI: 10.1016/S0140‐6736(16)32177‐8] ">Zhang 2016</a> to the hypothesis posited by <a href="./references#CD011260-bbs2-0033" title="AsturiasEJ , BandyopadhyayAS , SelfS , RiveraL , Saez‐LlorensX , LopezE , et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open‐label randomised controlled trial. Lancet2016;388(10040):158‐69. [DOI: 10.1016/S0140‐6736(16)00703‐0; PUBMED: 27212429] ">Asturias 2016</a>: that IPV‐bOPV sequential administration could be safer than bOPV‐IPV. Asturias and colleagues state that, in high‐ and middle‐income countries, the risk of VAPP is 6.6 times higher with the first dose of OPV than with later doses, while in low‐income countries, the majority of VAPP cases appear after receiving multiple, previous doses of OPV (<a href="./references#CD011260-bbs2-0033" title="AsturiasEJ , BandyopadhyayAS , SelfS , RiveraL , Saez‐LlorensX , LopezE , et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open‐label randomised controlled trial. Lancet2016;388(10040):158‐69. [DOI: 10.1016/S0140‐6736(16)00703‐0; PUBMED: 27212429] ">Asturias 2016</a>). However, as highlighted by <a href="./references#CD011260-bbs2-0097" title="PengX , HuX , SalazarMA . On reducing the risk of vaccine‐associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine. Lancet2018;392(10147):610‐2. [DOI: 10.1016/S0140‐6736(18)30483‐5; PUBMED: 29605427] ">Peng 2018</a>, this conclusion comes from a misinterpretation of a single study conducted in India, which showed that the risk of VAPP with the first dose of OPV was one case per 2.8 million of doses and the risk with subsequent doses was one case per 13.9 million doses (<a href="./references#CD011260-bbs2-0079" title="KohlerKA , BanerjeeK , Gary HladyW , AndrusJK , SutterRW . Vaccine‐associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bulletin of the World Health Organization2002;80(3):210‐6. [PMC2567745; PUBMED: 11984607] ">Kohler 2002</a>). Therefore, the risk of VAPP with the first dose of OPV was almost five times greater than the risk associated with subsequent doses. Other studies in countries of different socioeconomic status, such as the USA (<a href="./references#CD011260-bbs2-0001" title="AlexanderLN , SewardJF , SantibanezTA , PallanschMA , KewOM , PrevotsDR , et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA2004;292(14):1696‐701. [DOI: 10.1001/jama.292.14.1696; PUBMED: 15479934] ">Alexander 2004</a>), Brazil (<a href="./references#CD011260-bbs2-0045" title="deOliveiraLH , StruchinerCJ . Vaccine‐associated paralytic poliomyelitis: a retrospective cohort study of acute flaccid paralyses in Brazil. International Journal of Epidemiology2000;29(4):757‐63. [DOI: 10.1093/ije/29.4.757; PUBMED: 10922356] ">de Oliveira 2000</a>), China (<a href="./references#CD011260-bbs2-0120" title="WuW , WangH , LiK , Pekka NuortiJ , LiuD , XuD , et al. Recipient vaccine‐associated paralytic poliomyelitis in China, 2010‐2015. Vaccine2018;36(9):1209‐13. [DOI: 10.1016/j.vaccine.2018.01.019; PUBMED: 29395524] ">Wu 2018</a>) and Latin America and the Caribbean (<a href="./references#CD011260-bbs2-0082" title="LandaverdeJM , TrumboSP , Danovaro‐HollidayMC , CochiSE , GandhiR , Ruiz‐MatusC . Vaccine‐associated paralytic poliomyelitis in the postelimination era in Latin America and the Caribbean, 1992‐2011. Journal of Infectious Diseases2014;209(9):1393‐402. [DOI: 10.1093/infdis/jit602; PUBMED: 24520126] ">Landaverde 2014</a>), showed that the risk of VAPP with the first dose of OPV was between 4 and 13 times greater than the risk with subsequent doses. Considering the history of OPV vaccination, available for 49% of the total VAPP cases, 74% of cases occurred after the first dose of OPV, and 8%, 7%, and 11% occurred after the second, third, or fourth or more doses, respectively (<a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a>). Among contacts, 52% of cases had never been vaccinated with OPV and the risk of VAPP with the first dose of OPV seems more balanced, with 11%, 8%, and 28% after receiving 1, 2, or 3 or more previous OPV doses, respectively. A low number of recipient and contact VAPP cases reported a history of previous vaccination with IPV, almost any of these cases with enhanced‐potency IPV, that was introduced in the late 1960s (<a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a>). Although the studies were from tOPV, there is no reason to think that with the bOPV it would be very different. </p> <p>The evidence also suggests that the first dose of IPV can induce seroconversion and 'priming' (rapid seroconversion a week after challenge with OPV) in more than 90% of immunised children (<a href="./references#CD011260-bbs2-0099" title="ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541] ">Resik 2013</a>). A systematic review and meta‐analysis of studies documenting seroconversion following one or two full or fractional doses of enhanced‐potency IPV showed that routine immunisation with two full or fractional doses of IPV given after 10 weeks of age is likely to protect more than 80% of recipients against poliomyelitis (<a href="./references#CD011260-bbs2-0068" title="GrasslyNC . Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta‐analysis. Journal of Infectious Diseases2014;210 Suppl 1:S439‐46. [DOI: 10.1093/infdis/jit601; PMC4197908; PUBMED: 24634499] ">Grassly 2014</a>). More importantly, we found that VAPP was substantially prevented after the use of the sequential IPV‐OPV scheme in the immunisation programs in countries regardless of their income classification, suggesting that IPV makes subsequent doses of OPV safer. Additionally, multiple intramuscular injection during the 30‐day period after immunisation with OPV was found to be a risk factor for VAPP (<a href="./references#CD011260-bbs2-0105" title="StrebelPM , Ion‐NedelcuN , BaughmanAL , SutterRW , CochiSL . Intramuscular injections within 30 days of immunization with oral poliovirus vaccine‐‐a risk factor for vaccine‐associated paralytic poliomyelitis. New England Journal of Medicine1995;332(8):500‐6. [DOI: 10.1056/NEJM199502233320804; PUBMED: 7830731] ">Strebel 1995</a>). </p> <p>The burden caused by VDPV is another problem that is becoming increasingly important to manage. WHO databases reported 798 cases of cVDPV in 25 countries around the world between 2000 and 2016; none caused by IPV, two by IPV‐OPV and the remainder of cases (99.7%) caused by OPV or OPV‐IPV. A proportion meta‐analysis using a random‐effects model estimated an annual incidence of 14 cases of cVDPV per million. Although the cVDPV incidence is low, there is no evidence that cVDPV tends to disappear on its own (<a href="./references#CD011260-bbs2-0041" title="CiapponiA , GibbonsL . Global incidence of circulating vaccine‐derived poliovirus (cVDPV) during the period 2000‐2016: meta‐analysis [Incidencia mundial de poliovirus circulantes de origen vacunal (cVDPV) durante el período 2000‐2016: meta‐análisis]. XVI Reunión Anual de la Red Cochrane Iberoamericana: Síntesis y transferencia del conocimiento; 2017 Jun 5‐7; Medellín (CO). 2017. ">Ciapponi 2017</a>). Long‐term risks include the reintroduction of poliovirus serotype 2 from a laboratory or manufacturing facility breach, as occurred in 2002 to 2003 in India (<a href="./references#CD011260-bbs2-0048" title="DeshpandeJM , NadkarniSS , SiddiquiZA . Detection of MEF‐1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 &amp; 2003. Indian Journal of Medical Research2003;118:217‐23. [PUBMED: 14870793] ">Deshpande 2003</a>). For these reasons, immunity levels against polioviruses should be kept as high as possible in the population by the use of IPV, and both clinical and environmental surveillance should be maintained as high as possible. Moreover, if the use of mOPV serotype 2 is required to control an outbreak, it will be easier to reach the levels of immunity necessary to stop transmission in a population previously vaccinated with IPV. Therefore, the introduction of IPV could facilitate the control of outbreaks in the future (<a href="./references#CD011260-bbs2-0060" title="GentileÁ , AbateH . A new challenge for the world: the eradication of polio. Archivos Argentinos De Pediatria2016;114(6):557‐62. [DOI: 10.5546/aap.2016.eng.557; PUBMED: 27869415] ">Gentile 2016</a>). </p> <p>Many countries (n = 49, see <a href="#CD011260-tbl-0004">Table 1</a>) use IPV as the first dose in a sequential vaccination scheme. However, according to the WHO database of national vaccination schedules, in 2018, 89 countries used bOPV as the first dose of a sequential or combined scheme with IPV, and five used bOPV exclusively (<a href="./references#CD011260-bbs2-0119" title="World Health Organization. WHO vaccine‐preventable diseases: monitoring system. 2019 global summary. apps.who.int/immunization_monitoring/globalsummary/schedules (accessed 6 June 2018). ">WHO 2019</a>). The decision to use bOPV as the first dose is usually taken because bOPV can confer early protection, since it can be administered from birth (<a href="./references#CD011260-bbs2-0115" title="World Health Organization. Global wild poliovirus 2013‐2018. polioeradication.org/wp‐content/uploads/2018/03/global‐wild‐poliovirus‐2013‐2018‐20180320.pdf (accessed 6 March 2018). ">WHO 2015d</a>). In contrast, IPV is generally used at an older age (around two months old), to avoid interference from maternal antibodies and maximise immunogenicity. The initial use of bOPV is a good policy when the risk of infection with WPV is high. However, given that the global incidence of WPV has decreased to an unprecedented level and the relative risk of VAPP and cVDPV in low‐ and middle‐income countries (LMICs) is not as low as previously thought, it is perhaps time to review this recommendation. </p> <p>Availability and affordability of IPV is another key issue to consider. In countries with a shortage of IPV, two doses of intradermal fIPV prior to bOPV could be considered (<a href="./references#CD011260-bbs2-0032" title="AnandA , MolodeckyNA , PallanschMA , SutterRW . Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule. Vaccine2017;35(22):2993‐8. [DOI: 10.1016/j.vaccine.2017.03.008; PUBMED: 28434691] ">Anand 2017</a>; <a href="./references#CD011260-bbs2-0115" title="World Health Organization. Global wild poliovirus 2013‐2018. polioeradication.org/wp‐content/uploads/2018/03/global‐wild‐poliovirus‐2013‐2018‐20180320.pdf (accessed 6 March 2018). ">WHO 2015d</a>). In this review, we identified a study, <a href="./references#CD011260-bbs2-0002" title="AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>, which showed no differences between the sequential IbOI scheme (two fIPV) and two complete doses of IPV, and even found a slight, statistically significant effect in favour of IbOI in the P1 protective humoral response. In addition, a review found that two doses of flPV were more immunogenic than a single full dose (<a href="./references#CD011260-bbs2-0032" title="AnandA , MolodeckyNA , PallanschMA , SutterRW . Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule. Vaccine2017;35(22):2993‐8. [DOI: 10.1016/j.vaccine.2017.03.008; PUBMED: 28434691] ">Anand 2017</a>). Two doses of flPV represent only two fifths of a full IPV dose and would attenuate the current shortage of IPV. In fact, the scheme of two flPVs at six and 14 weeks of age has been supported by technical supervision committees and has been introduced in some affected countries (<a href="./references#CD011260-bbs2-0116" title="World Health Organization. Polio vaccines: WHO position paper ‐ March, 2016. Relevé épidémiologique hebdomadaire2016;91(12):145‐68. [www.who.int/wer/2016/wer9112.pdf?ua=1] ">WHO 2016</a>). However it should be considered that implementation of intradermal vaccines for fIPV could be more difficult because require trained personnel. Currently, 21 out of 49 countries using IPV‐OPV (43%) and 82 out of 86 countries using OPV‐IPV (95%) apply a single dose of IPV. Replacing this full IPV dose with two doses of fIPV, could improve immunogenicity, reduce costs and difficult coverage in a context of shortage of IPV (<a href="./references#CD011260-bbs2-0083" title="LewisI , OttosenA , RubinJ , BlancDC , ZipurskyS , WoottonE . A supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. Journal of Infectious Diseases2017;216(Suppl 1):S33‐9. [DOI: 10.1093/infdis/jiw550; PMC5853471; PUBMED: 28838159] ">Lewis 2017</a>). </p> <p>Several economic evaluations from different settings have studied the costs and cost‐effectiveness of introducing IPV into immunisation programs (<a href="./references#CD011260-bbs2-0035" title="BiffiMR . Economic evaluation of the sequential schedule of polio vaccination in Italy [Valutazione economica dell’attivazione in Italia della schedula sequenziale per la vaccinazione antipoliomielitica]. PharmacoEconomics ‐ Italian Research Articles2003;5(Suppl 1):47‐53. [DOI: 10.1007/BF03320615] ">Biffi 2003</a>; <a href="./references#CD011260-bbs2-0051" title="Duintjer TebbensRJ , SangrujeeN , ThompsonKM . The costs of future polio risk management policies. Risk Analysis2006;26(6):1507‐31. [DOI: 10.1111/j.1539‐6924.2006.00842.x; PUBMED: 17184394] ">Duintjer Tebbens 2006</a>; <a href="./references#CD011260-bbs2-0052" title="Duintjer TebbensRJ , PallanschMA , CochiSL , WassilakSGF , ThompsonKM . An economic analysis of poliovirus risk management policy options for 2013‐2052. BMC Infectious Diseases2015;15:389. [DOI: 10.1186/s12879‐015‐1112‐8; PMC4582932; PUBMED: 26404632] ">Duintjer Tebbens 2015</a>; <a href="./references#CD011260-bbs2-0088" title="MascareñasA , SalinasJ , Tasset‐TisseauA , MascareñasC , KhanMM . Polio immunization policy in Mexico: economic assessment of current practice and future alternatives. Public Health2005;119(6):542‐9. [DOI: 10.1016/j.puhe.2004.08.020; PUBMED: 15826896] ">Mascareñas 2005</a>; <a href="./references#CD011260-bbs2-0091" title="MillerMA , SutterRW , StrebelPM , HadlerSC . Cost‐effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA1996;276(12):967‐71. [PUBMED: 8805731] ">Miller 1996</a>; <a href="./references#CD011260-bbs2-0101" title="SartoriAM , VicentineMP , GryningerLC , Coelho de SoárezP , NovaesHM . Polio inactivated vaccine costs into routine childhood immunization in Brazil. Revista de Saúde Pública2015;49(8):1‐10. [DOI: 10.1590/S0034‐8910.2015049005492] ">Sartori 2015</a>). Although inconsistent, their results (summarised in <a href="#CD011260-tbl-0008">Table 5</a>), provide useful evidence for the design of future immunisation programs, taking into consideration their different frameworks, time periods, and discount over time (discounting tell us how much future benefits and costs are worth today). One way to make IPV more affordable is to reduce the dose by adding adjuvants (compounds that augment the immune response to the vaccine). A systematic review summarised the evidence from studies evaluating the potential efficacy and safety of adjuvants used with IPV (<a href="./references#CD011260-bbs2-0070" title="HawkenJ , TroySB . Adjuvants and inactivated polio vaccine: a systematic review. Vaccine2012;30(49):6971‐9. [DOI: 10.1016/j.vaccine.2012.09.059; PMC3529007 ; PUBMED: 23041122] ">Hawken 2012</a>). </p> <div class="table" id="CD011260-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Main results of economic evaluations identified</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID<br/> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Monetary unit</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Schedule</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total program cost $ millions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total program saving $ millions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total benefits $ millions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Net incremental cost $ millions per year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost per case of VAPP prevented $ millions per year</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011260-bbs2-0091" title="MillerMA , SutterRW , StrebelPM , HadlerSC . Cost‐effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA1996;276(12):967‐71. [PUBMED: 8805731] ">Miller 1996</a><br/> <b>USA</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1980‐1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>USD 1995</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 OPV (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>414.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 OPV 2 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> cost‐benefit and cost‐effectiveness models were formulated to compare the USA national 4‐OPV dose with a 4‐dose IPV schedule or a sequential schedule of 2 doses of IPV followed by 2 doses of OPV. Changing to an IPV‐only or a sequential schedule would cost $28.1 million and $14.7 million, respectively. The costs per case of VAPP prevented were estimated as $3.0 million and $3.1 million for each option, respectively. It concluded that the introduction of IPV into the routine vaccination schedule would not be cost‐beneficial at 1995 vaccine prices and with the current compensation awards paid to VAPP cases since, the costs are higher than other public health prevention programs. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD011260-bbs2-0035" title="BiffiMR . Economic evaluation of the sequential schedule of polio vaccination in Italy [Valutazione economica dell’attivazione in Italia della schedula sequenziale per la vaccinazione antipoliomielitica]. PharmacoEconomics ‐ Italian Research Articles2003;5(Suppl 1):47‐53. [DOI: 10.1007/BF03320615] ">Biffi 2003</a><br/> <b>Italy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2000 (life expectancy of 75 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Euros 2000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 OPV (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 OPV 2 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> in Italy, a sequential schedule based on two IVP doses followed by two OPV doses replaced in 1999 the OPV‐only schedule to reduce the incidence of VAPP, the most dangerous adverse event of OPV. Assuming an hypothetical VAPP reduction, an economic evaluation estimated that a sequential schedule would avoid 0.768 cases/year; however, the costs of the sequential schedule outweigh the expected economic benefits associated with a decreased incidence of VAPP. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011260-bbs2-0088" title="MascareñasA , SalinasJ , Tasset‐TisseauA , MascareñasC , KhanMM . Polio immunization policy in Mexico: economic assessment of current practice and future alternatives. Public Health2005;119(6):542‐9. [DOI: 10.1016/j.puhe.2004.08.020; PUBMED: 15826896] ">Mascareñas 2005</a><br/> <b>Mexico</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>USD 2002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 OPV (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100,454 to 156,614</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 OPV 2 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> a prospective Mexican, micro‐costing study estimated that changing from the current OPV‐based intensive and routine schedule to a sequential IPV‐OPV routine schedule would save US $14.52 per vaccinated child, and changing to a full IPV routine schedule would save US $9.41 per vaccinated child. It also estimated a national immunisation week (NIW) cost. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p><a href="./references#CD011260-bbs2-0101" title="SartoriAM , VicentineMP , GryningerLC , Coelho de SoárezP , NovaesHM . Polio inactivated vaccine costs into routine childhood immunization in Brazil. Revista de Saúde Pública2015;49(8):1‐10. [DOI: 10.1590/S0034‐8910.2015049005492] ">Sartori 2015</a><br/> <b>Brazil</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>USD 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 OPV + 2 NIDs (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,873,170</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV 4 OPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,608,419</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−26.50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV 3 OPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,852,799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.00%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV 2 OPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31,283,072</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,936,547</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41,681,259</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.70%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV 4 OPV + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,409,159</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.70%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV 3 OPV + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,653,539</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV 2 OPV + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,083,812</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.60%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV 4 + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45,737,287</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130.20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 IPV + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48,481,999</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143.90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV 4 OPV + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28,209,899</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV 3 OPV + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36,454,279</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV 2 OPV + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44,884,552</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125.90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV 4 + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52,538,027</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164.40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 IPV + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55,282,740</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178.20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> the introduction of IPV in Brazil increased the annual costs of the polio vaccines by 49.2% compared with the oral vaccine‐only regimen. This increase represented 1.13% of the expenditure of the national immunisation program on the purchase of vaccines in 2011. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p><a href="./references#CD011260-bbs2-0051" title="Duintjer TebbensRJ , SangrujeeN , ThompsonKM . The costs of future polio risk management policies. Risk Analysis2006;26(6):1507‐31. [DOI: 10.1111/j.1539‐6924.2006.00842.x; PUBMED: 17184394] ">Duintjer Tebbens 2006</a><br/> <b>Wordwide</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIC:</b> IPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIC:</b> AFP </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6900</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> IPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1300</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> OPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> AFP </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> IPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> OPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> AFP </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> IPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3900</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> OPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1900</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> AFP </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> Total </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8600</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> a model for the expected future costs of different polio strategies estimated that a global transition from routine immunisation with OPV to IPV would increase the costs of managing polio globally, although routine IPV use remains less costly than routine OPV use with supplemental immunisation activities. The uncertainty in the aggregated costs, the discount rate and price and administration cost of IPV drives the expected incremental cost of routine IPV vs OPV immunisation. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD011260-bbs2-0052" title="Duintjer TebbensRJ , PallanschMA , CochiSL , WassilakSGF , ThompsonKM . An economic analysis of poliovirus risk management policy options for 2013‐2052. BMC Infectious Diseases2015;15:389. [DOI: 10.1186/s12879‐015‐1112‐8; PMC4582932; PUBMED: 26404632] ">Duintjer Tebbens 2015</a><br/> <b>200 countries</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2013–2052</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>USD 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tOPV (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−400</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIC:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>World:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> an integrated dynamic poliovirus transmission and stochastic risk model simulated possible futures and estimate the health and economic outcomes of maintaining the 2013 status quo of continued OPV use in most developing countries compared with OPV cessation policies with various assumptions about global IPV adoption. The authors estimated a global incremental net benefits during 2013‐2052 of approximately 16 US $2013 billion (almost 20 billion in LMICs) with at least one IPV routine immunisation dose in all countries until 2024 compared to continued OPV use, although significant uncertainty remains associated with the frequency of exportations between populations and the implementation of long‐term risk‐management policies. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>AFP:</b> acute flaccid paralysis; <b>HIC:</b> high‐income country; <b>IPV:</b> inactivated poliovirus vaccine; <b>LIC:</b> low‐income country;<b>LMIC:</b> lower‐middle income country; <b>NID:</b> national immunisation days;<b>NIW:</b> national immunisation week; <b>OPV:</b> oral poliovirus vaccine; <b>SIA:</b> supplemental immunisation days; <b>UM:</b> upper‐middle‐income country; <b>USD:</b> US dollars; <b>VAPP:</b> vaccine‐associated paralytic poliomyelitis. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>For definition of schedules (e.g. sequential IOO), see Glossary in <a href="./appendices#CD011260-sec-0176">Appendix 1</a>. </p> </div> </div> <p>The Sabin IPV (sIPV) could also play an important role in the final phase of global polio eradication. sIPV has high production safety and low production cost, compared with the conventional wild‐virus‐derived IPV (<a href="./references#CD011260-bbs2-0050" title="DongSZ , ZhuWB . The role of Sabin inactivated poliovirus vaccine in the final phase of global polio eradication [萨宾灭活脊灰病毒疫苗在全球消灭脊髓灰质炎最后阶段的作用]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2016;50(12):1032‐5. [DOI: 10.3760/cma.j.issn.0253‐9624.2016.12.003; PUBMED: 28057104] ">Dong 2016</a>). Additionally, an RCT showed that sequential schedules of sIPV‐bOPV have good safety and immunogenicity, with the two‐dose sIPV group showing slight superiority to the one‐dose sIPV group (<a href="./references#CD011260-bbs2-0027" title="YeH , HuangT , YingZF , LiGL , CheYC , ZhaoZM , et al. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (I + III) in different dosage forms] [株脊髓灰质炎灭活疫苗与不同剂型Ⅰ+Ⅲ型脊髓灰质炎减毒活疫苗序贯接种的免疫原性和安全性比较]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2018;52(1):43‐9. [DOI: 10.3760/cma.j.issn.0253‐9624.2018.01.009; PUBMED: 29334707] ">Ye 2018</a>). It is likely that most new IPVs will be made with Sabin strain viruses, which reduce the risks to the population from a breach of containment. sIPV combined with tetanus and diphtheria toxoids and acellular pertussis vaccine was introduced in Japan in 2012, and two stand‐alone sIPVs have been licensed for distribution in China (<a href="./references#CD011260-bbs2-0093" title="ModlinJ , ChumakovK . Sabin strain inactivated polio vaccine for the polio endgame. Journal of Infectious Diseases 2019 Feb 21 [Epub ahead of print]. [DOI: 10.1093/infdis/jiz077; PUBMED: 30788498] ">Modlin 2019</a>). Additional to availability and affordability issues, good immunisation strategy can lead to high coverage with a new vaccine without negative impact attached to other vaccines (<a href="./references#CD011260-bbs2-0049" title="DominguesCM , deFátima PereiraS , Cunha MarreirosAC , MenezesN , FlanneryB . Introduction of sequential inactivated polio vaccine‐oral polio vaccine schedule for routine infant immunization in Brazil's National Immunization Program. Journal of Infectious Diseases2014;210 Suppl 1:S143‐51. [DOI: 10.1093/infdis/jit588; PMC4758462; PUBMED: 25316829] ">Domingues 2014</a>). </p> <p>The main potential benefit of the sequential IPV‐OPV scheme, compared to OPV alone, is that it may reduce or eliminate VAPP cases while limiting the risks of VDPVs and maintaining good mucosal immunity. The success in controlling outbreaks of polio during the final stage of eradication will depend, to a large extent, on the degree of immunity of the intestinal mucosa. A systematic review found that, compared with unvaccinated individuals, IPV did not induce intestinal mucosal immunity to reduce faecal vaccine virus shedding after challenge with OPV (OR 0.81, 95% CI 0.59 to 1.11) (<a href="./references#CD011260-bbs2-0075" title="HirdTR , GrasslyNC . Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLOS Pathogens2012;8(4):e1002599. [DOI: 10.1371/journal.ppat.1002599; PMC3330118; PUBMED: 22532797] ">Hird 2012</a>). An analytical cohort comprising 152 infants (<a href="./references#CD011260-bbs2-0036" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; NCT01841671; PMC6206105 ; PUBMED: 30376086] ">Brickley 2018</a>), derived from <a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>, supports this concept; 37% of infants, in the IPV‐bOPV groups and 26% in the IPV‐only arm had detectable serotype 2–specific stool neutralisation after the primary vaccine series and almost half of all study participants continued to shed the virus four weeks after the challenge. However, a challenge dose of mOPV2 induced intestinal immune responses in all groups, reflected by statistically significant (P &lt; 0.001) rises in serotype 2–specific stool neutralisation titres and immunoglobulin A concentrations in both arms, but Infants who received IPV alone presented with inferior serotype 1 intestinal immunity than participants who had received at least one dose of bOPV. </p> <p>IPV‐only shedding studies have shown that the odds of excreting poliovirus serotype 2 after OPV challenge are similar between unvaccinated children and children vaccinated with two or three doses of IPV (<a href="./references#CD011260-bbs2-0043" title="Cuba IPV Study Collaborative Group. Randomized, placebo‐controlled trial of inactivated poliovirus vaccine in Cuba. New England Journal of Medicine2007;356(15):1536‐44. [DOI: 10.1056/NEJMoa054960; NCT00260312; PUBMED: 17429085] ">Cuba 2007</a>; <a href="./references#CD011260-bbs2-0081" title="LaassriM , LottenbachK , BelsheR , WolffM , RennelsM , PlotkinS , et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. Journal of Infectious Diseases2005;192(12):2092‐8. [DOI: 10.1086/498172; PUBMED: 16288372] ">Laassri 2005</a>). These findings reinforce concerns that immunisation by inactivated, rather than live, vaccines have the potential to maintain transmission if OPV or WPV strains (or both) remain in circulation. </p> <p>Sequential schedules that currently use bOPV (IPV–bOPV) have the potential to achieve immunity to poliovirus serotype 2 by giving one or more IPV doses before bOPV, which could also prevent serotype 2 VAPP and VDPV. The overall protection rate against serotype 2 after an IPV–bOPV–bOPV schedule would be up to 92%, compared with the 98% to 100% noted after schedules with two or three doses of IPV. Additionally, some benefits could arise from enhanced mucosal immunity due to bOPV use, following the global introduction of IPV and switch to bOPV. The induction of cross‐protective intestinal immunity from bOPV to serotype 2 could provide enhanced individual immunity, and could also decrease transmission of WPV serotype 2 or vaccine‐related virus after withdrawal of tOPV from vaccination schedules (<a href="./references#CD011260-bbs2-0013" title="BrickleyEB , Wieland‐AlterW , ConnorRI , AckermanME , BoeschAW , AritaM , et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clinical Infectious Diseases2018;67(Suppl 1):S42‐50. [DOI: 10.1093/cid/ciy603; PMC6206105; PUBMED: 30376086] O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O'Ryan 2015</a>), </p> <p>Results from a randomised trial by <a href="./references#CD011260-bbs2-0087" title="LundN , AndersenA , HansenAS , JepsenFS , BarbosaA , Biering‐SørensenS , et al. The effect of oral polio vaccine at birth on infant mortality: a randomized trial. Clinical Infectious Diseases2015;61(10):1504‐11. [DOI: 10.1093/cid/civ617; NCT00710983; PMC4614411; PUBMED: 26219694] ">Lund 2015</a> suggest that OPV might have beneficial, non‐specific effects that reduce all‐cause mortality by 17% and possibly to a greater extent in boys than in girls, whereas previous evidence suggests that IPV increases all‐cause mortality by 10% (<a href="./references#CD011260-bbs2-0031" title="AabyP , GarlyML , NielsenJ , RavnH , MartinsC , BaléC , et al. Increased female‐male mortality ratio associated with inactivated polio and diphtheria‐tetanus‐pertussis vaccines: observations from vaccination trials in Guinea‐Bissau. Pediatric Infectious Disease Journal2007;26(3):247‐52. [PUBMED: 17484223] ">Aaby 2007</a>). Although controversial, these results support the idea that a sequential IPV‐OPV schedule might decrease VAPP without increasing mortality (<a href="./references#CD011260-bbs2-0058" title="FishEN , FlanaganKL , FurmanD , KleinSL , KollmannTR , JeppesenDL , et al. Changing oral vaccine to inactivated polio vaccine might increase mortality. Lancet2016;387(10023):1054‐5. [DOI: 10.1016/S0140‐6736(16)00661‐9; PMC4922306; PUBMED: 27025182] ">Fish 2016</a>). </p> <p>Additionally, poliovirus importations into polio‐free countries around the world represent a major concern during the final phases of global eradication of WPV. Extended dynamic transmission models demonstrate that as population immunity declines below the threshold required for preventing transmission, countries become at risk for re‐established transmission. All countries should invest in active management of population immunity to avoid the potential circulation of imported live polio viruses (<a href="./references#CD011260-bbs2-0109" title="ThompsonKM , KalkowskaDA , Duintjer TebbensRJ . Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine2015;33(13):1568‐77. [DOI: 10.1016/j.vaccine.2015.02.013; PUBMED: 25701673] ">Thompson 2015</a>). </p> <p>Although the WHO strategy is to stop OPV vaccination completely and replace it with IPV vaccination, this goal is not close yet, and the sequential IPV‐OPV vaccination schedule could have an important role during the transition period. Our findings reinforce the applicability of a sequential IPV‐OPV scheme during this transition period, which could reduce inequities between high‐ and low‐income countries due to limited access to IPV. </p> </section> <section id="CD011260-sec-0167"> <h3 class="title" id="CD011260-sec-0167">Quality of the evidence</h3> <p>This review included 21 studies, 16 of which were RCTs involving 6407 healthy infants; 28,330 infants in one ITS and four nationwide studies (two of which were nationwide ITSs, and two of which were nationwide UBAs). </p> <p>Below, we describe the key risk of bias of the studies (see also <a href="#CD011260-fig-0002">Figure 2</a>; <a href="#CD011260-fig-0003">Figure 3</a> and <a href="./full#CD011260-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011260-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011260-tbl-0003">summary of findings Table 3</a>). </p> <p><b>RCTs (n = 16)</b> </p> <p>The number of studies at low risk of bias varied across the seven domains: six studies for allocation concealment; 16 studies for blinding of participants and personnel and blinding of outcome assessment; four studies for incomplete outcome data; 16 studies for selective reporting; seven studies for potential bias related to vested interests and 16 studies seems to be free of other sources of bias. Incomplete outcome data was the only domain with studies rated at high risk of bias (n = 4). </p> <p><b>ITS studies (n = 3)</b> </p> <p>Regarding protection against secular changes we considered all three ITS studies to be at low risk of bias for the domain independent of other changes and the number of points. Only one ITS specified the shape of the intervention effect but we considered it to be at unclear risk of bias because we reanalysed the data as an ITS. We rated all three ITS studies at low risk of bias for the four domains related to detection bias also, but two ITSs considered as unclear risk of bias because they used national databases No study received industry funding and therefore we considered all studies at low risk of bias for vested interests. </p> <p><b>UBA studies (n = 3)</b> </p> <p>We considered two of the three UBA studies to be at unclear risk of bias for blinded assessment of primary outcomes. Although acute flaccid paralysis (AFP) and virological testing are objective outcomes, interpretation of VAPP is partially subjective, and we classified this as unclear risk of bias because the identification method was not clearly stated in the report. We rated the other, remaining study at low risk of bias on this domain. </p> <p>We rated all three UBA studies at low risk of bias for primary outcome reliability since the surveillance systems are of good quality. We also rated all three studies at low risk of bias for follow‐up issues, since national AFP surveillance suggests a complete, nationwide follow‐up; the follow‐up period was long enough; and no changes to the protocols were reported. No study received industry funding and therefore we considered all three studies to be at low risk of bias for vested interests. </p> <p>For the comparisons IPV‐OPV versus OPV (<a href="./full#CD011260-tbl-0001">summary of findings Table for the main comparison</a>) and IPV‐OPV versus IPV (<a href="./full#CD011260-tbl-0002">summary of findings Table 2</a>), we downgraded the certainty of the body of evidence for each outcome for the following reasons: study limitations (most studies were at unclear risk of bias regarding random sequence generation and allocation concealment), imprecision (the confidence intervals (CIs) were consistent with both a clinically important increase or reduction of the effect), and inconsistency (there was considerable heterogeneity; however, it was in the same direction of the effect). For the comparison IPV(3)‐OPV versus IPV(2)‐OPV (<a href="./full#CD011260-tbl-0003">summary of findings Table 3</a>), we downgraded for imprecision only. We present our reasons for downgrading the certainty of the evidence for each outcome in the footnotes of each ‘Summary of findings’ table. </p> <p>We rated the certainty of the evidence for most outcomes as low or moderate. Overall, there is insufficient evidence to draw conclusions about the effectiveness of IPV‐OPV for preventing paralytic polio, but the evidence is quite solid for VAPP, protective immune response (humoral and intestinal) and serious adverse events. </p> </section> <section id="CD011260-sec-0168"> <h3 class="title" id="CD011260-sec-0168">Potential biases in the review process</h3> <p>Our review methods, which followed Cochrane guidelines, were unlikely to have introduced bias. We conducted a comprehensive search without restriction on date or language and we undertook independent screening of eligible studies. Although we are confident we were able to obtain most of the relevant data, our review may have omitted important unpublished data that were not reported to WHO from countries' health databases. This could be important, particularly for infrequent events like polio, VAPP or cVDPV cases. Another potential source of bias is that we were unable to obtain further data from many authors of included studies to clarify certain aspects of methodology that would have enabled a more thorough assessment of the risk of bias. </p> </section> <section id="CD011260-sec-0169"> <h3 class="title" id="CD011260-sec-0169">Agreements and disagreements with other studies or reviews</h3> <p>Our finding that IPV‐OPV may reduce cases of VAPP without affecting vaccination coverage or safety, compared to OPV, is consistent with several UBA sub‐nationwide studies which did not meet our nationwide inclusion criteria. <a href="./references#CD011260-bbs2-0122" title="ZhaoD , MaR , ZhouT , YangF , WuJ , SunH , et al. Introduction of inactivated poliovirus vaccine and impact on vaccine‐associated paralytic poliomyelitis ‐ Beijing, China, 2014‐2016. Morbidity and Mortality Weekly Report2017;66(49):1357‐61. [DOI: 10.15585/mmwr.mm6649a4; PMC5730215; PUBMED: 29240729] ">Zhao 2017</a>, in a province‐wide study in China, assessed the introduction of one dose of IPV into Beijing's Expanded Program on Immunization on December 2014, changing the schedule from OPV only to sequential IPV‐OPV. Coverage with the first dose of polio vaccine was maintained from 96.2% to 96.9%, similar to coverage with the first doses of diphtheria and tetanus toxoids and pertussis vaccine (DTP; 96.5% in 2014, and 97.2% in 2015); the percentage of children who received the first dose of polio vaccine but failed to complete the series was 1.0% in 2015 and 0.4% in 2016, which again, was similar to that for DTP. No cases of VAPP were identified between 2014 and 2016. <a href="./references#CD011260-bbs2-0085" title="LiuY , WangJ , LiuS , DuJ , WangL , GuW , et al. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010‐2014. Vaccine2017;35(9):1281‐6. [DOI: 10.1016/j.vaccine.2017.01.034; PUBMED: 28161421] ">Liu 2017</a> analysed 566,894 Chinese children, born between 2010 and 2014 and registered in Hangzhou's Immunization Information System, who were exposed to OPV‐only, IPV‐only and sequential IPV‐OPV, and found consistent results with our findings. VAPP cases were detected through the acute flaccid paralysis surveillance system. The incidence of VAPP in the 2010 to 2014 birth cohorts was 3.76 per 1 million doses of OPV. Five VAPP cases were identified during the study years; all cases occurred following the first OPV. </p> <p>In the early 1970s, the WHO Consultative Group conducted an extensive epidemiological study of VAPP cases in 13 countries (<a href="./references#CD011260-bbs2-0042" title="CockburnWC . The work of the WHO Consultative Group on poliomyelitis vaccines. Bulletin of the World Health Organization1988;66(2):143‐54. [PMC2491049; PUBMED: 2840219] ">Cockburn 1988</a>). After 15 years of continual surveillance, they found evidence that P3 strains caused most cases of post‐vaccination paralysis; the P1 strain was almost never implicated, suggesting that it is safe and effective, as is the P2 strain, although occasionally, it can cause paralysis in contacts of the vaccine. The only country where children were primarily immunised with IPV and given reinforcing doses of tOPV ("hidden name of the country #2 with a population of 5.1 million", quote from <a href="./references#CD011260-bbs2-0042" title="CockburnWC . The work of the WHO Consultative Group on poliomyelitis vaccines. Bulletin of the World Health Organization1988;66(2):143‐54. [PMC2491049; PUBMED: 2840219] ">Cockburn 1988</a>), reported zero confirmed cases of VAPP (<a href="./references#CD011260-bbs2-0042" title="CockburnWC . The work of the WHO Consultative Group on poliomyelitis vaccines. Bulletin of the World Health Organization1988;66(2):143‐54. [PMC2491049; PUBMED: 2840219] ">Cockburn 1988</a>). </p> <p><a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a> conducted a systematic review summarising the epidemiology of VAPP, and estimated the global VAPP burden applying a bootstrap method. Since many high‐income countries have replaced OPV with IPV, over 90% of the VAPP burden is concentrated in low‐ and middle‐income countries in Southeast Asia, Africa, the Western Pacific, and Eastern Mediterranean regions. <a href="./references#CD011260-bbs2-0098" title="PlattLR , EstívarizCF , SutterRW . Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases2014;210 Suppl 1:S380‐9. [DOI: 10.1093/infdis/jiu184; PUBMED: 25316859] ">Platt 2014</a> estimated that the planned universal introduction of IPV is likely to substantially decrease the global VAPP burden by 80% to 90%. </p> <p>Two reviews addressed our review question. <a href="./references#CD011260-bbs2-0034" title="BandyopadhyayAS , ModlinJF , WengerJ , GastC . Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame: a review. Clinical Infectious Diseases2018;67(Suppl 1):S35‐41. [DOI: 10.1093/cid/ciy633; PMC6206125 ; PUBMED: 30376081] ">Bandyopadhyay 2018</a> conducted a narrative review of studies that assessed humoral and intestinal immunogenicity induced by the newly recommended IPV‐bOPV schedules. They included five sequential and three non‐sequential IPV‐bOPV RCTs and reported that differences in seroconversion rates were closely associated with both timing of first IPV administration and number of doses administered. Consistent with our larger body of evidence, they found that all studies demonstrated high levels of immunity for poliovirus serotypes 1 and 3 regardless of immunisation schedule, and that IPV doses and administration schedules showed limited impact on poliovirus serotype 2 excretion following challenge. They also reported that a second dose of IPV narrows the humoral immunity gap for poliovirus serotype 2, largely irrespective of the primary immunisation schedule. </p> <p><a href="./references#CD011260-bbs2-0108" title="TangG , YinW , CaoY , TanL , WuS , CaoY , et al. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: a systematic review and meta‐analysis. Human Vaccines &amp; Immunotherapeutics2018;14(11):2636‐43. [DOI: 10.1080/21645515.2018.1489188; PMC6314415 ; PUBMED: PMC6314415 ] ">Tang 2018</a> performed a systematic review and meta‐analysis to compare the immunogenicity of sequential IPV‐OPV versus IPV‐alone in healthy infants. They included four case‐series studies and two RCTs. They concluded that seroconversion rates against all three poliovirus serotypes were non‐inferior and geometric mean antibody titres were superior in sequential schedules, compared with an IPV‐only schedule. We included five additional RCTs for this comparison in our review, and we obtained similar findings for seroconversion rates for all three poliovirus serotypes but different results for mean antibody titres depending the scheme used. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011260-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011260-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph by experimental / quasi‐experimental design: review authors' judgements about each risk of bias item presented as percentages across all studies" data-id="CD011260-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph by experimental / quasi‐experimental design: review authors' judgements about each risk of bias item presented as percentages across all studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="A summary table of review authors' judgements for each 'Risk of bias' item for each study" data-id="CD011260-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>A summary table of review authors' judgements for each 'Risk of bias' item for each study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 IPV‐OPV vs OPV, outcome: 1.1 Persons with P1 Protective humoral response." data-id="CD011260-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 IPV‐OPV vs OPV, outcome: 1.1 Persons with P1 Protective humoral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 IPV‐OPV vs IPV, outcome: 2.1 Persons with P1 Protective humoral response." data-id="CD011260-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 IPV‐OPV vs IPV, outcome: 2.1 Persons with P1 Protective humoral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 1 Persons with P1 Protective humoral response." data-id="CD011260-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 1 Persons with P1 Protective humoral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 2 Persons with P1 Protective humoral response by time of first dose." data-id="CD011260-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 2 Persons with P1 Protective humoral response by time of first dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 3 Persons with P1 Protective humoral response by type of dose sequence." data-id="CD011260-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 3 Persons with P1 Protective humoral response by type of dose sequence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 4 Persons with P1 Protective humoral response by countries' income." data-id="CD011260-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 4 Persons with P1 Protective humoral response by countries' income. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 5 Persons with P2 Protective humoral response." data-id="CD011260-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 5 Persons with P2 Protective humoral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 6 Persons with P2 Protective humoral response by time of first dose." data-id="CD011260-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 6 Persons with P2 Protective humoral response by time of first dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 7 Persons with P2 Protective humoral response by type of dose sequence." data-id="CD011260-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 7 Persons with P2 Protective humoral response by type of dose sequence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 8 Persons with P2 Protective humoral response by countries' income." data-id="CD011260-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 8 Persons with P2 Protective humoral response by countries' income. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 9 Persons with P3 Protective humoral response." data-id="CD011260-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 9 Persons with P3 Protective humoral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 10 Persons with P3 Protective humoral response by time of first dose." data-id="CD011260-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 10 Persons with P3 Protective humoral response by time of first dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 11 Persons with P3 Protective humoral response by type of dose sequence." data-id="CD011260-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 11 Persons with P3 Protective humoral response by type of dose sequence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 12 Persons with P3 Protective humoral response by countries' income." data-id="CD011260-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 12 Persons with P3 Protective humoral response by countries' income. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 13 Mean titres of P1 neutralising antibody." data-id="CD011260-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 13 Mean titres of P1 neutralising antibody.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 14 Mean titres of P2 neutralising antibody." data-id="CD011260-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 14 Mean titres of P2 neutralising antibody.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 15 Mean titres of P3 neutralising antibody." data-id="CD011260-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 15 Mean titres of P3 neutralising antibody.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 16 Long term mean titres of P1 neutralising antibody." data-id="CD011260-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 16 Long term mean titres of P1 neutralising antibody. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 17 Long term mean titres of P2 neutralising antibody." data-id="CD011260-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 17 Long term mean titres of P2 neutralising antibody. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 18 Long term mean titres of P3 neutralising antibody." data-id="CD011260-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 18 Long term mean titres of P3 neutralising antibody. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 19 Persons with polio faecal excretion after OPV challenge." data-id="CD011260-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 19 Persons with polio faecal excretion after OPV challenge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 20 Vaccination coverage." data-id="CD011260-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 20 Vaccination coverage.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IPV‐OPV versus OPV, Outcome 21 Serious adverse events classified by MedDRA." data-id="CD011260-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 IPV‐OPV versus OPV, Outcome 21 Serious adverse events classified by MedDRA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 1 Persons with P1 Protective humoral response." data-id="CD011260-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 1 Persons with P1 Protective humoral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 2 Persons with P2 Protective humoral response." data-id="CD011260-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 2 Persons with P2 Protective humoral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 3 Persons with P3 Protective humoral response." data-id="CD011260-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 3 Persons with P3 Protective humoral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 4 Mean titres of P1 neutralising antibody." data-id="CD011260-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 4 Mean titres of P1 neutralising antibody.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 5 Mean titres of P2 neutralising antibody." data-id="CD011260-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 5 Mean titres of P2 neutralising antibody.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 6 Mean titres of P3 neutralising antibody." data-id="CD011260-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 6 Mean titres of P3 neutralising antibody.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 7 Long term mean titres of P1 neutralising antibody." data-id="CD011260-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 7 Long term mean titres of P1 neutralising antibody. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 8 Long term mean titres of P2 neutralising antibody." data-id="CD011260-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 8 Long term mean titres of P2 neutralising antibody. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 9 Long term mean titres of P3 neutralising antibody." data-id="CD011260-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 9 Long term mean titres of P3 neutralising antibody. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 10 Persons with polio faecal excretion after OPV challenge." data-id="CD011260-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 10 Persons with polio faecal excretion after OPV challenge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IPV‐OPV versus IPV, Outcome 11 Serious adverse events (≥1 symptom related to study drug or not)." data-id="CD011260-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 IPV‐OPV versus IPV, Outcome 11 Serious adverse events (≥1 symptom related to study drug or not). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011260-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/urn:x-wiley:14651858:media:CD011260:CD011260-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_t/tCD011260-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 IPV(3)‐OPV versus IPV(2)‐OPV, Outcome 1 Persons with polio protective humoral response." data-id="CD011260-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 IPV(3)‐OPV versus IPV(2)‐OPV, Outcome 1 Persons with polio protective humoral response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/media/CDSR/CD011260/image_n/nCD011260-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011260-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IPV‐OPV compared to OPV for preventing poliomyelitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IPV‐OPV compared to OPV for preventing poliomyelitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants<br/> <b>Setting:</b> USA, UK, China, Thailand, Israel, Oman, Guatemala, Bangladesh<br/> <b>Intervention:</b> IPV‐OPV<br/> <b>Comparison:</b> OPV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with OPV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV‐OPV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paralytic wild polio cases</b> </p> <p>(Change in slope at 3 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>−0.2 (−1.3 to 0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−21%</b> </p> <p>(−137% to 95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 ITS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Re‐analysis considering the year of schedule change as transition period</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Vaccine‐associated paralytic polio (VAPP) cases</b> </p> <p>(Range of follow‐up from 2 to 15 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6.6 cases per year</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.0 cases per year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−54.3%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 USA nationwide UBA study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OPV (1990‐6):</b> 46 cases (0.34 cases per million of OPV doses) </p> <p><b>IPV‐OPV (1997‐9):</b> 13 cases, none with IPV‐OPV or all‐IPV schedules </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.64 cases per million newborns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.56 cases per million newborns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−80%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 Russian Federation nationwide UBA study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OPV</b> (1998‐2007): 1 VAPP case per 1.59 million OPV doses </p> <p>I<b>PV‐OPV</b> (2008‐14): 1 case per 4.18 million doses </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 cases</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 case</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−100%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 Hungary nationwide UBA study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OPV</b> (1959‐92): 90 cases </p> <p><b>IPV‐OPV</b> (1992‐2006): 0 cases </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Persons with protective humoral response</b> </p> <p>(Range of follow‐up from 4.4 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1: 973 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>973 per 1000</b><br/> (963 to 982) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.99 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3189</p> <p>(12 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No important differences with other vaccination schemes</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2: 989 per 1000</b> #subgroup with 2 IPV doses </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>989 per 1000</b><br/> (979 to 999) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.99 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2361<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IIbO:</b> 0 (−70 to + 70) persons </p> <p><b>IbObO vs tOPV:</b> −210 (−38 to −344) persons </p> <p><b>IbObO vs bOPV:</b> + 672 (± 428 to + 1018) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3: 962 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>953 per 1000</b><br/> (933 to 972) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/> (0.97 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3184<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> −300 (−180 to −400) persons </p> <p><b>IOO / IOOO:</b> −19 (−39 to 0) persons </p> <p><b>IIO/IIOO/IIIO:</b> −10 (−39 to 10) persons </p> <p><b>IOI:</b> −9 (−47 to + 28) persons </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Neutralising antibodies with 2 IPV doses</b> </p> <p>Geometric mean titres (GMT)</p> <p>(Range of follow‐up from 5 to 16 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1</b> (IIO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>244 lower</b><br/> (−827 to + 339)<sup>SE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>795<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> + 362 (−330 to + 1054) </p> <p><b>IOO:</b> −181 (−594 to 232) </p> <p><b>IIIOO / IIIO:</b> + 439 (−355 to + 1233) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2</b> (IIO) </p> <p><b>P2</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 higher</b> (−84 to + 619)<sup>SE</sup> </p> <p><b>218 lower</b> (−305 to −130)<sup>LE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> <p>(3 RCTs)</p> <p>125</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,c</sup> </b> </p> <p>⊕⊕⊕⊝ <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> −260 (−347 to −174) </p> <p><b>IOO:</b> + 29 (−22 to + 79) </p> <p><b>IIIOO/IIIO:</b> + 486 (−698 to + 1670) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3</b> (IIO) </p> <p><b>P3</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 higher</b> (+ 9 to + 171)<sup>SE</sup> </p> <p><b>592 higher</b> (+ 185 to + 998)<sup>SE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667</p> <p>(3 RCTs)</p> <p>125</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> + 221 (+ 10 to + 432) </p> <p><b>IOO:</b> + 44 (−1.47 to + 90) </p> <p><b>IIIOO/IIIO:</b> + 248 (−181 to + 677) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Persons with polio faecal excretion after OPV challenge</b> </p> <p>(Range of follow‐up from 4.4 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1: 86 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>193 per 1000</b><br/> (60 to 613) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.24</b><br/> (0.70 to 7.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>916<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>c,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2: 279 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>497 per 1000</b><br/> (416 to 598) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b><br/> (1.49 to 2.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>916<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>c</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3: 74 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>173 per 1000</b><br/> (108 to 276) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.35</b><br/> (1.47 to 3.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>916<br/> (2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccination coverage</b> </p> <p>(Follow‐up 24 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91.9%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92.4%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> </p> <p>(0.96 to 1.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 ITS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> (classified by MedDRA) </p> <p>(Range of follow‐up from 5 to 16 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/> (26 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/> (0.46 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1948<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> # <b>2 IPV doses (IIO)</b> was selected as the main subgroup for this outcome since it is the most studied scheme </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>P1</b> , <b>P2</b> , <b>P3</b> : Poliovirus Serotypes 1, 2, 3 respectively; <b>SE</b> : Small effect; <b>ME</b> ; Moderate effect.<b>LE</b>: Large effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>I</b> = IPV, <b>O</b> = OPV, <b>bO</b> = bOPV (see detailed acronyms in <a href="./appendices#CD011260-sec-0176">Appendix 1</a>). </p> <p><sup>a</sup>Serious study limitations: most studies have unclear risk of bias regarding random sequence generation and allocation concealment.<br/> <sup>b</sup>These are data from quasi‐experimental studies and therefore evidence was graded as low, we have not downgraded or upgraded the evidence.<br/> <sup>c</sup>Serious imprecision: confidence interval limits include clinically important increase or reduction of the effect.<br/> <sup>d</sup>Serious inconsistency: considerable heterogeneity but in the same direction. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IPV‐OPV compared to OPV for preventing poliomyelitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011260-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">IPV‐OPV compared to IPV for preventing poliomyelitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IPV‐OPV compared to IPV for preventing poliomyelitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants<br/> <b>Setting:</b> USA, UK, China, Guatemala, Chile, Bangladesh<br/> <b>Intervention:</b> IPV‐OPV<br/> <b>Comparison:</b> IPV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV‐OPV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paralytic wild polio cases at 4 years</b> (Change level from IPV‐OPV to IPV) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>−1.2 (−6.2 to 3.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−<b>100%</b> </p> <p>(−517% to 317%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 ITS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Re‐analysis considering the year of schedule change as transition period</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine‐associated paralytic polio cases</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persons with protective humoral response</b> </p> <p>(Range of follow‐up from 4.4 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1</b>: 970 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>972 per 1000<br/> (961 to 980) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.99 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2858<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IOO:</b> −0 (−20 to + 20) persons </p> <p><b>IIO(O):</b> 0 (−10 to + 10) persons </p> <p><b>IbOI:</b> + 46 (0 to + 91) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2</b>: 960 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>931 per 1000<br/> (985 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/> (0.95 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2907<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> −236 (−89 to −354) persons </p> <p><b>IOO:</b> 0 (−39 to + 39) persons </p> <p><b>IbOI:</b> −43 (−103 to + 17) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3</b>: 972 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>962 per 1000<br/> (953 to 982) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/> (0.97 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2620<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IOO:</b> −10 (−30 to + 20) persons </p> <p><b>IIO(O):</b> −10 (−40 to + 20) persons </p> <p><b>IbOI:</b> + 9 (−37 to + 47) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Comment: A nationwide ITS (Denmark) reported a median proportion of persons with protective humoral response for PV1, 2 and 3 as 82.06%, 91.94% and 76.67%, respectively, during IPV scheme; the proportions were higher during IPV‐OPV scheme: 98.44%; 97.67%; and 97.57%, respectively. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Neutralising antibodies with 2 IPV doses</b> </p> <p>Geometric mean titres</p> <p>(Follow‐up 5 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1</b> (IIO) </p> <p><b>P1</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>768 higher</b> (+ 338 to + 1198)<sup>ME</sup> </p> <p><b>867 higher</b> (+ 479 to + 1254)<sup>ME</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363</p> <p>(2 RCTs)</p> <p>127</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>b,c</sup> </b> </p> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> + 1521 (+ 1085 to + 1956) </p> <p><b>IOO:</b> + 799 (+ 531 to + 1068) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2</b> (IIO) </p> <p><b>P2</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2224 higher</b> (−1146 to + 5594)<sup>LE</sup> </p> <p><b>83 lower</b> (−133 to −34)<sup>LE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362</p> <p>(2 RCTs)</p> <p>127</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Very low<sup>a,b,e</sup> </b> </p> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> −126 (−175 to −77) </p> <p><b>IOO:</b> + 142 (+ 58 to + 227) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3</b> (IIO) </p> <p><b>P3</b> (IIbO) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 higher</b> (−212 to + 581)<sup>SE</sup> </p> <p><b>698 higher</b> (+ 301 to + 1096)<sup>SE</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> <p>(2 RCTs)</p> <p>127</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Very low<sup>a,b,c</sup> </b> </p> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IbObO:</b> + 328 (+ 135 to + 520) </p> <p><b>IOO:</b> + 110 (−78 to + 299) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Persons with faecal polio excretion after OPV challenge</b> </p> <p>(Range of follow‐up from 4.4 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1</b>: 427 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000<br/> (60 to 841) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b><br/> (0.14 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a,b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ibOI:</b> −356 (−297 to −394) persons </p> <p><b>IIO/IIOO:</b> + 7 (−72 to + 148) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2</b>: 572 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000<br/> (177 to 537) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b><br/> (0.31 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1351<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ibOI/IIbO:</b> + 7 (−72 to + 148) persons </p> <p><b>IIO/IIOO:</b> −329 (−282 to −357) persons </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3</b>: 450 per 1000 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000<br/> (144 to 212) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.39</b><br/> (0.32 to 0.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ibOI:</b> −233 (−170 to −274) persons </p> <p><b>IIO/IIOO:</b> −470 (−392 to −533) persons </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccination coverage</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>(≥ 1 symptom related to study drug or not)</p> <p>(Range of follow‐up from 5 to 7 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000<br/> (57 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/> (0.60 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1063<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p># <b>2 IPV doses (IIO)</b> was selected as the main result for this outcome since it is the most frequent scheme. </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>P1</b> , <b>P2</b> , <b>P3</b>: Poliovirus Serotypes 1, 2, 3 respectively. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>I</b> = IPV, <b>O</b> = OPV, <b>bO</b> = bOPV (see detailed acronyms in <a href="./appendices#CD011260-sec-0176">Appendix 1</a>). </p> <p><sup>a</sup>Serious imprecision: confidence interval limits include clinically important increase or reduction of the effect.<br/> <sup>b</sup>Serious study limitations: most studies have unclear risk of bias regarding random sequence generation and allocation concealment.<br/> <sup>c</sup>Considerable heterogeneity but in the same direction.<br/> <sup>d</sup>Serious imprecision: only one study with low number of participants.<br/> <sup>e</sup>Very serious imprecision: confidence interval limits include a marked effect increase or reduction. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">IPV‐OPV compared to IPV for preventing poliomyelitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011260-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">IPV(3)‐OPV compared to IPV(2)‐OPV for preventing poliomyelitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>3 IPV‐OPV compared to 2 IPV‐OPV for preventing poliomyelitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> preventing poliomyelitis<br/> <b>Setting:</b> India<br/> <b>Intervention:</b> 3 IPV‐OPV<br/> <b>Comparison:</b> 2 IPV‐OPV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV(2)‐OPV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IPV(3)‐OPV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paralytic polio</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VAPP cases</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Persons with protective humoral response</b> </p> <p>(Follow‐up 7 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P1: 1000 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>980 per 1000</b><br/> (930 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/> (0.93 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P2: 1000 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/> (970 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.97 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P3: 989 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>998 per 1000</b><br/> (959 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b><br/> (0.97 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neutralising antibodies</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persons with faecal excretion after OPV challenge</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccination coverage</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% Cl) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious imprecision: confidence interval limits include clinically important increase or reduction of the effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">IPV(3)‐OPV compared to IPV(2)‐OPV for preventing poliomyelitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011260-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Countries currently using sequential IPV‐OPV schemes</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Year of introduction in entire country</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>IPV</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>OPV</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Doses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Schedule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Doses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Schedule</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigua and Barbuda</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months; 2, 6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Argentina</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 15‐18 months; 6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bahamas (the)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bahrain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 18 months; 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 5 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barbados</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 18 months; 4.5, 10‐11 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 4.5, 10‐11 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belize</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bolivia (Plurinational State of)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bosnia and Herzegovina</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 5‐6 months; 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months; 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 15 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chile</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4, months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 5 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dominica</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 3, 10‐12 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dominican Republic (the)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ecuador</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, &gt; 1 year</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Georgia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 3, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 7, 18 months; 4‐5, ≥ 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grenada</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guatemala</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guyana</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18, months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haiti</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5, 3.5, 9 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Honduras</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Israel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jamaica</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5, 3, 5‐6, 18 months; 4‐6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 5‐6, 18 months; 4‐6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jordan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4, 5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 9, 18 months; 6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kazakhstan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months OR 3, 18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kuwait</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 12, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lebanon</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4‐5, 10‐12, 16‐18 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexico</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 6 months; &lt; 5 Years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montenegro</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9, 17, 23 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months; 6, 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nicaragua</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oman</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 weeks‐2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 6, 18 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paraguay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peru</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qatar</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4‐6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russian Federation (the)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4.5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18, 20 months; 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saint Kitts and Nevis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4.5‐5, 15 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saint Lucia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 5, 11‐12 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saint Vincent and the Grenadines</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saudi Arabia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 12, 18 months; 6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serbia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 3.5, 18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suriname</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The former Yugoslav Republic of Macedonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐3.5, 6‐18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trinidad and Tobago</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 3, 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4‐5 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tunisia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months; 6,12, 18 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 6, 18 months; 6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 18 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ukraine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1959</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 18 months; 6, 14 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>United Arab Emirates</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 5‐6 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venezuela (Bolivarian Republic of)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 6, 18 months; 4‐5 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>IPV:</b> inactivated poliovirus vaccine; <b>OPV:</b> oral poliovirus vaccine. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>Sources:</b> WHO vaccine‐preventable diseases: monitoring system. 2018 global summary, available at: <a href="http://apps.who.int/immunization_monitoring/globalsummary/schedules" target="_blank">apps.who.int/immunization_monitoring/globalsummary/schedules</a> (accessed 6 June 2018) and <a href="http://www.who.int/entity/immunization/monitoring_surveillance/data/year_vaccine_introduction.xls?ua=1" target="_blank">www.who.int/entity/immunization/monitoring_surveillance/data/year_vaccine_introduction.xls?ua=1</a> (accessed 6 June 2018) </p> <p>In summary, <b>86</b> countries use <b>OPV‐IPV</b> , <b>3 OPV + IPV</b> , <b>51 exclusively IPV</b> and <b>5 exclusively OPV.</b> </p> <p>The number of countries using use a single IPV dose varies according the scheme used: with IPV‐OPV scheme, 21/49 countries (43%) and with OPV‐IPV or OPV+IPV 82/89 (92%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Countries currently using sequential IPV‐OPV schemes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011260-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Countries that have used sequential IPV‐OPV schemes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Schemes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Belarus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 IPV, 3 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014‐2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bermuda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 1 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978‐1979</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyprus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 3 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003‐2008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Croatia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV, 6 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003‐2008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV, 3 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1968‐1997</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gaza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 OPV, 2 IPV/OPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978‐1988</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hungary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV, 5 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1992‐2006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999‐2002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latvia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV, 3 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001‐2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithuania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004‐2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 IPV, 1 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009‐2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 IPV, 1 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1958‐2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV, 5 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008‐2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syrian Arab Republic (The)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 IPV, 4 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2008‐2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV, 1 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997‐1999</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>West Bank</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 IPV, 2 OPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978‐1988</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>IPV:</b> inactivated poliovirus vaccine; <b>OPV:</b> oral poliovirus vaccine. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Countries that have used sequential IPV‐OPV schemes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011260-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Planned methods that could not be performed</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Section</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unused methods</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason for nonuse</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of treatment effect</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dichotomous data</b> </p> <p>We planned to use the Peto odds ratio (OR) for very infrequent outcomes. We planned to report the risk difference (RD) if the result obtained by this measure was different from the RR. </p> <p><b>Continuous</b> </p> <p>We planned to calculate the standardised mean difference (SMD) with 95% CI if the same outcomes were measured by different scales. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not necessary.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unit of analysis issues</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For studies in which clusters of individuals were randomised (cluster‐RCTs, cluster quasi‐RCTs) or allocated (cluster CBAs) to intervention groups, but where inference is intended at the level of the individual, we planned to analyse them appropriately to account for correlation of observations within clusters. Standard statistical methods assume independence of observations, and their use in these types of studies will generally result in artificially small P values and overly narrow CIs for the effect estimates (<a href="./references#CD011260-bbs2-0110" title="UkoumunneOC , GullifordMC , ChinnS , SterneJA , BurneyPG . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999; Vol. 3, issue 5:iii‐92. [PUBMED: 10982317] ">Ukoumunne 1999</a>). These studies can generally be re‐analysed by making assumptions about the intra‐cluster correlation (ICC). We planned to obtain estimates of the ICC by contacting study authors or imputing them from data presented in the study. Where this was not feasible, we planned to use external estimates from similar studies, if available (<a href="./references#CD011260-bbs2-0037" title="CampbellM , GrimshawJ , SteenN . Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). Journal of Health Services Research and Policy2000;5(1):12‐6. [DOI: 10.1177/135581960000500105; PUBMED: 10787581] ">Campbell 2000</a>). If this was not possible, we planned not to combine the findings of these studies in a meta‐analysis, but to present the results in an additional table. We also planned to combine the adjusted measures of effects of cluster‐RCTs with the results of non‐cluster trials, and to perform a <a href="#CD011260-sec-0067">Sensitivity analysis</a> on meta‐analyses, including cluster‐RCTs, in which we would compare the effect estimates with and without the inclusion of the cluster trials. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not include cluster trials.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dealing with missing data</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to impute missing dichotomous data through an intention‐to‐treat (ITT) analysis based on the available data (all participants analysed in the group to which they were allocated, whether they received the allocated intervention or not). We also planned to perform a <a href="#CD011260-sec-0067">Sensitivity analysis</a>, assigning the worst outcome to those lost to follow‐up, to assess the impact of a 'worse case' scenario. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not impute dichotomous data.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup analysis and investigation of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to conduct the following subgroup analyses.</p> <p> <ul id="CD011260-list-0007"> <li> <p>Comorbidities (for example, HIV or tuberculosis)</p> </li> <li> <p>Baseline socioeconomic status (where available)</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not have enough data to perform these subgroup analyses.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Data synthesis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where there were multiple, appropriate outcomes, we planned to selected the median effect. Where there were only two, we planned to selected the more conservative result. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This scenario did not arise.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to use the generic inverse‐variance model of analysis if we needed to combine continuous and dichotomous data or clustered and non‐clustered data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This scenario did not arise.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to estimate a regression coefficient (with its standard error) that describes the effect of the interventions. We planned to standardise the direction of effect (for example, positive or negative) so that a negative coefficient planned to describe an improvement in outcome attributable to the intervention. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We performed an ARIMA analysis.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It may not be appropriate to combine the results quantitatively when the assessed outcomes, settings, and interventions are diverse. For these results, we planned to provide a descriptive summary of the data using one of the following methods: </p> <p> <ul id="CD011260-list-0008"> <li> <p>median effect size across included studies;</p> </li> <li> <p>interquartile ranges of effect sizes across included studies; and</p> </li> <li> <p>range of effect sizes across included studies.</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In these cases, we presented the results of the subgroup analysis.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to conduct sensitivity analyses based on the following characteristics.</p> <p> <ul id="CD011260-list-0009"> <li> <p>Risk of bias in the included studies: we planned to repeat the analysis excluding trials at high risk of bias for allocation concealment in order to test the robustness of the results. </p> </li> <li> <p>Unit of analysis: we planned to compare outcomes from cluster‐randomised with outcomes from individually‐randomised trials. </p> </li> </ul> </p> <p>We also planned to conduct additional sensitivity analyses:</p> <p> <ul id="CD011260-list-0010"> <li> <p>based on specific decisions made during the review process, such as how the intra‐cluster correlation coefficients were imputed for cluster trials; </p> </li> <li> <p>if one or more studies reported outcomes using either a continuous scale or a dichotomous scale and, in either scenario, were transformed into a dichotomous or continuous variable respectively; and </p> </li> <li> <p>based on the effect of including those lost to follow‐up or not, where the available cases were used as the basis for analysis. </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not perform the first analysis because no study was at high risk of bias for allocation concealment. </p> <p>We did not include cluster trials so did not perform the third analysis. The last three scenarios did not arise. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ARIMA: autoregressive integrated moving average; CBAs: controlled before and after study; CI: confidence interval; RCT: randomised controlled trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Planned methods that could not be performed</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011260-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Efficacy of IPV‐OPV by serotype P1, P2 and P3</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serotype</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Favours</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b><i>IPV‐OPV vs OPV</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="15" valign=""> <p><b>P1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.1 Persons with protective humoral response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1.1 Sequential IOO/IOOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.98 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1.2 Sequential IIO/IIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1.3 Sequential IOI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.93 to 1.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.13 Mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13.1 Sequential IbObO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>362.12 (−329.70 to 1053.94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13.2 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−181.13 (−594.25 to 231.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13.3 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−244.37 (−827.31 to 338.57)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13.4 Sequential IIIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439.07 (−354.63 to 1232.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.16 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16.1 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.48 to 0.48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16.2 Sequential IOO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (−0.33 to 0.73)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16.3 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.22 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16.4 Sequential IIO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.01 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.19.1 Persons with polio faecal excretion after OPV challenge</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.86 (1.21 to 2.86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="19" valign=""> <p><b>P2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.7 Persons with protective humoral response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.97 to 1.04)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.1 Sequential IbObO (bOPV)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.78 to 0.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.2 Sequential IOO/IOOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.98 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.3 Sequential IIO/IIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.4 Sequential IbOI (vs bObObO)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.85 (4.10 to 8.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.5 Sequential IbOI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.75 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7.6 Sequential IOI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.99 to 1.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.14 Mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.1 Sequential IbObO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−260.38 (−347.21 to −173.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.2 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.64 (−22.16 to 79.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.3 Sequential IIbO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−217.90 (−305.36 to −130.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.4 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267.40 (−83.95 to 618.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14.5 Sequential IIIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>486.17 (−698.02 to 1670.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.17 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17.1 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (−0.26 to 0.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17.2 Sequential IOO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (−0.30 to 0.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17.3 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.38 to 0.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17.4 Sequential IIO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (−0.11 to 0.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.10.2 Persons with polio faecal excretion after OPV challenge</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 (1.49 to 2.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="17" valign=""> <p><b>P3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.11 Persons with protective humoral response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.96 to 1.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11.1 Sequential IbObO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.60 to 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11.2 Sequential IOO/IOOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 ([0.96 to 1.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11.3 Sequential IIO/IIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.96 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11.4 Sequential IOI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.95 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.15 Mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.1 Sequential IbObO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>221.03 (9.66 to 432.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.2 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.07 (−1.47 to 89.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.3 Sequential IIbO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>591.78 (185.14 to 998.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.4 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.97 (8.98 to 170.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15.5 Sequential IIIOO/IIIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>248.39 (−180.58 to 677.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.18 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18.1 Sequential IOO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.50 (−1.14 to 0.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV (NS)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18.2 Sequential IOO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.61 to 0.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18.3 Sequential IIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.02 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18.4 Sequential IIO + O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (−0.34 to 0.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.19.3 Persons with polio faecal excretion after OPV challenge</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42 (1.60 to 3.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OPV</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>IPV‐OPV vs IPV</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="16" valign=""> <p><b>P1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1 Persons with P1 protective humoral response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.98 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1.2 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1.3 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (1.00 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.4 Mean titres of P1 neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1520.59 (1084.80 to 1956.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>799.47 (530.82 to 1068.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>866.53 (478.83 to 1254.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>767.90 (337.75 to 1198.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.7 Long‐term mean titres of P1 neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.20 (−0.73 to 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7.2 Sequential IOO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.30 (−0.83 to 0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (−0.04 to 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7.4 Sequential IIO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.40 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.1 Persons with faecal excretion after OPV challenge (ibOI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.19 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.2 Persons with faecal excretion after OPV challenge (IIO/IIOO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.59 to 1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="17" valign=""> <p><b>P2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.2 Persons with protective humoral response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.64 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.96 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2.3 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.99 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2.4 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.5 Mean titres of neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−125.93 (−174.77 to −77.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142.25 (57.65 to 226.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−83.45 (−133.40 to −33.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>787.97 (573.84 to 1002.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.8 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (−0.06 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8.2 Sequential IOO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.60 (−0.96 to −0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (−0.19 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8.4 Sequential IIO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.40 (−0.78 to −0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.3 Persons with faecal excretion after OPV challenge (ibOI/IIbO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.68 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.4 Persons with faecal excretion after OPV challenge (IIO/IIOO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.09 to 0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="16" valign=""> <p><b>P3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.3 Persons with protective humoral response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.98 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.97 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3.2 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.96 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3.3 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.96 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.6 Mean titres of neutralising</b> a<b>ntibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327.62 (134.82 to 520.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110.39 (−77.98 to 298.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>698.37 (301.06 to 1095.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184.52 (−211.93 to 580.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.9 Long‐term mean titres of neutralising antibody</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.60 (−1.22 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9.2 Sequential IOO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.30 (−0.76 to 0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (−0.04, 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9.4 Sequential IIO + O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.10 (−0.46 to 0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>=</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.5 Persons with faecal excretion after OPV challenge(ibOI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.26 to 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10.6 Persons with faecal excretion after OPV challenge (IIO/IIOO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.32 to 0.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPV‐OPV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>IPV:</b> inactivated poliovirus vaccine; <b>MD:</b> mean difference; <b>NS:</b> non‐statistically significant; <b>OPV:</b> oral poliovirus vaccine; <b>P:</b> poliovirus; <b>RR:</b> risk ratio; <b>=:</b> non‐statistically and non‐clinically significant </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>For definition of each sequence (e.g. sequential IOO), see Glossary in <a href="./appendices#CD011260-sec-0176">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Efficacy of IPV‐OPV by serotype P1, P2 and P3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011260-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Main results of economic evaluations identified</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID<br/> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Monetary unit</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Schedule</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total program cost $ millions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total program saving $ millions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total benefits $ millions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Net incremental cost $ millions per year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost per case of VAPP prevented $ millions per year</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011260-bbs2-0091" title="MillerMA , SutterRW , StrebelPM , HadlerSC . Cost‐effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA1996;276(12):967‐71. [PUBMED: 8805731] ">Miller 1996</a><br/> <b>USA</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1980‐1991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>USD 1995</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 OPV (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>414.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 OPV 2 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> cost‐benefit and cost‐effectiveness models were formulated to compare the USA national 4‐OPV dose with a 4‐dose IPV schedule or a sequential schedule of 2 doses of IPV followed by 2 doses of OPV. Changing to an IPV‐only or a sequential schedule would cost $28.1 million and $14.7 million, respectively. The costs per case of VAPP prevented were estimated as $3.0 million and $3.1 million for each option, respectively. It concluded that the introduction of IPV into the routine vaccination schedule would not be cost‐beneficial at 1995 vaccine prices and with the current compensation awards paid to VAPP cases since, the costs are higher than other public health prevention programs. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD011260-bbs2-0035" title="BiffiMR . Economic evaluation of the sequential schedule of polio vaccination in Italy [Valutazione economica dell’attivazione in Italia della schedula sequenziale per la vaccinazione antipoliomielitica]. PharmacoEconomics ‐ Italian Research Articles2003;5(Suppl 1):47‐53. [DOI: 10.1007/BF03320615] ">Biffi 2003</a><br/> <b>Italy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2000 (life expectancy of 75 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Euros 2000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 OPV (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 OPV 2 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> in Italy, a sequential schedule based on two IVP doses followed by two OPV doses replaced in 1999 the OPV‐only schedule to reduce the incidence of VAPP, the most dangerous adverse event of OPV. Assuming an hypothetical VAPP reduction, an economic evaluation estimated that a sequential schedule would avoid 0.768 cases/year; however, the costs of the sequential schedule outweigh the expected economic benefits associated with a decreased incidence of VAPP. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011260-bbs2-0088" title="MascareñasA , SalinasJ , Tasset‐TisseauA , MascareñasC , KhanMM . Polio immunization policy in Mexico: economic assessment of current practice and future alternatives. Public Health2005;119(6):542‐9. [DOI: 10.1016/j.puhe.2004.08.020; PUBMED: 15826896] ">Mascareñas 2005</a><br/> <b>Mexico</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>USD 2002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 OPV (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100,454 to 156,614</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 OPV 2 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> a prospective Mexican, micro‐costing study estimated that changing from the current OPV‐based intensive and routine schedule to a sequential IPV‐OPV routine schedule would save US $14.52 per vaccinated child, and changing to a full IPV routine schedule would save US $9.41 per vaccinated child. It also estimated a national immunisation week (NIW) cost. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p><a href="./references#CD011260-bbs2-0101" title="SartoriAM , VicentineMP , GryningerLC , Coelho de SoárezP , NovaesHM . Polio inactivated vaccine costs into routine childhood immunization in Brazil. Revista de Saúde Pública2015;49(8):1‐10. [DOI: 10.1590/S0034‐8910.2015049005492] ">Sartori 2015</a><br/> <b>Brazil</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>USD 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 OPV + 2 NIDs (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,873,170</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV 4 OPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,608,419</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−26.50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV 3 OPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,852,799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.00%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV 2 OPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31,283,072</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,936,547</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41,681,259</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.70%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV 4 OPV + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,409,159</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.70%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV 3 OPV + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,653,539</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV 2 OPV + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,083,812</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.60%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV 4 + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45,737,287</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130.20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 IPV + 1 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48,481,999</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143.90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 IPV 4 OPV + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28,209,899</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 IPV 3 OPV + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36,454,279</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 IPV 2 OPV + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44,884,552</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125.90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 IPV 4 + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52,538,027</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164.40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 IPV + 2 NID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55,282,740</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178.20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> the introduction of IPV in Brazil increased the annual costs of the polio vaccines by 49.2% compared with the oral vaccine‐only regimen. This increase represented 1.13% of the expenditure of the national immunisation program on the purchase of vaccines in 2011. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p><a href="./references#CD011260-bbs2-0051" title="Duintjer TebbensRJ , SangrujeeN , ThompsonKM . The costs of future polio risk management policies. Risk Analysis2006;26(6):1507‐31. [DOI: 10.1111/j.1539‐6924.2006.00842.x; PUBMED: 17184394] ">Duintjer Tebbens 2006</a><br/> <b>Wordwide</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIC:</b> IPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIC:</b> AFP </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6900</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> IPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1300</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> OPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> AFP </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> IPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> OPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> AFP </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> IPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3900</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> OPV </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1900</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> AFP </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> Total </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8600</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> a model for the expected future costs of different polio strategies estimated that a global transition from routine immunisation with OPV to IPV would increase the costs of managing polio globally, although routine IPV use remains less costly than routine OPV use with supplemental immunisation activities. The uncertainty in the aggregated costs, the discount rate and price and administration cost of IPV drives the expected incremental cost of routine IPV vs OPV immunisation. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD011260-bbs2-0052" title="Duintjer TebbensRJ , PallanschMA , CochiSL , WassilakSGF , ThompsonKM . An economic analysis of poliovirus risk management policy options for 2013‐2052. BMC Infectious Diseases2015;15:389. [DOI: 10.1186/s12879‐015‐1112‐8; PMC4582932; PUBMED: 26404632] ">Duintjer Tebbens 2015</a><br/> <b>200 countries</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2013–2052</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>USD 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tOPV (<b>Ref</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LIC:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4700</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LMIC:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>UMIC:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−400</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIC:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>World:</b> ≥ 1 IPV no SIAs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Summary:</b> an integrated dynamic poliovirus transmission and stochastic risk model simulated possible futures and estimate the health and economic outcomes of maintaining the 2013 status quo of continued OPV use in most developing countries compared with OPV cessation policies with various assumptions about global IPV adoption. The authors estimated a global incremental net benefits during 2013‐2052 of approximately 16 US $2013 billion (almost 20 billion in LMICs) with at least one IPV routine immunisation dose in all countries until 2024 compared to continued OPV use, although significant uncertainty remains associated with the frequency of exportations between populations and the implementation of long‐term risk‐management policies. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>AFP:</b> acute flaccid paralysis; <b>HIC:</b> high‐income country; <b>IPV:</b> inactivated poliovirus vaccine; <b>LIC:</b> low‐income country;<b>LMIC:</b> lower‐middle income country; <b>NID:</b> national immunisation days;<b>NIW:</b> national immunisation week; <b>OPV:</b> oral poliovirus vaccine; <b>SIA:</b> supplemental immunisation days; <b>UM:</b> upper‐middle‐income country; <b>USD:</b> US dollars; <b>VAPP:</b> vaccine‐associated paralytic poliomyelitis. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>For definition of schedules (e.g. sequential IOO), see Glossary in <a href="./appendices#CD011260-sec-0176">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Main results of economic evaluations identified</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/full#CD011260-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011260-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IPV‐OPV versus OPV</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persons with P1 Protective humoral response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Persons with P1 Protective humoral response by time of first dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 First dose at birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 First dose at 2 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Persons with P1 Protective humoral response by type of dose sequence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Sequential IOO/IOOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.98, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Sequential IIO/IIOO/IIIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Sequential IOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.93, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Persons with P1 Protective humoral response by countries' income <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 LMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 HIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.99, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Persons with P2 Protective humoral response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 IPV‐tOPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.93, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 IbObO vs tOPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.64, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 IbObO vs bOPV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.80 [4.06, 8.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Persons with P2 Protective humoral response by time of first dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.98, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 First dose at birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.87, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 First dose at 2 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.98, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Persons with P2 Protective humoral response by type of dose sequence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Sequential IbObO (bOPV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Sequential IOO/IOOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.98, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Sequential IIO/IIOO/IIIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Sequential IbOI (vs bObObO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.85 [4.10, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.75, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Sequential IOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.99, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Persons with P2 Protective humoral response by countries' income <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.98, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 LMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.96, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 HIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Persons with P3 Protective humoral response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.97, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Persons with P3 Protective humoral response by time of first dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.97, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Fist dose at birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.87, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 First dose at 2 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.97, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Persons with P3 Protective humoral response by type of dose sequence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.96, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.60, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Sequential IOO/IOOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.96, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Sequential IIO/IIOO/IIIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Sequential IOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.95, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Persons with P3 Protective humoral response by countries' income <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.97, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 LMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.98, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 HIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.94, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mean titres of P1 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>362.12 [‐329.70, 1053.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐181.13 [‐594.25, 231.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐244.37 [‐827.31, 338.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Sequential IIIOO/IIIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>439.07 [‐354.63, 1232.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Mean titres of P2 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐260.38 [‐347.21, ‐173.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.64 [‐22.16, 79.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐217.90 [‐305.36, ‐130.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>267.40 [‐83.95, 618.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 Sequential IIIOO/IIIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>486.17 [‐698.02, 1670.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Mean titres of P3 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>221.03 [9.66, 432.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>44.07 [‐1.47, 89.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>591.78 [185.14, 998.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>89.97 [8.98, 170.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 Sequential IIIOO/IIIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>248.39 [‐180.58, 677.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Long term mean titres of P1 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.07, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.48, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Sequential IOO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.33, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.22, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Sequential IIO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.01, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Long term mean titres of P2 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.07, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.26, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Sequential IOO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.30, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.38, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Sequential IIO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.11, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Long term mean titres of P3 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.29, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.14, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Sequential IOO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.61, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.02, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Sequential IIO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.34, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Persons with polio faecal excretion after OPV challenge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Persons with P1 faecal excretion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.70, 7.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Persons with P2 faecal excretion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.49, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Persons with P3 faecal excretion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.47, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Vaccination coverage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Serious adverse events classified by MedDRA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.46, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IPV‐OPV versus OPV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011260-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IPV‐OPV versus IPV</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persons with P1 Protective humoral response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.98, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [1.00, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Persons with P2 Protective humoral response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.95, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.64, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Persons with P3 Protective humoral response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.97, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Sequential IIO(O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Sequential IbOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean titres of P1 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1520.59 [1084.80, 1956.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>799.47 [530.82, 1068.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>866.53 [478.83, 1254.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>767.90 [337.75, 1198.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mean titres of P2 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐125.93 [‐174.77, ‐77.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>142.25 [57.65, 226.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐83.45 [‐133.40, ‐33.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2224.48 [‐1145.70, 5594.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean titres of P3 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Sequential IbObO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>327.62 [134.82, 520.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>110.39 [‐77.98, 298.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Sequential IIbO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>698.37 [301.06, 1095.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>184.52 [‐211.93, 580.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Long term mean titres of P1 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.73, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Sequential IOO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.83, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.04, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Sequential IIO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.40, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Long term mean titres of P2 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.06, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Sequential IOO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.96, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.19, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Sequential IIO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.78, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Long term mean titres of P3 neutralising antibody <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Sequential IOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.22, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Sequential IOO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.76, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Sequential IIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.04, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Sequential IIO+O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.46, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Persons with polio faecal excretion after OPV challenge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Persons with P1 faecal excretion (ibOI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.19, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Persons with P1 faecal excretion (IIO/IIOO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Persons with P2 faecal excretion (ibOI/IIbO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1048</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Persons with P2 faecal excretion (IIO/IIOO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.09, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Persons with P3 faecal excretion (ibOI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.26, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Persons with P3 faecal excretion (IIO/IIOO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.32, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serious adverse events (≥1 symptom related to study drug or not) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.60, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IPV‐OPV versus IPV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011260-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">IPV(3)‐OPV versus IPV(2)‐OPV</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Persons with polio protective humoral response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 P1 protective humoral response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 P2 protective humoral response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.97, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 P3 protective humoral response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.97, 1.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">IPV(3)‐OPV versus IPV(2)‐OPV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011260.pub2/references#CD011260-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011260.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011260-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011260-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011260-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011260-note-0014">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011260\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011260\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011260\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011260\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011260\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011260.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011260.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011260.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011260.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011260.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728909100"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011260.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728909103"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011260.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecff40a9a9368',t:'MTc0MDcyODkxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 